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ABSTRACT 
 
The epigenetic component of cancer is now well-established and epigenetic 
therapeutics targeting histone deacetylase and DNA methyltransferase enzymes have 
received FDA approval. Histone lysine methyltransferases (HKMTs) are a new and 
promising epigenetic target class for cancer treatment, but the search for HKMT 
inhibitors is still in its infancy. 
 
 
Figure 1 Chaetocin 
First, chaetocin, a fungal metabolite belonging to the 
3,6-epidithio-diketopiperazine (ETP) class, was previously 
described as a specific inhibitor of the HKMT 
SU(VAR)3-9. Like other ETP molecules however, it 
exhibits a broad cytotoxicity due to the presence of the 
disulfide bridge. The requirement of this moiety for 
HKMT inhibition has been questioned.  
We reasoned that access to semi-synthetic analogues devoid of such functionality 
would provide valuable insight into its reported HKMT inhibitory activity. Our results 
revealed a total loss in inhibitory potency upon modification of the disulfide bridge. 
In addition, we conducted biochemical and mass spectroscopy studies on the 
mechanism of action of chaetocin. Our results demonstrated the ETP functionality of 
chaetocin to be responsible for its reported HKMT inhibitory activity and suggest that 
chaetocin is a non-specific inhibitor.  
The stereochemical course of ETP desulfurisation by triphenylphosphine has 
also been investigated by comparison of experimental and computationally simulated 
chiroptical spectra. Our data showed that all ETPs are desulfurised with retention of 
stereochemistry. 
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Figure 2 BIX-01294 
Second, BIX-01294 has been identified as an inhibitor of 
G9a/GLP HKMTs. In light of the expected structural 
similarities of EZH2’s peptide binding site with that of 
G9a, we felt we could use this molecule as a starting point 
for the reversal of H3K27-mediated gene silencing.  
 
We anticipated that upon derivatisation of BIX-01294, it might be possible to expand 
the biological activities of the parent compound and gain EZH2 inhibitory activity. A 
library of analogues has been prepared in collaboration with co-workers in the 
Fuchter group and has been assessed in biological assays. Three compounds have 
been identified in a cell-based assay to lead to re-expression of EZH2 target genes and 
their biological activities have been further assessed. 
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“There has been an alarming increase in the number of things that I know 
nothing about.” 
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Chapter I 
 
Introduction 
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Cancer and drug discovery 
 
 Cancer is a leading cause of death worldwide. In 2008, it accounted for 13% 
of all deaths (7.6 million) and this situation is expected to worsen with an estimated 
13.1 million people dying from cancer in 2030.1 Although lifestyle choices have now 
been shown to have some significant influence (e.g. tobacco or alcohol use, high body 
mass index), inherited genetic factors and increasing age are uncontrollable variables 
that also strongly contribute to the incidence of cancer. The complex nature of the 
disease makes it one that is difficult to detect, treat and understand. Nevertheless, 
research in oncology has become one of the major focus areas in both academia and 
pharmaceutical companies, strongly illustrated by the high number of cancer-related 
clinical trials (in 2009, ca. 16,000 which represent about 40% of all trials registered 
on ClinicalTrials.gov).2  
 
Cancer can be defined as a class of diseases in which cells have acquired the 
ability to proliferate abnormally and to invade surrounding normal tissue.3 In 
advanced stages of the disease, cancer cells can metastasize, whereby they migrate 
from their initial location and spread to another site to develop a secondary tumour. 
This abnormal proliferation state is the outcome of a complex multi-step process 
whereby the cell acquires a number of capabilities (“hallmarks of cancer” as 
described by Hanahan and Weinberg)4,5 allowing it to evade control by the regulatory 
machinery. Acquisition of these capabilities is primarily the result of deregulation of 
the expression of a number of key genes, which can be separated in two main 
families: proto-oncogenes and tumour suppressor genes. Proto-oncogenes are genes 
that, when mutated or overexpressed, contribute to the transformation of a normal cell 
into a cancer cell, thus becoming oncogenes. They are commonly involved in the 
regulation of cell growth or proliferation and are usually implicated in signal 
transduction pathways; receiving and transmitting growth stimulatory signals (that 
originate from the extracellular environment). The activation of proto-oncogenes into 
oncogenes can be achieved via diverse pathways leading to overexpression or hyper-
active proteins, such as chromosomal translocation, point mutation or gene 
amplification. Once activated, oncogenes become overly active growth-promoting 
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genes and will drive the cell to proliferate independently from extracellular 
signalling.6 In contrast, tumour suppressor genes (TSG) counterbalance these growth-
promoting genes and are involved in numerous cell processes for regulating cell 
growth and death. Their deactivation is believed to be as, if not more, important than 
the activation of oncogenes for cancer formation.6 However, the two alleles of a TSG 
have to be inactivated for the malignant phenotype to be expressed, since it is 
generally recessive. This rare situation can be achieved in various ways such as 
mutation, loss of heterozygosity or epigenetic silencing, as will be described below. 
Once both copies of the TSG are inactivated, the cell no longer receives anti-
proliferative signals, thus meeting another requirement for carcinogenesis.6 
 
 The first approach to cancer chemotherapeutic treatment was the development 
of cytotoxic agents. Amongst these are the nitrogen mustards, which originate from 
the discovery that mustard gas used during World Wars I and II exhibits an anti-
carcinogenic effect.7 A number of cytotoxic drugs have received FDA approval over 
the years and are still the first line treatment for cancer patients today. Such drugs 
include Taxol (an anti-microtubule agent which blocks cell division), Cis- and 
Carboplatin (DNA crosslinking agents) and the anthracyclines (DNA intercalating 
agents). While these drugs have had an important impact on patients’ lives, they all 
induce very severe side effects due to their lack of specificity for cancer cells over 
healthy cells. Next generation chemotherapies promise to address this major issue. 
The increasing understanding of molecular biology and the discovery of cancer-
causing genes (oncogenes and TSG mentioned above) led to the opportunity of 
specifically targeting cancerous cells. Targeted chemotherapy, which includes both 
small molecule inhibitors and monoclonal antibodies, aims to affect these deregulated 
pathways specifically and consequently hopes to have only minor impact on healthy 
cells. The FDA approval of the Bcr-Abl kinase inhibitor Gleevec (Imatinib) in 2001 
for the treatment of multiple cancers, most notably chronic myeloid leukaemia (CML), 
confirmed the viability of this approach and translated into impressive survival rates 
for patients.8  
While cancer cells exhibit numerous genetic alterations as mentioned above, it 
can appear counterintuitive that selective inhibition of a single (or a limited number 
of) protein(s) would lead to cancer cell death. The concept of “oncogene addiction” 
has been proposed to rationalise this phenomenon, with dependence of some cancer 
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cells on one (or a few) gene(s) for the maintenance of the malignant phenotype.9 This 
hypothesis implies that the development of cancer is not the result of a simple 
addition of the individual effects of oncogene activation and tumour suppressor gene 
inactivation. It suggests that the proteins encoded by these cancer-related genes are 
implicated in different, more essential, roles in cancer cells than in normal cells. In 
other words, the regulatory machinery is severely altered in cancer cells and their 
survival can become dependent on distinctive pathways. Identification of this 
“Achilles heel” in a given cancer cell type is an essential step for selecting the 
appropriate drug target to pursue.9,10 
 
Epigenetics and therapy 
 
 The genetic origin of cancer is now well established, whereby alterations of 
critical genes regulating cell growth, proliferation, or death lead to the malignant 
phenotype. However, intense research over the past two decades has shed light onto 
the crucial role of the transcriptional regulatory pathways in the cell, known as 
epigenetic processes in cancer. As implied by its name (“Epi” comes from the Greek 
word for “over”), epigenetic processes control the regulation of gene expression 
without involving genetic alteration of the DNA sequence. It is now clearly 
established that epigenetic modifications play a critical role at every stage of 
carcinogenesis through deregulation of the expression of critical cancer-related 
genes.11,12 
 
Epigenetic modifications 
 Epigenetic processes are modifications that influence the structure of 
chromatin, which consists of DNA and histone proteins (Figure 1). Within the nucleus, 
ca. 147 base pairs of DNA are wrapped around an octamer of histone proteins: two 
dimers of histones H3 and H4, complemented by two dimers of histones H2A and 
H2B.13 Together, this complex makes up the fundamental repeating unit of chromatin 
called a nucleosome.14 DNA methylation and post-translational modifications (PTM) 
of histones are examples of epigenetic modifications and will be further described 
below (Figure 1).  
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Figure 1 Chromatin and epigenetic modifications (Adapted from Cherblanc et al.14) 
 
 
DNA methylation 
DNA methylation is carried out by DNA methyltransferases (DNMTs) which 
transfer a methyl group from the endogenous co-factor S-adenosylmethionine (SAM) 
to the C-5 position of specific cytosine nucleotide (Scheme 1).15 DNA hyper-
methylation at promoter proximal CpG-rich regions (Cytosine-phosphate-Guanidine, 
or CpG island) is generally associated with gene silencing. Two main mechanisms 
have been proposed to relate DNA methylation to transcriptional silencing.16 Firstly, 
DNA methylation leads to a decrease in binding affinity between transcription factors 
and their target DNA sequence, which can be regarded as a direct mechanism for 
inhibition of transcription.17 Secondly, methylated cytosines are recognition elements 
for methyl-CpG-binding proteins (MBPs), which are in turn able to recruit further 
transcriptional repressive complexes. 18,19 
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Scheme 1 A. General scheme for DNA methylation of cytosine at C-5. B. Mechanism of the methylation reaction. 
The DNMT is depicted in pink, S-adenosylmethionine/S-adenosylhomocysteine cofactors in blue and the 
transferred methyl group in red. Adapted from Cherblanc et al.20 
 
Histone modifications 
Histone proteins not only act as a scaffold for DNA condensation but also as a 
dynamic structure that influences gene expression. In particular, the poorly structured 
N-terminal region of histone proteins (histone tail, Figure 1) is subject to a variety of 
post-translational modifications (PTMs) including acetylation, methylation, 
phosphorylation, ubiquitination, sumoylation and ADP ribosylation (see Figure 2 for 
selected examples).13,21 Acetylation and methylation of histone residues are the most 
characterised modifications and will be described in further detail. 
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Figure 2 Selected examples of post-translational modifications of histones (Adapted from Cherblanc et al.14,20) 
 
Acetylation of specific lysine residues of histones is regulated by the 
counteracting action of histone acetyltransferases (HATs) and histone deacetylases 
(HDACs), which respectively add or remove an acetyl group to specific lysine 
residues (Figure 2). Similarly, methylation of specific lysine or arginine residues is 
mediated by histone lysine methyltransferases (HKMTs) and protein arginine 
methyltransferase (PRMTs) respectively (Figure 2). While lysine residues can be 
mono-, di- or trimethylated, arginine residues can be mono- or di-methylated, in a 
symmetrical or asymmetrical fashion. Demethylation of lysine residues is performed 
by lysine demethylases (KDMs). However, no direct arginine demethylase has yet 
been reported. Protein arginine deiminase (PADs) have been suggested to lead to 
demethylation of arginine via deimination of both arginine and 
monomethylarginine.22  
Similarly to DNA methylation, these PTMs are key to epigenetic gene 
regulation by two main mechanisms. Firstly, the three-dimensional structure of 
chromatin can be controlled as a result of the presence of these epigenetic marks.23 
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Acetylation is thought to lead to a more “open” chromatin (i.e. accessible to the 
transcription machinery) via neutralisation of the positive charge on the lysine residue, 
which is suggested to lead to a lower electrostatic affinity of the histone tail for the 
negatively charged DNA backbone.23 Secondly, these PTMs constitute docking sites 
for regulatory effector proteins. Each PTM is specifically recognised by a “reader” of 
histone modifications,24 which includes bromodomain-containing proteins (bind to 
acetylated lysine residues), and chromo-, PHD-, or tudor domain-containing proteins 
(specific for methylation marks). Transcription is consequently repressed or activated 
by the recruitment of further transcriptional regulatory protein complexes and further 
chromatin modifications.25  
Importantly, the downstream effects of a PTM on a histone tail will depend on 
the site of modification (position of the lysine or arginine residue) but also the nature 
and multiplicity of the mark (e.g. ac, me, me2, me3).13 Most commonly, 
transcriptionally active chromatin presents elevated levels of acetylation in 
combination with specific tri-methylation marks at lysine 4 on histone 3 (H3K4), 
H3K36, and H3K79. Conversely, repressive chromatin is associated with reduced 
levels of acetylation together with elevated levels of tri-methylation at H3K9, H3K27 
and H4K20.13,26 
Further complexity in the deciphering function of single chromatin marks and 
their impact on gene expression stems from the crosstalk between the different 
modifications, often referred to as the “histone code” hypothesis.27 Active gene 
transcription or silencing is a result of the combination of epigenetic marks, including 
histone PTMs and DNA methylation. Furthermore, the enzymes mediating and 
reading these marks are also interrelated (e.g. have the ability to recruit each other or 
are part of the same complexes) which results in an intricate network currently not 
fully understood.25 
 
Epigenetic therapy for cancer 
Deregulation of epigenetic marks have unsurprisingly been observed in a 
variety of cancer types.11 Epigenetic aberrations in cancer can stem from a variety of 
alterations to the enzymes mediating the installation or removal of these marks, such 
as mutations, chromosomal translocations or overexpression.28-33 The ensuing 
abnormal epigenetic modifications result in the aberrant expression of oncogenes or 
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conversely the anomalous silencing of TSGs.34 For example, numerous TSGs have 
been reported to be silenced by DNA hyper-methylation in a variety of cancer types.35 
This includes genes involved in DNA repair, signal transduction, cell cycle regulation, 
apoptosis or angiogenesis.33,36,37 Similarly, mutations of MLL1 (a HKMT specific for 
the methylation of H3K4, an activating mark) are suggested to be responsible for 
various types of leukaemia,38 while overexpression of EZH2, the main enzyme 
responsible for the silencing H3K27me3 mark, has been reported in breast and 
prostate cancers.39 
An important feature of epigenetic modifications, in contrast with genetic 
mutations, is their reversibility. Pharmacological disruption of the enzymes mediating 
these epigenetic marks is expected to lead to reversal of the aberrant epigenetic 
landscape of a cancer cell, resulting in a more normal state. The removal of 
anomalous silencing marks is for example accepted to lead to the re-expression of 
aberrantly silenced pathways and induce beneficial downstream effects such as 
triggering apoptosis of the cancer cells. Similarly to the oncogene addiction concept 
outlined above, it is possible that cancer cells become addicted to their aberrant 
epigenetic landscape and that its disruption may lead to cancer cell death selectively 
over healthy cells.40 It is also envisaged that the combination of several epigenetic 
modifiers may be required to significantly restore the epigenetic state of a cancer cell 
to that of a normal cell. For example the synergistic effect of DNMT and HDAC 
inhibitors has already been reported.41-43 Furthermore, the resulting re-expression of a 
large set of genes is also expected to re-sensitise cancer cells to conventional therapies 
(chemo or radiotherapy).44  
Cognisant of the implication of epigenetic modifications in cancer and their 
potential reversibility, the enzymes mediating the installation or removal of these 
marks have become attractive targets for the development of new cancer treatment.40 
 
Successful epigenetic therapies 
The initial validation of the concept of epigenetic therapy came with the 
development of DNMT inhibitors,45 which culminated in the FDA approval of two 
drugs for the treatment of myelodysplastic syndromes (MDS, pre-leukemic disease): 
Azacitidine and Decitabine (Figure 3A).33 These two drugs, originally developed as 
classical cytostatic agents,46 are azanucleosides which act as prodrugs: upon 
phosphorylation in the cellular environment and partial deoxygenation in the case of 
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Azacitidine (a riboside), the unnatural nucleotides become incorporated into DNA to 
subsequently trap DNMT via covalent linkage. They subsequently lead to DNA 
hypomethylation following cell division (Figure 3B).47  
 
  
Figure 3 A. Structure of the two FDA-approved DNMT inhibitors. B. Mechanism of action of azanucleoside 
DNMT inhibitors. The DNMT is depicted in pink, S-adenosylmethionine/S-adenosylhomocysteine cofactors in 
blue and the transferred methyl group in red. For clarity only the cytosine part of the inhibitor is depicted in black. 
Adapted from Cherblanc et al.20 
 
Further success in epigenetic therapeutic discovery was the approval of two 
HDAC inhibitors as a treatment for cutaneous T-cell lymphoma (CTCL).48-51 
Interestingly, both compounds, Vorinostat (SAHA) and Romidepsin (FK228) 
(Figure 4) were first identified as anti-tumour compounds reported to induce 
differentiation; their molecular targets, HDACs, were identified much later. A number 
of novel, isoform specific, HDAC inhibitors are currently in clinical trials.52-54 
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Figure 4 Structure of the FDA approved HDAC inhibitors 
 
Given the success in developing inhibitors of DNMTs and HDACs, it is 
anticipated that enzymes regulating histone methylation would also constitute a 
promising class of drug targets. While the therapeutic potential of arginine 
methytransferases22 and lysine demethylases38,55 has been recognised, we will 
concentrate here on HKMTs, the most extensively characterised class and the main 
focus of this project.56 
 
HKMTs as an emerging target class in cancer 
 An important number of studies in the past 10–15 years have gathered 
significant evidence on the pathogenic role of several HKMTs in a variety of cancer 
types. Table 1 presents selected examples of HKMTs and their alteration in cancer. 
 Enzymes involved in installing silencing (EZH2, G9a) or activating (DOT1L, 
MLL1) marks have both been linked to cancer pathogenesis. Furthermore, 
overexpression of several HKMTs, including EZH2, has been suggested to be a 
marker of the aggressiveness of the disease and poor prognosis.57-59 A significant 
amount of biological data points to EZH2 as the most therapeutically relevant HKMT 
enzyme.39 Chapter IV will describe our efforts at developing novel EZH2 inhibitors. 
 
H
N
O
O
HN
OO
SS
HN
O
NH
O
Romidepsin
(FK228, depsipeptide)
H
N
O
N
H
O
OH
Vorinostat (suberoylanilide hydroxamic acid, SAHA)
 	  
31	  
	  
	   	  
Table 1 Association of HKMTs with particular tumour types 
Enzyme Modification Cancer type Alteration 
EZH2 H3K27me3 
Bladder carcinoma 
Breast cancer 
Colorectal cancer 
Gastric cancer 
Prostate cancer 
Overexpression 
Overexpression 
Overexpression 
Overexpression 
Overexpression 
Lymphomas 
Mutation at Tyr641, 
Ala677 or Ala687 
MLL1 H3K4 Leukaemia 
Chromosomal 
translocation, 
amplification 
G9a H3K9me1/2 
Hepatocellular 
carcinomas 
Overexpression 
Gastric cancer Up-regulation 
SUV39H1 H3K9me2/3 Colon cancer Overexpression 
NSD1 H3K36me2/3 
Neuroblastoma and 
gliomas 
Acute myeloid 
leukaemia 
Silencing by promoter 
hyper-methylation 
Chromosomal 
translocation 
DOT1L H3K79 Leukaemia 
Chromosomal 
translocation 
Adapted from Cherblanc et al., 20 data from 59-61  
 
Structure of HKMTs 
 The HKMT family is composed of 52 closely related enzymes.61 With the 
exception of DOT1L, the catalytic site of HKMTs is contained within the so-called 
SET domain (Suvar3-9, Enhancer of Zeste, Trithorax).62,63 The active site of HKMTs 
is characterised by the presence of three interconnected domains: the cofactor SAM 
binds in a pocket on one side of the protein, the H3 substrate binds to a cleft on the 
opposite side and a narrow hydrophobic channel, where the side chain of the lysine to 
be methylated is positioned, connects the two binding sites (Figure 5).64 
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Figure 5 SAH (grey carbons) and H3 peptide (black carbon) with methylated lysine 9 co-crystallised with GLP. 
Generated from pdb file 2RFI, the surface represents the electrostatic potential.65 
 
 HKMTs have been reported to be specific for the degree of methylation they 
perform and the residue they modify (e.g. EZH2 only trimethylates H3K27, SET7/9 
only monomethylates H3K4), although the latter is becoming a challenged view as 
non-histone targets have been identified for a number of HKMTs.23,66 Depending on 
the enzyme involved, multiple methylation events have been shown to be performed 
in a processive (i.e. without release of the substrate, e.g. G9a)67 or non-processive (e.g. 
SUV39H1)68 manner. Crystallographic and mutagenesis studies of different HKMTs 
(DIM-5, G9a and SET7/9) have shed light on the mechanism controlling the 
specificity in the degree of methylation. The presence of either a phenylalanine or a 
tyrosine residue at a conserved position in the active site was shown to act as a switch 
between single methylation or multiple methylation capabilities.69 The hydroxyl 
moiety of the tyrosine residue was suggested to prevent the necessary rotation of the 
monomethylated lysine (via hydrogen bonding) thus impeding the next methylation 
step. 
 
Reported HKMT inhibitors 
 Based on the catalytic mechanism and the overall structure of HKMTs, it has 
been suggested than this enzyme class would be amenable to small molecule 
inhibition.70 In particular, the presence of a small, well-defined, cofactor binding 
pocket has given confidence in the possibility of designing such inhibitors.62 An 
increasing number of HKMTs have now been crystallised and this has opened the 
way for rational design.71 
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Rational design of cofactor analogues 
 The first HKMT inhibitors were designed as cofactor (SAM) analogues, 
including S-adenosylhomocysteine  (SAH, the product of the methylation reaction), 
methylthioadenosine and the natural product sinefungin (SAM analogue found in 
bacteria) (Figure 6). Unsurprisingly, although the compounds exhibited inhibitory 
activity, they were not selective for a particular HKMT.62,72  
 
 
Figure 6 Structure of SAM analogues HKMT inhibitors 
 
More recently, based on intensive crystallographic studies and iterative 
medicinal chemistry, Daigle et al. reported a highly potent (IC50 = 0.4 nM) and 
selective (>1000-fold) inhibitor of DOT1L.73 DOT1L has been suggested as a 
potential therapeutic target in mixed lineage leukaemia (MLL) as a result of a 
chromosomal translocation of the MLL gene. This translocation leads to the 
recruitment of DOT1L to aberrant gene locations and subsequently to abnormal 
methylation patterns. As depicted in Figure 6, EPZ00477 retained the nucleoside core 
of SAM and was confirmed by kinetic analysis to bind in the cofactor binding pocket. 
Treatment of MLL cells with the compound resulted in the reduction of H3K79 
methylation together with the inhibition of expression of key MLL fusion target genes. 
The compound induced selective killing of cells bearing the MLL fusion and this 
further translated into anti-tumour activity in a mouse MLL xenograft model.73 
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HKMT inhibitors identified by HTS 
The current prevailing approach to identify hit compounds for a drug 
discovery project is through the use of a high throughput screen (HTS). Epigenetic 
drug discovery is no exception; a number of HKMT inhibitors were discovered by 
screening large libraries of compounds.  
Chaetocin (1, Figure 7), a fungal metabolite, has been identified to inhibit 
SU(VAR)3-9, the drosophila orthologue of SUV39H1, in the low micromolar range 
(IC50 = 0.6 µM).74 The biological activity of chaetocin and its synthetic analogues will 
be the focus of Chapter II. 
Upon screening a preselected fraction of the Boehringer Ingelheim library, 
Jenuwein and co-workers identified two compounds that inhibited the H3K9 
dimethylase G9a (Figure 7).75 While BIX-01294 (2) and BIX-01338 both inhibited 
G9a in the low micromolar range (IC50 of 2.7 and 4.7 µM respectively), BIX-01338 
was found to be competitive with the cofactor SAM whereas BIX-01294 was reported 
to be uncompetitive with SAM, suggesting that it binds to the enzyme-cofactor 
complex but not to the free enzyme. Furthermore, most likely in line with their modes 
of action, BIX-10338 inhibited all HKMTs tested in an unspecific manner while 
BIX-01294 inhibited G9a and only the closely related GLP (but with a lower potency 
of 38 µM). SAR studies have been reported around the BIX-01294 scaffold and will 
be described in more detail in Chapter IV. With the aim of improving BIX-01338 
selectivity, Schreiber and co-workers synthesised a library of analogues based on its 
benzimidazole scaffold and discovered BRD9539 (Figure 7) which displayed 
moderate in vitro potency against G9a as well as EZH2 (IC50 ≈ 6 µM for both 
enzymes) but was selective over SUV39H1, NSD2, DNMT1, 16 other chromatin-
modifying enzymes, and 100 kinases.76 BRD4770 (Figure 7), the methyl ester of 
BRD9539, was used as a prodrug for cell-based studies and was found, using mass 
spectrometry, to reduce cellular levels of H3K9 di- and trimethylation, while not 
affecting the methylation level of H3K27.76 This suggested that EZH2 activity, which 
is responsible for the methylation of H3K27, was not inhibited in cells, in contrast 
with the data from the biochemical assay. Nevertheless, BRD4770 induced 
senescence in pancreatic cancer cells and represents a useful tool to study the role of 
G9a in these aggressive cancer types. 
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Figure 7 Structure of the HKMT inhibitors identified by HTS and derivatives (BRD compounds) 
 
Recently, screening efforts also delivered hit compounds that have been 
developed into potent and selective EZH2 inhibitors by a number of academic groups 
and pharmaceutical companies.77-81 These studies will be described with greater detail 
in Chapter IV. 
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Global objectives of the project 
 
 The initial purpose of the work presented in this thesis was to contribute to 
epigenetic cancer drug discovery efforts by developing and studying inhibitors of 
HKMTs.  
We first endeavoured to further characterise the inhibitory activity of the 
natural product chaetocin (1, Figure 7), which has been described as a specific 
inhibitor of SU(VAR)3-9.74 The preparation of analogues, and their biological activity 
will be described in Chapter II. Since the stereochemistry of one of our chaetocin 
analogues required further characterisation, our efforts to address this problematic 
assignment together with that of molecules of similar structure, will be presented in 
Chapter III.  
Finally, we attempted to improve EZH2 inhibitors, based on the quinazoline 
scaffold of BIX-01294 (2, Figure 7),75 recently discovered in the group. The design, 
synthesis and biological assessment will be described in Chapter IV. 
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Chapter II 
 
Design, synthesis and 
biological evaluation of 
chaetocin analogues 
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Introduction 
 
 In 2005, Imhof and co-workers performed a high throughput screen (HTS) 
with the aim to discover new small molecule inhibitors against Drosophila 
melanogaster SU(VAR)3-9 (dSU(VAR)3-9), a histone lysine methyltransferase 
reported to specifically methylate lysine 9 of histone H3 (H3K9).74,82 Of the ca. 3,000 
compounds screened, the natural product chaetocin (1, Figure 7) was identified as the 
most potent inhibitor (IC50 of 0.6 µM against SU(VAR)3-9).74 Moreover, it was 
shown that chaetocin could inhibit the human orthologue of dSU(VAR)3-9 
(SUV39H1) with a similar IC50 value (0.8 μM), and other members of the 
SU(VAR)3-9 class of HKMTs including mouse G9a (IC50 = 2.5 μM) or Neurospora 
crassa DIM5 (IC50 = 3 μM). Chaetocin was shown however to be inactive against 
HKMTs not belonging to the SU(VAR)3-9 class, such as dE(z)-complex (the 
orthologue of human EZH2/PRC2 complex), PRSET7 or SET7/9. Chaetocin was 
therefore reported to be specific for the SU(VAR)3-9 class of enzymes. 
 
 
Figure 8 Examples of ETP containing natural products 
 
Chaetocin is a fungal metabolite first isolated from the fermentation of 
Chaetomium minutum.83 It belongs to the 3,6-epidithio-diketopiperazine (ETPs) class 
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of fungal toxins, which contain a characteristic diketopiperazine (DKP) scaffold 
bridged by two sulfur atoms (ETP core, Figure 8).84,85 ETP compounds are believed to 
be primarily involved in the chemical defence and virulence mechanisms of fungi.85 
Their toxicity extends outside the fungi class and they have been reported to exhibit a 
variety of biological activities in higher organisms, including mammals, both 
beneficial and detrimental.85 For example, sporidesmins (Figure 8), produced by 
Pithomyces chartarum on infected grasses, has been implicated in the development of 
facial eczema and liver disease in sheep.86 Conversely, the toxicity of ETPs has also 
made them attractive for potential therapeutic uses: gliotoxin (Figure 8), the best-
characterised ETP, has been shown to have antibacterial, antifungal, 
immunosuppressive, antiviral and anti-tumour activities.87 A large number of 
structurally, functionally, and evolutionary unrelated enzymes have been shown to be 
inhibited by ETP compounds. Gliotoxin has, for example, been reported to target 
reverse transcriptase,88 the transcription factor NF-κB,89 poliovirus polymerase 
3Dpol,90 farnesyltransferase and geranylgeranyltransferase91 amongst many others.92 
Several mechanisms have been proposed to account for the broad toxicity and various 
inhibitory activities of ETP compounds. These include protein cross-linking through 
reaction of the disulfide functionality with cysteine residues (Figure 9A), the 
generation of reactive oxygen species via redox cycling (Figure 9B), and the ejection 
of structurally important zinc ions from the protein (Figure 9C).84,85,93,94 All these 
mechanisms rely on the chemical reactivity of the ETP disulfide bridge. 
Similarly, chaetocin has also been shown to target several enzymes other than 
HKMTs, including thioredoxin reductase,95 and to disrupt the protein-protein 
interaction between p300:HIF-1α (hypoxia-inducible factor).93 Interestingly, both 
targets are involved in the sensing and scavenging of harmful reactive oxygen species 
(ROS) in cells and in each study, the disulfide bond has been suggested to be central 
to chaetocin’s activity. 
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Figure 9 Suggested toxicity pathways for ETP compounds, adapted from 84,93 
 
Nevertheless, one important point in the initial report by Imhof and 
co-workers warranted further investigation on the HKMT inhibitory activity of 
chaetocin: Based on the fact that the reducing agent dithiothreitol (DTT) had no 
noticeable effect on the inhibitory activity of chaetocin against the biochemical 
activity of SU(VAR)3-9,74 the authors have suggested that the disulfide bridge of this 
ETP molecule is not required for its HKMT inhibitory activity. Should this hypothesis 
prove correct, removal of the reactive disulfide functionality from chaetocin, while 
retaining the skeletal framework should result in the discovery of a novel HKMT 
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inhibitor with increased specificity and reduced off-target toxicity. However, most 
ETP analogues where the disulfide moiety has been removed or converted to an 
unreactive functionality have been found to be inactive compared to their parental 
ETP.85,96 
 
Aims of the project and strategy of the inhibitor design 
The initial aim of this project was to assess the requirement of the disulfide 
bridge of chaetocin for its HKMT inhibitory activity and to attempt to expand its SAR. 
A number of analogues were designed without the reactive disulfide bond while 
retaining the structure of chaetocin (1, Figure 7). The monosulfide analogue 3 
(Figure 10) was particularly interesting as it differs from the parent molecule by only 
one sulfur atom and most importantly retains the bicyclic structure of the ETP core. 
This analogue was indeed crucial to probe whether the three-dimensional structure of 
chaetocin influenced its inhibitory activity. The methylthioether derivative 4 
(Figure 10) was also designed to convert the reactive disulfide bond into an unreactive 
functionality while conserving all sulfur atoms. A fully desulfurised compound 5 
(Figure 10) was also interesting to further assess the dependence of chaetocin’s 
inhibitory activity on the presence of the sulfur atoms.  
 
 
Figure 10 Selected analogues of chaetocin 
 
While the total synthesis of chaetocin and its analogues would have been an 
attractive synthetic challenge, it was considered beyond the remit of this project. A 
semi-synthetic approach was preferred, whereby the natural product could be isolated 
from its natural source and then derivatised selectively around its disulfide 
functionality.96 Isolation of chaetocin from one of the producing fungi, as previously 
reported,97-99 was envisaged to allow access to significant amounts of the natural 
product in a more cost-effective manner than obtaining it from commercial sources.  
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Background on ETP synthesis in the literature 
In order to develop a reliable methodology for derivatisation at the disulfide 
bridge of chaetocin, a simplified model ETP compound was studied in order to probe 
the reactivity of the ETP moiety prior to studying the precious natural product. Over 
the years, the synthesis of ETP-containing natural or synthetic molecules has 
generated considerable interest due to their high structural complexity.100 Here, we 
will give an overview of selected examples focused on the various methods developed 
to build the ETP core. Scheme 2 shows the most common retrosynthetic analyses. 
 
 
Scheme 2 Retrosynthetic analyses to the ETP core101-105 
 
Schmidt and co-workers reported an efficient sulfenylation method of the 
DKP core by treatment with elemental sulfur and sodium amide in liquid ammonia 
(Scheme 3).101 The methodology was further improved by Nicolaou and co-workers, 
who devised a more convenient procedure whereby NaHMDS was used as the base, 
and THF as the solvent.100,102 Nicolaou and co-workers reported the synthesis of a 
large number of natural products using this methodology with variable yields (20 to 
70%).100 This approach was applied to the synthesis of a gliotoxin analogue and will 
be further described in Chapter III. 
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Scheme 3 Schmidt and Nicolaou’s approach to the ETP core101,102 
 
Sodeoka and co-workers accomplished the first total synthesis of chaetocin 
using also a late stage sulfenylation of the DKP ring, the general approach of which is 
depicted in Scheme 4A.104 The DKP ring was subjected to radical bromination using 
N-bromosuccinimide (NBS) and V70 (a diazo-containing radical initiator); 
subsequent treatment with water led to the formation of an hemiaminal. The dithiol 
was then obtained by substitution reaction of the tetraol with H2S in presence of 
BF3•OEt2 as Lewis acid, via a putative iminium intermediate. Final oxidation of the 
dithiol with iodine afforded the ETP core (44% yield from the hemiaminal in the case 
of chaetocin’s scaffold).104 The synthesis of chaetocin is depicted Scheme 4B. 
 
A number of additional sulfenylating agents have been used for the formation 
of the ETP core, including potassium thioacetate (KSAc)106, sodium tetrasulfide,107 
and more recently Movassaghi and co-workers pioneered the use of potassium 
trithiocarbonate (K2CS3) to generate the ETP moiety from monosilylated 
3,6-dihydroxydiketopiperazine intermediate in the total synthesis of 
(+)-11,11'-dideoxyverticillin A (general approach in Scheme 5).105 
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Scheme 4 Sodeoka’s approach to the ETP core (A) and synthesis of chaetocin (1)104 
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Scheme 5 Movassaghi’s approach to the ETP core105 
 
While most efforts have been focused on the late stage sulfenylation of the 
preformed diketopiperazine core, Motherwell and co-workers developed a mild and 
convenient method to rapidly access the ETP core without involving the formation of 
the DKP, which are known to endow the molecule with solubility issues.103 As 
depicted in Scheme 6, the route incorporates two three-component reactions in a four-
step synthetic sequence. The alkyl group on the nitrogen atoms can be conveniently 
modified and this method is applicable to the synthesis of compound libraries.93 This 
method has been employed for the synthesis of a model ETP compound (6, 
R1 = R2 = Bn, Scheme 6) and the synthesis will be described in greater details in the 
next section. 
 
 
Scheme 6 Motherwell’s approach to the ETP core103 
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Results and Discussion 
 
Synthesis and derivatisation of a model ETP compound 
 
Synthesis of a model ETP compound 
 A simple benzyl-protected ETP (6, R1 = R2 = Bn, Scheme 6) was devised as a 
model compound to probe the reactivity of the disulfide bridge. The route developed 
by Motherwell and co-workers was considered the most convenient to access 
substantial amount of material for derivatisation studies and was followed to generate 
the ETP model compound 6 (Scheme 6) on a gram-scale.93,103 
Acetyl chloride 7 was first synthesised following the literature procedure:108 
acetylation of glyoxylic acid monohydrate (8) with acetic anhydride followed by 
chlorination with thionyl chloride afforded the acetyl chloride 7 bearing the protected 
aldehyde in excellent yield (89%) (Scheme 7). 
 
 
Scheme 7 
 
The second coupling partner ester 9 was obtained via a three component 
reaction optimised by Hilton et al. (Scheme 8).109 Reaction of benzylamine (10), ethyl 
glyoxalate (11) and para-methoxybenzylmercaptan (12) in toluene afforded ester 9 in 
moderate yield (49%). 
 
 
Scheme 8 
 
Subsequently, acetyl chloride 7 was coupled with amine 9 to afford amide 
13 in good yield (76%) under Schotten – Baumann biphasic conditions (Scheme 9).103 
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Scheme 9 
 
The cyclisation to form diketopiperazine 14 proceeded in a moderate yield 
via a second three-component reaction in the presence of a catalytic amount of TFA 
to perform the in situ deprotection of the acetal. This step allowed the introduction of 
the second amide bond and installed the second PMB protected sulfur moiety. 
Importantly the desired cis isomer was obtained exclusively (Scheme 10), as 
previously described. Indeed, Aliev et al. reported that upon heating the reaction at 
reflux for over 16 h, the cis isomer was obtained solely.103 Intrigued by this 
preference, they performed gas phase DFT calculations which supported this 
thermodynamically favoured configuration by revealing that the cis arrangement is 
~9 kJ.mol-1 more stable than the trans configuration.103 In the last step, the PMB 
protecting groups were cleaved with boron tribromide, followed by in situ oxidation 
of the di-thiol with iodine to afford ETP 6 in good yield (Scheme 10). 
 
 
Scheme 10 
 
Derivatisation studies on the model ETP compound 
 The preparation of monosulfide-bridged diketopiperazines by treatment of 
ETP compounds with triphenylphosphine is very well precedented.110 Monosulfide 15 
was prepared following recent literature procedure and was obtained in a moderate 
yield from ETP 6 (Scheme 11).111 
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The methylthioether derivative 16 was prepared in a two-step one-pot 
reaction.111 The disulfide bridge of ETP 6 was first reduced to the dithiol 17 with 
sodium borohydride and this was then directly alkylated with methyl iodide to afford 
the desired dithioether 16 in good yield (Scheme 12).  
 
 
Scheme 12 
 
Next, we assessed the feasibility of accessing a fully desulfurised compound. 
Raney nickel is generally the reagent of choice for the reduction of carbon–sulfur 
bonds and it has some precedent in the desulfurisation of ETP compounds,112 however, 
various attempts at using Raney nickel in refluxing ethanol only furnished the 
expected desulfurised product 18 in very low yield (10%) or led to degradation when 
larger amount of reagent was used (Table 2). It was decided to explore other reagents 
for this reaction as shown in Table 2. 
 
Table 2 Conditions for the desulfurisation of ETP 6 
 
Conditions Comments or Yields 
Raney nickel, Ethanol, Reflux112 
10% and decomposition products if 
amount of Raney nickel doubled 
NaH, t-AmOH, Ni(OAc)2 (5/2/1 ratio) 
THF Reflux113 
No product 
NiCl2.6H2O, NaBH4, Ethanol, 
Reflux114,115 
75% 
 
 Nickel-containing complex reducing agent (NiCRA) has been developed by 
Caubère and co-workers as powerful desulfurisating agent with a greater chemo- and 
stereoselectivity than Raney nickel, as well as being much easier to handle.113 Its 
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reducing abilities is believed to rely on single electron transfer (SET) from NaH 
whose basicity is decreased and SET ability increased by the presence of a sodium 
alkoxide and metal salts.116 This methodology was surveyed to desulfurise ETP 6 
(Table 2) but unfortunately no product was observed by NMR or MS analysis. 
Finally, the use of in situ generated nickel boride, which also has some 
precedent in desulfurisation reactions, was attempted although the utility of this 
method for disulfides was reported to be diminished by the formation of sulfides as 
by-products.115 The reaction of nickel chloride salts with sodium borohydride is 
believed to form a nickel boride complex Ni2B (of observed dark colour), which is 
thought to be the active reducing agent. It was shown that the extruded sulfur atoms 
remained on the metal, explaining the requirement for a stoichiometric amount of 
nickel.117 While the precise mechanism is unclear, it has been suggested by labelling 
experiment that the dihydrogen generated by the reduction of Ni(II) by NaBH4 could 
be adsorbed and activated at the nickel boride surface followed by formation of 
transient nickel hydride intermediate.117 Gratifyingly, the use of this reagent finally 
afforded the desulfurised product 18 in good yield (75%).115 
 
 
Isolation of chaetocin and semi-synthesis of analogues 
 
Production and isolation of chaetocin 
The production of chaetocin was investigated by culturing a strain of the 
fungus (Chaetomium virescens var. thielavioideum) under various conditions.83,97 
First, a conidial suspension (spores) of the fungus was prepared in water and was 
plated on solid complete media and incubated for 5 days at 37 ˚C (Figure 11).118 
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Figure 11 Culture of Chaetomium virescens var. thielavioideum 
 
From those plates a conidial inoculum was prepared in distilled water, which 
was then inoculated to a liquid complete media and cultured at room temperature for a 
week. As secondary metabolites (like chaetocin) are thought to be part of the defence 
mechanism of microorganisms, it was expected that the metabolite should be located 
outside the cell (i.e. in the supernatant). The fungal suspension was therefore filtered 
to separate the supernatant from the mycelia. Two different solvents (CH2Cl2 and 
EtOAc) were used to extract the supernatant. Unfortunately, HPLC-MS analysis did 
not show any trace of chaetocin in the extracts, or in the supernatant. Accordingly, we 
decided to extract the mycelia as well. HPLC-MS analysis showed traces of chaetocin 
in the mycelia extract. As the signal was very weak it was decided to culture the 
fungus on a larger scale and to switch to a solid media as it has been more commonly 
described in the literature.83,96 Chaetomium virescens var. thielavioideum was then 
cultured on solid complete media (5 plates) for two weeks and then extracted with 
CH2Cl2. After purification by column chromatography, milligram quantities of a solid 
were obtained. 1H NMR and LC-MS analysis were consistent with that of chaetocin, 
however, the amount of chaetocin isolated was so small that it was not possible to 
obtain a completely pure sample.  
The incubation was thus repeated on a larger scale (ten 1 L bottles half filled 
with ca. 400 mL of solid complete media) (Figure 12). 
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Figure 12 Large scale production of chaetocin 
 
After three weeks of incubation at room temperature, the cultures were 
extracted with CH2Cl2 and the extracts were purified by column chromatography and 
trituration in hexane. Pure chaetocin could also be obtained by precipitation (in a 
mixture of CH2Cl2 and hexane followed by sonication). 
Pleasingly, approximately 200 – 400 mg of pure chaetocin were isolated, the 
structure of which was confirmed by NMR (1H and 13C), LC-MS and measurement of 
the specific rotation α !!". For biological testing, chaetocin was further purified by 
HPLC as trace amount of an analogue with a higher number of sulfur atoms could be 
identified by MS. Indeed, Saito et al. described the isolation of chaetocin B (trisulfide 
bridge over one of the diketopiperazine ring) and chaetocin C (trisulfide bridge at 
both diketopiperazine rings) from the same fungal culture (Figure 13).96 
 
 
Figure 13 Structures of chaetocin B and C96 
 
Derivatisation of chaetocin 
With a substantial amount of chaetocin in hand, the synthesis of the various 
analogues was undertaken. The monosulfide derivative 3 was first synthesised by 
treatment of chaetocin (1) with triphenylphosphine, as described for the ETP model 
compound 6, in high yield (Scheme 13).111 The stereochemistry of monosulfide 3 was 
assigned based on a range of chiroptical techniques (see Chapter III). 
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Scheme 13 
 
The methylthioether derivative 4 was also prepared in moderate yield 
following an analogous method to that used for the synthesis of model compound 16 
(Scheme 14).111 
 
 
Scheme 14 
 
The complete desulfurisation of chaetocin (1) was then attempted (Table 3). 
The optimal conditions developed for the desulfurisation of ETP 6, a nickel boride 
complex formed in situ by reaction of NiCl2 and NaBH4,115 were first tried but 
unfortunately, no desulfurised product 5 could be observed. Following the reported 
successful desulfurisation of gliotoxin, an aluminium amalgam was prepared,119-121 
but again, no product could be obtained. In both cases, a product of low molecular 
weight was observed, which lead to the suspicion that the bond connecting the two 
monomers of chaetocin was not stable to these conditions. The use of Raney 
nickel111,120 was nevertheless attempted but did not afford the product in isolable 
quantity. 
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Table 3 Attempts for the complete desulfurisation of chaetocin 
 
Conditions Observations 
NiCl2.6 H2O, NaBH4, EtOH/H2O115 
(RT or 0 ˚C) 
No expected product formation 
MS: Starting material + unidentified 
product (Mass ion  = 308 g/mol) 
Al-Hg amalgam, EtOH/H2O119-121, RT 
No expected product formation 
MS: Starting material + unidentified 
product (Mass ion = 308 g/mol) 
RaNi, EtOH (RT then reflux) 
Traces of 5 by MS, Not isolable nor 
identifiable by 1H NMR 
 
 Another strategy to desulfurise the ETP core was proposed by Öhler and 
co-workers in their work on the synthesis of ETP-containing natural product.122 It was 
shown that the treatment of the methylthioether 19 with boron trifluoride led to 
unsaturated compound 20 by elimination of methanethiol, most likely through the 
iminium species (Scheme 15). 
 
 
Scheme 15 
 
It was hoped that a similar elimination would be possible for chaetocin 
methylthioether 4, (Scheme 16, where only half of the molecule is presented for 
clarity). Reduction of the formed iminium functionalities (or the enamine and 
aldehyde tautomers) could then potentially lead to the expected desulfurised 
analogue 5. 
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Scheme 16 
 
Chaetocin methylthioether derivative 4 was treated with boron trifluoride etherate in 
THF (Scheme 17) until consumption of all the starting material. Half of the reaction 
mixture was treated with sodium borohydride, while the other half was directly 
quenched. Unfortunately, a mixture of unidentified decomposition products was 
obtained in both cases. 
 
 
Scheme 17 
 
 Hg(OAc)2 was also tested as Lewis acid tested for this desulfurisation reaction 
using the methylthioether model compound 16 (Scheme 18), but it did not yield the 
expected product 18 (starting material and decomposition products only).  
 
 
Scheme 18 
 
While we were conducting this work, Sodeoka and co-workers performed the 
total synthesis of the desired fully desulfurised analogue of chaetocin 5 and they 
assessed its biological activity against G9a, which will be discussed in the next 
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section.104 The preparation of this analogue was thus considered unnecessary and 
further synthetic work was abandoned. 
 
The low quantities and the peculiar reactivity of chaetocin brought some 
difficulties in the synthesis and isolation of analogues. Nevertheless, two structurally 
important derivatives were successfully prepared: the monosulfide analogue 3 and the 
methylthioether 4. Biological assessment of these two compounds was thought to be 
sufficient to allow us to address the role of the disulfide bridge in chaetocin’s HKMT 
activity. In addition, it was also decided to assess the biological activity of the ETP 6 
to test whether the presence of the intact ETP core (including the disulfide bridge) 
would lead to some inhibitory activity towards HKMTs. 
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Biological evaluation of chaetocin and analogues 
 
Preliminary data against SUV39H1 
 
The inhibitory activity of chaetocin and its derivatives was first assessed by a 
commercially available chemiluminescent assay kit against SUV39H1. This assay 
relies on the recognition of the methylation mark at lysine 9 by a specific ‘primary’ 
antibody (Figure 14). This primary antibody is in turn recognised by a secondary 
antibody, specific for the primary antibody. The secondary antibody is conjugated 
with the Horseradish peroxidase (HRP) enzyme. HRP is able to catalyse the oxidation 
of luminol by hydrogen peroxide resulting in an excited product, which will produce 
light upon decay (an enhancer is also added to increase the signal). This light, or 
chemiluminescence, is the signal monitored. A number of washes between each step 
allows for a specific signal to be obtained with low background only when the methyl 
mark is present in the given well. The sensitivity of the assay allows monitoring of the 
reduction in the signal if the methylation reaction has been successfully inhibited. 
 
 
Figure 14 Principle of the chemiluminescent assay against SUV39H1 
 
Chaetocin (1), the methylthioether derivative 4, the monosulfide derivative 3 
and ETP 6 were thus assayed against SUV39H1 (Figure 15).  
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Figure 15 Inhibitory activities of compounds 1, 3, 4 and 6 at 20 µM in the SUV39H1 assay kit 
The assay was run at a single concentration (20 µM) in duplicate, error bars represent SEM. 
 
Interestingly, while chaetocin (1) did confirm a good inhibitory activity (95% 
inhibition), no activity could be observed for the derivatives of chaetocin 3 and 4 (an 
unexplained increased in activity was actually observed and this will be further 
discussed in Chapter IV). Remarkably, the simple ETP 6 showed a considerable 
inhibitory activity (74% inhibition). These results suggested that the disulfide bridge 
of the ETP core was necessary for activity and potentially sufficient for inhibition 
since the ETP 6, lacking chaetocin’s complex framework, retained significant 
inhibitory activity. 
 We were therefore interested in further characterising the inhibitory 
mechanism of ETP-containing molecules towards HKMTs (e.g. time-dependency, 
reversibility, denaturation). Unfortunately, the assay kit was unsuitable to further 
assess our derivatives. The peptide being covalently attached to the plate and the 
amount of reagent given limited, no variation of the assay conditions was possible. 
 
Development of an AlphaLISA assay 
In order to further explore the mechanism of inhibition of HKMTs by 
chaetocin and other ETP compounds, it was decided to develop an AlphaLISA assay, 
which would offer more flexibility in the assay settings to assess various parameters. 
 
Description of the assay 
The AlphaLISA assay is a homogeneous proximity immunoassay using Alpha 
donor and AlphaLISA acceptor beads (the acronym "Alpha" stands for amplified 
luminescent proximity homogeneous assay). As shown in Figure 16, a biotinylated 
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histone H3-derived peptide is used as substrate. After incubation with the cofactor 
(SAM) and the methyltransferase enzyme, the methylated substrate is detected by 
addition of a specific antibody (anti-H3K9meX). This antibody can either be bound to 
Protein A coated AlphaLISA acceptor beads (Protein A is known to bind strongly to 
antibodies) or alternatively directly coated on AlphaLISA acceptor beads. 
Streptavidin or Strep-Tactin coated AlphaLISA donor beads bind to the biotin tag of 
the peptide substrate thus bringing the two types of bead in close proximity. 
 
   
Figure 16 Schematic representation of the AlphaLISA assay principle (adapted from 123) 
 
Donor beads contain a photosensitizer, phthalocyanine (blue-green-coloured 
aromatic macrocyclic compound) potentially coordinating a metal ion 
(Figure 17),124,125 which converts ambient oxygen to singlet oxygen, upon 
illumination at 680 nm.  
 
 
Figure 17 Structure of phthalocyanine 
The grey ball represents the metal ion (e.g. ZnII, AlIII) 
 
Singlet oxygen has a limited lifetime prior to falling back to ground state: its 
4 µs half-life allows it to diffuse approximately 200 nm in solution. If the acceptor 
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beads are in close proximity with the donor beads (<200 nm, i.e. bound to the same 
peptide), energy will be transferred from the singlet oxygen to the acceptor bead. 
AlphaLISA acceptor beads contain thioxene and a europium chelate (Figure 18). The 
singlet oxygen emitted by the donor beads leads to the conversion of thioxene into a 
di-ketone derivative and to emission of light at 340 nm. This light will in turn excite 
the europium chelate will be then generating an intense light detectable within a 
narrow wavelength bandwidth centred around 615 nm, which will be the detected 
signal. 
 
Figure 18 Chemistry of the AlphaLISA acceptor bead 
 
If the acceptor beads are not in close proximity (i.e. not bound to the peptide 
via the antibody recognition), singlet oxygen falls to ground state and no signal is 
produced. Consequently, the intensity of light emission is proportional to the level of 
peptide modification and this allows quantification of the methylation. 
 
Preliminary assay development with anti-H3K9me3 antibody and protein A coated 
beads 
 As aforementioned, SUV39H1 is a trimethylase enzyme and measuring its 
activity thus required the use of an anti-trimethyl-Histone H3 Lysine 9 (H3K9me3) 
antibody. The anti-H3K9me3 AlphaLISA acceptor Beads are not commercially 
available and it was thus necessary to use an anti-H3K9me3 antibody in combination 
with Protein A coated acceptor beads (Figure 19). 
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Figure 19 Protein A coated acceptor beads binding to anti-H3K9me3 antibody 
 
 First a Protein A – anti-H3K9me3 antibody titration was performed to 
investigate which concentration of the reagents would give the highest specific signal. 
The assay was performed using a trimethylated (H3K9me3) peptide and without the 
peptide as a negative control. The ratio of specific to non-specific signal (value 
obtained without peptide) was found to be around 2-fold for all the concentration 
systems tested (Figure 20). 
 
 
Figure 20 Ratio specific to non-specific signal at various concentrations of antibody and protein A 
The assay was run as single points, with H3K9me3 peptide (1 µM), Protein A (2.5 – 20 µg/mL), anti-H3K9me3 
(1/800 – 1/100). 
 
 Despite the fact that these results were not very satisfactory and gave only a 
very small window of opportunity to detect inhibition, we nevertheless proceeded 
with a peptide titration (using H3K9me3 peptide) to define the adequate concentration 
of peptide substrate to use to get the highest signal while avoiding the “hook 
effect”.126 This effect is commonly observed for bimolecular detection systems 
involving saturable reagents (e.g. the beads) used to bind specific partners (e.g. the H3 
peptide). Saturation of the beads results in a characteristic signal decrease which is 
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observed after an initial concentration-dependent signal increase. Figure 21 gives a 
schematic explanation of the origin of this effect. 
 
 
Figure 21 Schematic representation of the hook effect. A. Optimal concentration of peptide: maximal bead 
association leading to maximal signal. B. Hook effect: Excessive peptide concentration and decreased signal due 
to saturation of the binding sites and poor bead association126 
 
In parallel, the unmethylated peptide was also titrated as a negative control to 
assess the specificity of the antibody for the trimethylation mark. To our surprise, the 
signals obtained for unmethylated and trimethylated peptides were similar (Figure 22), 
showing a total lack of specificity. 
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Figure 22 Peptide titration with both trimethylated (H3K9me3) and unmethylated peptide 
The assay was run with Protein A (20 µg/mL), anti-H3K9me3 (1/100) and peptide (0.06 nM – 1 µM). The data 
shown is mean of duplicates; error bars represent SEM. 
 
 This technical issue is either attributable to the poor specificity of the anti-
H3K9me3 antibody or alternatively to a reduced binding between the protein A and 
the antibody (leading to nonspecific binding). 
 
 The assay setting therefore had to be modified. Surveying the commercially 
available acceptor beads, anti-dimethyl-Histone H3 Lysine 9 (H3K9me2) AlphaLISA 
acceptor beads were considered. Firstly, the use of acceptor beads already coated with 
antibody would avoid the lengthy optimisation of a two-component system as is 
required for the antibody and Protein A setup (and considerably diminishes the risk of 
poor quality reagents). Secondly, G9a is responsible for the dimethylation of lysine 9 
on histone 3 and is also a reported biological target of chaetocin.67,74,104 In light of the 
fact that the two enzymes methylate the same residue and are highly similar in 
sequence and in structure,63 it was reasoned that the mechanism of action of chaetocin 
toward this two enzymes would most likely be the same. Finally, SUV39H1 has been 
reported to trimethylate lysine 9 on the histone 3 in a non-processive way (i.e. 
releasing the peptide after each methylation step).68 It seemed plausible therefore that 
the H3K9me2 mark would be detectable, in the right time window.  
Consequently it was decided to use the anti-H3K9me2 AlphaLISA acceptor 
beads first with G9a to develop the assay conditions and then to verify whether 
detection could be achieved when using SUV39H1 as the methylating enzyme.  
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Preliminary assay development with anti-H3K9me2 coated acceptor beads 
 In light of the previous experience with the antibody – Protein A complex, the 
specificity of the antibody coated acceptor beads was first tested. The H3K9 
dimethylated peptide was therefore titrated together with unmethylated and 
trimethylated peptides as controls (Figure 23). 
 
 
Figure 23 Peptide titration with tri-, di- and unmethylated H3 peptide 
The assay was run with peptide (0.06 – 1000 nM) and anti-H3K9me2 coated acceptor beads (20 µg/mL). The data 
shown is mean of duplicates; error bars represent SEM. 
 
 The signal obtained was much stronger (up to half a million counts) than with 
the previous conditions, and importantly the specificity toward the dimethylated 
peptide was remarkable. The “hook effect” can be observed for peptide 
concentrations over 500 nM (Figure 23). For the subsequent experiments, the H3 
peptide was therefore used at a concentration below 500 nM. For IC50 determination 
(see next section), the peptide was used at 100 nM in accordance with our titration 
results and as suggested by the manufacturer. 
Next, in light of chaetocin’s reactivity, we felt it was important to check 
whether the natural product and its analogues would interfere with the assay 
components. H3K9me2 peptide was then used with increasing amount of compounds 
(Figure 24). 
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Figure 24 Influence of compounds on the assay reading 
The assay was run with H3K9me2 peptide (500 nM) and compounds 1, 3, 4 and 6 (3.12 – 100 µM) while keeping 
the final amount of DMSO constant (1%). The data shown is mean of duplicates; error bars represent SEM. 
 
 As shown in Figure 24, a decrease in signal was observed for all compounds at 
higher concentration. This is commonly observed in biochemical assays, especially 
when very high concentrations of compounds are used (up to 100 µM here). It is 
nonetheless important to keep this in mind if a weak inhibition is observed at very 
high compound concentration. 
 
Assay optimisation for G9a 
 Since the use of the anti-H3K9me2 coated acceptor beads gave suitable 
preliminary results (specificity for the dimethylated peptide and limited interference 
with our compounds), we undertook the optimisation of the other assay variables first 
using G9a as the methylating enzyme. 
We initially sought to establish the optimal enzyme concentration and reaction 
time for the assay. A time course experiment was therefore performed at various 
enzyme concentrations. As the AlphaLISA assay is a stopped assay (non continuous), 
it was necessary to run several reactions in parallel and to stop them at a given time 
point. For practical reasons, the reactions were actually started with various delays by 
addition of the substrates at different time points to allow all reactions to be stopped at 
the same time, which allows the whole plate to be read at once (Figure 25). 
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Figure 25 Time course at different G9a concentrations 
The assay was run with H3K9 peptide (100 nM), SAM (20 µM) and G9a (0.01 – 6 nM). The data shown is mean 
of duplicates; error bars represent SEM. 
 
 The graph corresponding to the G9a concentration of 6 nM has the expected 
shape, with a decrease of the signal after a certain time, indicating the formation of 
the (undetected) trimethylated lysine (G9a has been reported to perform also 
trimethylation in vitro).123,127,128 In addition, in order to remain in the linear range, the 
incubation time should be less than 20 min at this enzyme concentration. 
 
 Next, the concentration of the cofactor SAM was investigated to determine its 
Michaelis-Menten constant, KM. KM is defined as the substrate concentration that 
gives half maximal velocity of an enzymatic reaction. It represents the affinity of an 
enzyme for its substrate (with the lower the KM, the higher the affinity). Screening 
using biochemical assays is usually performed at substrate concentration close to their 
KM to allow unbiased approach to determining inhibitor potency. A time course at 
different SAM concentrations was thus performed. The signal obtained (proportional 
to the amount of product formed) was plotted against time, and the slope obtained by 
linear regression was therefore proportional to the reaction rate for each cofactor 
concentration investigated (Figure 26). 
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Figure 26 Time course with G9a at different SAM concentrations 
The assay was run with G9a (6 nm), H3 peptide (100 nM) and SAM (0.87 – 100 µM). The data shown is mean of 
duplicates; error bars represent SEM. 
 
The reaction rates obtained were then plotted against the concentration of 
SAM (Figure 27). Fitting of the data by non-linear regression into Michaelis-Menten 
equation (Equation 1) gave the expected KM with a value of 8 µM (SE of 0.55), in 
close agreement with the manufacturer’s data (KM = 12 µM).123 
 ! = ![!]!" = !!"#  ×  [!]!! + [S]  
Equation 1 Michaelis-Menten equation 
 
 
Figure 27 Michaelis-Menten curve: reaction rates plotted against SAM concentrations 
 
 A SAM concentration of 15 µM (close to KM and recommended by the 
manufacturer123) was finally chosen for the subsequent experiments.  
Finally, a new time course was run at this cofactor concentration with two 
concentrations of G9a (6 nM and 1 nM) to determine an adequate reaction time under 
these assay conditions. Also, the possibility of miniaturising the assay was 
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investigated: the volumes of all reagents were halved and the concentration of the 
beads was also halved (Figure 28). 
 
 
Figure 28 Time course with G9a at [SAM] = KM 
The assay was run as single points with H3 peptide (100 nM), G9a (1 or 6 nM) and SAM (15 µM). Two beads 
concentrations were investigated: normal (20 µg/mL for both acceptor and donor beads) and halved (10 µg/mL) 
 
 From this experiment, it was noticed that the linear range was too narrow for 
the high enzyme concentration (less than 10 min) hence it was decided to use G9a at 
the lower concentration (1 nM) for the subsequent experiments. Concurrently, as 
halving the volume of reagents did not seem to affect the assay and as the signal 
monitored with half the concentration of beads suggested in the supplier’s protocol123 
was still very high (greater than a million counts), it was decided to use these 
conditions. A final time course was run under these optimised conditions to define the 
best incubation time (Figure 29). 
 
 
Figure 29 Time course under the selected conditions 
The assay was run as single points with H3 peptide (100 nM), G9a (1 nM) and SAM (15 µM). Beads were used at 
10 µg/mL. 
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 From this experiment, a 40-minute incubation time was selected for the IC50 
measurement against G9a in order to remain in the linear range and get the highest 
signal. 
 
Assay optimisation for SUV39H1 
 A similar approach as that described for G9a has been followed to optimise 
the assay conditions using SUV39H1. 
First, a time course at various enzyme concentrations was run. According to 
the supplier’s datasheet, the specific activity (which could be defined as the amount of 
product formed by an enzyme in a given amount of time under given conditions per 
milligram of total protein, expressed in pmol/min/µg) of SUV39H1 is much lower 
than that of G9a (0.05 – 0.7 versus 10 pmol/min/µg, depending on the enzyme batch). 
In other words, the amount of active enzyme per total amount of protein is much 
lower in the case of SUV39H1. Consequently, a larger amount of SUV39H1 
compared to G9a would likely be required for good signal production. A wider range 
of enzyme concentrations was thus explored (0.4 – 50 nM) as well as longer reaction 
times (up to two hours) (Figure 30).  
 
 
Figure 30 Time course at different SUV39H1 concentrations 
The assay was run as single points with H3 peptide (100 nM), SAM (15 µM) and SUV39H1 (0.4 – 50 nM). 
 
No signal could be detected for short time points or low enzyme concentration. 
It was apparent that the detection of the transient H3K9me2 mark would not be a 
problem as initially suspected, thanks to the weak activity of SUV39H1 (a 
trimethylase). Indeed, during the 2 h time course with 50 nM of SUV39H1, the 
dimethylation mark signal had not started to decrease (Figure 30) which constitute 
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evidence that further methylation of the dimethylated peptide has not significantly 
started. 
 
 The low signal detected could result from low enzyme activity or alternatively 
insufficient concentration of cofactor. We therefore decided to determine the KM of 
SAM for SUV39H1 using a similar method as used for G9a and using SUV39H1 at 
high concentration (100 nM) (Figure 31). The value derived from the Michaelis-
Menten curve for KM was 42.3 µM (SEM 14.5). 
 
 
 
Figure 31 Michaelis-Menten kinetic analysis for determining the KM of SAM for SUV39H1 
The assay was run with SUV39H1 (100 nm), H3 peptide (100 nM) and SAM (6.25 – 400 µM). The data shown is 
mean of duplicates; error bars represent SEM. 
 
 Consequently, an additional time course was run with SAM concentration 
closer to its KM (40 µM) to determine the enzyme concentration and the reaction time 
to use in the assay. As expected with a higher SAM concentration, a much higher 
signal was obtained (Figure 32). From this experiment, an enzyme concentration of 
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50 nM and a reaction time of 1.5 h were chosen for the IC50 measurement against 
SUV39H1. 
 
 
Figure 32 Time course at various concentration of SUV39H1 and [SAM] = KM 
The assay was run as single points with H3 peptide (100 nM), SAM (40 µM) and SUV39H1 (3.12 – 50 nM). 
 
 
IC50 values determination 
 
 With the established optimised conditions for the assay, we next evaluated the 
inhibitory activity of our compounds against both G9a and SUV39H1.  
 
Determination of IC50 values against G9a 
Chaetocin (1), the monosulfide analogue 3, the methylthioether analogue 4 
and ETP 6 were thus assayed against G9a. SAH, the endogenous HKMT inhibitor of 
the cell, was used as a control. The inhibition curves are presented in Figure 33. pIC50 
values were derived for the active compounds and their average is presented in 
Table 4. No IC50 value could be derived for the methylthioether analogue 4 since no 
inhibition was observed. 
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Figure 33 Concentration-inhibition curves for chaetocin and analogues against G9a. Adapted from Cherblanc et 
al.129 
The assay was run with H3 peptide (100 nM), SAM (15 µM) and G9a (1 nM), with 30 min pre-incubation time 
and 40 min reaction time. Representative data set from one experiment, the data shown is mean of duplicates; error 
bars represent SEM. 
 
The concentration-inhibition curve obtained for monosulfide analogue 3 does 
not present the expected sigmoidal shape (low Hill slope value) and even at a 
concentration of 25 µM, 36% enzyme activity on average remains (Table 4). The IC50 
value derived from such a curve should be interpreted with caution. It should be noted 
that epimonothiodiketopiperazines compounds such as analogue 3 are known to be 
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relatively unstable due to their highly strained sulfur containing ring.130 The observed 
weak inhibition and low Hill slope value for this compound are most likely linked to 
its chemical reactivity. In addition, as mentioned earlier, interference with the assay 
setting at high concentration was observed with all the compounds tested, which 
could also partially account for the weak inhibition detected here. 
 
Table 4 pIC50 values and characteristics of inhibition of G9a by compounds 1, 3, 6 and SAH. Adapted from 
Cherblanc et al.129 
 1 3 6 SAH 
pIC50 ± SEM (n=5) 5.59 ± 0.18 4.97 ± 0.29 5.31 ± 0.10 5.98 ± 0.10* 
IC50 (µM) 2.6 10.6 4.9 1.0 
Hill Slope ± SEM -1.20 ± 0.17 -0.60 ± 0.09 -0.85 ± 0.12 -1.21 ± 0.08 
% Activity at 25 µM (n=4) 8 36 19 0‡ 
IC50 values were determined from the average of the pIC50 values obtained in each independent experiment (run as 
duplicates), n (number of independent experiments); *n=4 for SAH, ‡n=3 for SAH;  
 
These results and the subsequent data on G9a inhibition have been accepted 
for publication in the Journal of Medicinal Chemistry in October 2013.129 
 
Determination of IC50 values against SUV39H1 
 To corroborate the results obtained against G9a and for a direct comparison 
with the original literature report,74 chaetocin (1), methylthioether analogue 4 and 
ETP 6 were also assayed against SUV39H1. The inhibition curves are presented in 
Figure 34. 
 The inhibitory activity of chaetocin (1) was also confirmed against SUV39H1: 
it was found to have significant inhibitory potency (IC50 = 0.11 µM) on purified 
human SUV39H1 in excellent agreement with the data of Greiner et al. 
(IC50 = 0.8 µM) against dSU(VAR)3-9, the Drosophila orthologue of SUV39H1.74 
Similar to the observations against G9a, the methylthioether 4 was found to be 
inactive while the structurally simplified ETP 6 was found to have significant 
inhibitory activity (IC50 = 3.2 µM). 
 These results and the following data generated against SUV39H1 have been 
published in Nature Chemical Biology in March 2013.131 
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Figure 34 Inhibition curves for compound 1, 4 and 6 against SUV39H1. Adapted from Cherblanc et al.131 
The assay was run with H3 peptide (100 nM), SAM (40 µM) and SUV39H1 (50 nM), with 30 min pre-incubation 
time and 90 min reaction time. Data shown are collated data of n=3 independent experiments run as duplicates, the 
data shown is mean of replicates; error bars represent SEM. 
 
These data were in good agreement with our preliminary results against 
SUV39H1 and further confirmed that the disulfide bridge of chaetocin is required for 
its HKMT inhibitory activity, against both SUV39H1 and G9a. The simple ETP 
compound 6 confirmed its activity against both enzymes, highlighting the fact that the 
ETP core appears to be sufficient for inhibition of HKMTs. 
 
Mechanistic studies 
 Cognisant of the requirement of the disulfide moiety, we next sought to 
establish the mechanism of action by which chaetocin mediates its inhibitory activity 
against HKMTs. As aforementioned, a number of mechanisms have been suggested to 
underlie the biological activities of ETP-containing natural products (Figure 9). 
 
Reactive oxygen species generation test 
 ETP-containing compounds have been reported to generate reactive oxygen 
species (ROS) by redox cycling in presence of reducing agent (Figure 9B).132,133 We 
therefore decided to assess the presence of ROS under our assay conditions (typically 
with 1 mM DTT in the buffer) by evaluating the presence of in situ generated 
H2O2.134 The protocol we used has been developed by Johnston et al. and it is a 
colorimetric assay which relies on the ability of the HRP enzyme to catalyse the 
oxidation of phenol red by hydrogen peroxide into an oxidised product which absorbs 
light at 610 nm (Figure 35).135  
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Figure 35 Assay principle for the detection of H2O2 production and detection via redox cycling 
 
 The data were normalised to the hydrogen peroxide control and IRC-083864 
(a quinone136 previously shown to undergo redox cycling137) was used as a positive 
control. As expected the quinone did lead to a strong absorbance signal, which was 
efficiently abolished by addition of catalase (also known as hydroperoxidases, 
enzymes which catalyse the decomposition of hydrogen peroxide to water and 
oxygen)138 (Figure 36). 
 
 
Figure 36 H2O2 generation test. Adapted from Cherblanc et al.129 
The assay was performed as described (see experimental section),134 and was run as duplicates, error bars represent 
SEM. Data were normalised to H2O2 control  
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No generation of H2O2 was detected at 10 or at 100 µM of chaetocin 
(Figure 36), which indicates that the in vitro inhibitory activity of chaetocin towards 
HKMTs is not dependent on the generation of ROS. 
 
Influence of pre-incubation time on inhibition 
Since cross-linking with cysteine residues is another mechanism of action 
proposed for ETP-containing natural products (Figure 9A), we reasoned that such 
effect would most likely be dependent on the pre-incubation time allowed to the 
compound to react with the enzyme. 
It was thus decided to check whether chaetocin’s inhibition was time-
dependent or not. The IC50 of chaetocin was derived after various pre-incubation 
times and under different reducing conditions. Previously, Greiner et al. reported that 
the HKMT activity of chaetocin was not dependent on the presence of increasing 
concentrations of DTT,74 and we therefore felt it was important to further assess the 
influence of DTT on the supposed time-dependency.  
 
The time-dependency of G9a inhibition by chaetocin (1) was first assessed 
both in the presence and absence of DTT. Inhibition was measured after a variety of 
pre-incubation time-points (0, 5, 15, 30 min), where the enzyme and inhibitor had 
been pre-mixed (Figure 37). Inhibition by SAH and ETP 6 was also measured at 
0 min and 30 min pre-incubation, with and without DTT, as controls. 
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Figure 37 Influence of pre-incubation on the inhibitory activity of chaetocin (1), ETP 6 and SAH against G9a. 
Adapted from Cherblanc et al.129 
a) and b) the effect on chaetocin (1) potency with 5, 15, 30 min or without pre-incubation time before measuring 
G9a activity inclusive and exclusive of DTT (1 mM in the buffer); c) the effect of pre-incubation of SAH or d) 
compound 6 with G9a, at 0 or 30 min pre-incubation, inclusive and exclusive of DTT. Collated data from n=3 
independent experiments run as duplicates, the activity was normalised to DMSO control and the data shown is 
mean of replicates and error bars represents SEM.  
 
 Strikingly, the potency of chaetocin significantly increased with longer 
pre-incubation with G9a, displaying only weak inhibition when the substrate was 
added to the enzyme prior to the inhibitor (i.e. at 0 min pre-incubation). The 
difference in pIC50 values for chaetocin between 0 and 30 min of pre-incubation time 
was found to be statistically significant, with and without DTT (Table 5). ETP 6 
showed analogous behaviour with little inhibition detected without pre-incubation, 
with and without DTT (Figure 37d). Notably, SAH did not exhibit such behaviour 
(Figure 37c). 
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Interestingly, the presence of DTT as a reducing agent did not have a 
statistically significant influence on the HKMT inhibitory activity of chaetocin, which 
corroborates the initial report by Greiner et al..74  
 
Table 5 Time dependency effect of chaetocin on pIC50 values against G9a with (A) and without DTT (B). Adapted 
from Cherblanc et al.129 
Table A With DTT 
Pre-incubation time 0 min 5 min 15 min 30 min 
pIC50 (n=3) ± SEM 4.43 ± 0.34 4.90 ± 0.05 5.22 ± 0.05 5.45 ± 0.07 
IC50 (µM) 37.2 12.7 6.1 3.5 
Difference in pIC50 
with 0 min 
__ 0.29 (ns) 0.60 (*) 0.81 (**) 
 
Table B Without reducing agent 
Pre-incubation time 0 min 5 min 15 min 30 min 
pIC50 (n=3) ± SEM 4.71 ± 0.15 5.21 ± 0.11 5.63 ± 0.06 5.84 ± 0.08 
IC50 (µM) 19.5 6.2 2.3 1.5 
Difference in pIC50 
with 0 min 
__ 0.60 (**) 0.97 (***) 1.19 (***) 
pIC50 values were derived for 0, 5, 15 and 30 min pre-incubation and are average of n=3 independent experiments 
run as duplicates. P values were calculated by one-way ANOVA followed by Bonferroni's multiple comparison 
test. ***: P < 0.001 (Extremely significant), **: 0.001 < P < 0.01 (Very significant), *: 0.01 < P < 0.05 
(Significant), ns: P > 0.05 (Not significant). 
 
 The time dependency of chaetocin inhibition was also assessed against 
SUV39H1 (Figure 38). In the presence of DTT, no time dependency could be 
observed while there was a slight increase in potency with longer pre-incubation time 
in the absence of reducing agent. 
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Figure 38 Influence of chaetocin pre-incubation on SUV39H1 activity. Adapted from Cherblanc et al.131 
The effect on chaetocin (1) potency with 5, 15, 30 min or without pre-incubation time before measuring G9a 
activity a) inclusive and b) exclusive of DTT (1 mM in the buffer); Collated data from n=3 independent 
experiments run as duplicates, the activity was normalised to DMSO control and the data shown is mean of 
replicates and error bars represents SEM.  
 
Table 6 Time dependency effect of chaetocin on pIC50 values against SUV39H1 without reducing agent 
 Without reducing agent 
Pre-incubation time 0 min 5 min 15 min 30 min 
pIC50 (n=3) ± SEM 6.33 ± 0.14 6.74 ± 0.08 6.86 ± 0.02 6.96 ± 0.05 
IC50 (µM) 0.45 0.18 0.14 0.11 
Difference in pIC50 
with 0 min 
__ 0.41 (ns) 0.54 (*) 0.63 (*) 
pIC50 values were derived for 0, 5, 15 and 30 min pre-incubation and are average of n=3 independent experiments 
run as duplicates. P values were calculated by one-way ANOVA followed by Bonferroni's multiple comparison 
test. ***: P < 0.001 (Extremely significant), **: 0.001 < P < 0.01 (Very significant), *: 0.01 < P < 0.05 
(Significant), ns: P > 0.05 (Not significant). 
 
 Although more apparent in the case of G9a than SUV39H1, chaetocin’s 
inhibitory activity was found to be increased with longer pre-incubation times, which 
is consistent with the cross-linking mechanism. Moreover, this effect appeared to be 
intensified in absence of reducing agent. 
 
Reversibility of chaetocin’s inhibition 
Since the activity of chaetocin was found to be dependent on the presence of 
the chemically reactive disulfide ETP bridge and exhibited time dependence, we next 
wanted to assess whether such inhibitory effects were reversible. A “dilution test”139 
was used to assess the reversibility of G9a inhibition by chaetocin. In this test, G9a, at 
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100-fold over the typical assay concentration, was incubated for 30 minutes with the 
inhibitor, at a concentration of 10-fold the IC50. The mixture was then diluted 
100-fold into the reaction buffer containing the substrates. At this final dilution, the 
concentration of the enzyme has returned to the standard assay concentration, and the 
concentration of the inhibitor is 10 times lower than the IC50 (which should 
correspond to only 9% inhibition). For reversible inhibition, the enzyme should 
recover its activity. Controls experiments were run with the compound at 0.1 times 
the respective IC50 without dilution to illustrate that no significant inhibition is 
expected at this concentration. 
In the presence of the reducing agent DTT, the inhibition by chaetocin (1) was 
reversible (Figure 39a), with G9a activity fully recovered. In the absence of such a 
reducing agent however, G9a did not recover its activity, which is strongly suggestive 
of irreversible inhibition under these conditions. ETP 6 displayed analogous 
behaviour with the reversibility of its inhibition being dependent on the presence of 
DTT (Figure 39c). As control, SAH inhibition was found to be reversible with and 
without DTT (Figure 39b). These data clearly show that the reversibility of G9a 
inhibition for ETP-containing compounds is different depending on the assay 
conditions. The fact that a reducing agent is able to impact the reversibility suggests 
that the bonding of the ETP compound to the enzyme is most likely via a mixed 
disulfide bridge (Figure 9A). 
 
Unfortunately, it has not been possible to assess the reversibility of the 
inhibition of SUV39H1 by chaetocin. The technical issue stemmed from the 
commercial enzyme, which is formulated in a buffer containing 3 mM of DTT. To 
assess the effect of DTT on the reversibility of chaetocin’s inhibition, it was first 
necessary to remove (or reduce) the amount of DTT present in the stock solution. 
Indeed, as the concentration of enzyme used for the reversibility test is initially 
100-fold higher than the concentration used to measure the IC50 (50 nM), the stock 
enzyme (5 µM) had to be used directly (no dilution into the buffer with and without 
DTT), and consequently the amount of DTT would not be negligible as it was the 
case for G9a. 
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Figure 39 Dilution test to assess the reversibility of inhibition of G9a, with and without DTT. Adapted from 
Cherblanc et al.129 
Data were normalised to DMSO controls. Experiments were run as duplicates. Data shown are mean values of n=3 
independent experiments, error bars represent SEM. Controls experiments were run with the compound at 0.1 
times the respective IC50 without dilution. 
 
Two techniques were attempted to remove DTT. First the ZipTip technology 
was used: commercially available pipette tips with bed of chromatography media 
fixed at its end which are commonly used for concentrating and purifying samples, 
including desalting. The second technique attempted was through the use of a dialysis 
membrane. Unfortunately, both techniques led to the deactivation of the enzyme. Is it 
unclear whether the absence of DTT was responsible for this deactivation or whether 
the enzyme was simply not stable to these processes. 
 
Enzyme concentration dependence for SUV39H1 
In order to reduce the concentration of DTT for the reversibility test, we also 
attempted to reduce the enzyme concentration while increasing the cofactor SAM 
concentration to obtain a suitably high signal. Although it was not possible to 
decrease SUV39H1 concentration enough for the reversibility assay, it was noticed 
that the IC50 value appeared to be dependent on the enzyme concentration. The IC50 of 
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chaetocin was thus measured at a high (50 nM) and low (5 nM) concentration with a 
high concentration of SAM (4 mM) to increase the rate of the methylation reaction 
(Figure 40). A long reaction time (4.5 h) was required for the low enzyme 
concentration in order to obtain an acceptable signal. 
 
 
Figure 40 Influence of enzyme concentration on chaetocin’s inhibition of SUV39H1. Adapted from Cherblanc et 
al.131 
The assay was run with SAM at a concentration of 4 mM and SUV39H1 at 5 or 50 nM. Collated data of n=4 
independent experiments, run in duplicates, the data shown is mean of replicates and error bars represent SEM.  
 
 A slight increase (2.4-fold) in potency was observed with the lower enzyme 
concentration compared to the higher one (IC50 of 0.34 µM for 50 nM SUV39H1 and 
0.14 µM for 5 nM, statistically significant by t-test). This effect was not consistently 
observed in the case of G9a. 
 This type of behaviour was reported to be characteristic of a specific type of 
promiscuous inhibitors:140 it was proposed that the actual active form of these 
promiscuous inhibitors might be an aggregate of many individual molecules. 
However, it was reported that the use of detergent would abolish the aggregate 
formation process and lead to a drop in the inhibitor potency.141 The detergent 
Tween20 has been used throughout the studies on SUV39H1 hence it is unlikely that 
aggregate formation is responsible for the behaviour observed. It is therefore likely 
that this observation results from the nonspecific inhibition of the enzyme by 
chaetocin. 
 
Competition test with SAM 
 While taken together our data were suggesting that the interaction of chaetocin 
with the two HKMTs under investigation was not a conventional inhibition (e.g. time-
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dependency, irreversibility under non-reducing conditions), Greiner et al. reported 
however that chaetocin was competitive with the cofactor SAM. This implied a well-
defined binding into the cofactor pocket and was not consistent with our emerging 
data. It was thus decided to first assess the influence of SAM concentration on 
chaetocin inhibitory activity against SUV39H1, at high (4 mM) versus usual (40 µM) 
SAM concentration. As shown (Figure 41), increasing the amount of SAM 100-fold 
did not influence chaetocin’s inhibition. 
 
 
Figure 41 Inhibition curve of chaetocin against SUV39H1 at high and low SAM concentration. . Adapted from 
Cherblanc et al.131 
The assay was run with SUV39H1 (50 nM) and SAM (40 µM or 4 mM). The data shown are collated data from 
n=3 independent experiments, run as duplicates. Shown as the mean of replicates and error bars represent SEM. 
 
 To further validate this piece of data, pIC50 values were then derived at a wide 
range of SAM concentrations against both SUV39H1 and G9a. The pIC50 values 
obtained were then plotted against [SAM]/KM (Figure 42) as this has been reported 
recently to assess SAM-competition.81  
 
 For both SUV39H1 and G9a, there was no variation in pIC50 values when 
SAM concentration was varied and this was further confirmed by linear regression 
(Figure 42, slope equivalent to zero). These data strongly indicate that chaetocin is not 
acting in a competitive manner with SAM for the inhibition of both enzymes. 
Statistical analysis of the pIC50 values (by one-way ANOVA followed by 
Bonferroni’s test) also showed that the difference between them was not statistically 
significant. 
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Figure 42 Influence of SAM concentration on pIC50 values against a) SUV39H1 and b) G9a. . Adapted from 
Cherblanc et al.129,131 
a: The pIC50 values were derived from 4-point curves at chosen concentrations around the IC50 region (0.2 – 
0.05 µM), SAM concentration ranged from 800 µM to 6 µM, the data represent the averaged pIC50 values of the 
n=6 independent experiments run as duplicates, the error bars represent SEM. 
b: The pIC50 values were derived from 6-point curves (32 – 0.03 µM) , SAM concentration ranged from 160 µM to 
10 µM, the data represent the averaged pIC50 values of the n=3 independent experiments run as duplicates, the 
error bar represents SEM.  
For a) and b), the line corresponds to the linear regression of the data points. 
 
 
 Additionally, pIC50 values for the ETP compound 6 were also derived against 
G9a at high and low SAM concentrations (Figure 43) and as for chaetocin, there was 
no significant difference between the two values (difference of the means: 0.07 µM), 
as assessed by t-test. 
 
Figure 43 Influence of SAM concentration on ETP compound 6 pIC50 values against G9a  
The pIC50 values were derived from 6-point curves (100 – 0.1 µM) , SAM concentration of 160 µM and 10 µM, 
the horizontal bars represent the averaged pIC50 values of the n=3 independent experiments run as duplicates, the 
error bar represents the SEM. Each data point corresponds to the averaged pIC50 value derived from one 
experiment run as duplicates. 
 
 It could be argued that the time-dependent and potentially covalent nature of 
the inhibition by chaetocin may mask the competition with the cofactor SAM. It 
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should be noted however that this experiment was run in the presence of DTT (1 mM 
in the assay buffer), conditions under which G9a inhibition by chaetocin is fully 
reversible (See Figure 39). Also, a constant pre-incubation time of 30 min was applied 
in each case to avoid time-dependent potency changes. Indeed, as shown in Figure 37 
and Table 5, an important (and statistically significant) improvement in IC50 against 
G9a was observed when one compares 0 or 5 to 30 min pre-incubation, but no 
significant change between 15 and 30 min. It can therefore be considered that at 
30 min steady-state phase has been reached. Also, at 30 min reaction time, it was 
shown that G9a has regained its full activity in the presence of DTT (Figure 39). 
Therefore even if the binding and dissociation were slow, there should have been 
sufficient time for SAM to displace chaetocin. Consequently, the absence of effect of 
SAM on chaetocin’s inhibition observed here is strongly supportive that the 
compound is not competitive with the cofactor. 
 
Denaturation test 
 The absence of competition with SAM was yet another indication that 
chaetocin did not display a conventional inhibitor behaviour and was most likely 
inhibiting the target HKMTs by nonspecific effects. A common mechanism of 
nonspecific inhibition is protein denaturation.140 ETP natural products have 
previously been reported to alter the folding of proteins by NMR spectroscopy and 
circular dichroism.142,143 We therefore decided to test biochemically whether 
chaetocin acts as denaturant by assessing its inhibitory potency in the presence of 
another denaturant, urea. This test relies on the idea that if a compound acts as 
denaturant, its potency should increase in the presence of another one, here, urea.140 
Urea was titrated to determine the optimal concentration at which G9a still displays 
acceptable enzymatic activity (Figure 44) and a concentration of 0.7 M was chosen 
for the denaturation test.  
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Figure 44 Urea titration against G9a. Adapted from Cherblanc et al.129 
Urea was used in the concentration range: 0.29 – 5 M, the assay was run as single points. 
 
The inhibitory potency of chaetocin was found to be (statistically) 
significantly increased in the presence of urea, while this was not observed for SAH 
(Figure 45, Table 7). This indicates that chaetocin inhibits G9a at least partially by 
nonspecific denaturation. It should be noted that these data were generated in 
presence of DTT as the signal obtained in the absence of DTT and in the presence of 
urea was highly variable, most likely due to poor stability of the enzyme under these 
conditions. 
 
 
 
Figure 45 Influence of urea on chaetocin (a) or SAH (b) inhibition of G9a. Adapted from Cherblanc et al.129 
The assay was run in the presence of urea (0.7 M) and DTT (1 mM). The data shown are collated data of n=3 
independent experiments, run as duplicates, and error bars represent SEM. 
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Table 7 pIC50 values against G9a with and without urea. Adapted from Cherblanc et al.129 
Compound pIC50 With Urea  pIC50 Without Urea  P value Summary 
Chaetocin 6.248 ± 0.06 5.970 ± 0.04 0.0061 ** 
SAH 5.721 ± 0.16 5.481 ± 0.03 0.2920 ns 
Mean pIC50 values are reported as average of the pIC50 derived for n=3 independent experiments, run in duplicate 
(±SEM). P values were determined by paired t-test.**: P value < 0.01, ns: not statistically significant 
 
Mass spectrometry studies  
 To further validate the results obtained in the reversibility studies, we decided 
to obtain mass spectrometry data to verify whether chaetocin was forming a covalent 
adduct with G9a. A denaturing mass spectrometry experiment was first run by 
Dr. Marina Demetriades in Prof. Christopher Schofield lab (University of Oxford). To 
assess the influence of the reducing agent (as observed in the reversibility test), the 
mass spectrometry experiment was run in presence and absence of DTT (Figure 46). 
G9a and chaetocin were mixed and pre-incubated for 30 min (bottom panels) or not 
pre-incubated (top panels) and the mixture was denatured by treatment with formic 
acid just prior to ESI-MS analysis. 
In the absence of reducing agent, an adduct of mass closely matching G9a–
chaetocin was detected, with and without the 30 min pre-incubation time (right panels, 
Figure 46). Importantly, in the presence of DTT, such adduct was not observed, (left 
panels, Figure 46) which strongly suggests that chaetocin binds to G9a via mixed 
disulfide linkage, in agreement with the reversibility studies. 
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Figure 46 Binding of chaetocin to G9a with and without DTT under denaturing conditions 
Deconvoluted MS spectra of G9a (1 eq.) with chaetocin (2 eq.) and with a-b) DTT (10 eq.), c-d) no reducing agent 
under denaturing conditions at 60 V cone voltage without incubation (top panels) and after 30 min incubation 
(bottom panels). Peaks correspond A: G9a, B: G9a–Chaetocin 
 
Further validation of these data was obtained by Dr. Peter DiMaggio and 
Aaron Borg (Department of Chemical Engineering, Imperial College London). An 
elegant strategy was designed to identify the residues involved in disulfide bonding 
with chaetocin. The assay principle is depicted in Figure 47. G9a was incubated with 
chaetocin for 30 min and was then denatured by treatment with guanidine 
hydrochloride, followed by labelling of the cysteine residues not involved in bonding 
with chaetocin with N-ethylmaleimide. Treatment with DTT lead to the reduction of 
the disulfide bridges (mixed (between G9a and chaetocin) or native) and the released 
cysteine residues were labelled with iodoacetamide. The sample was then digested 
and the peptides analysed by LC-MS/MS and compared to untreated control samples. 
 	  
91	  
	  
	   	  
 
Figure 47 Principle of the mass spectrometry experiment designed to identify the cysteine residues involved in 
disulfide linkage with chaetocin 
 
Out of the 12 quantitated cysteine residues in G9A (913-1193), five exhibited a 
greater than 2-fold change in carbamidomethyl (from iodoacetamide treatment) 
labelling upon chaetocin treatment (Figure 48): Cys994 (4.8 fold increase), Cys1017, 
Cys1021 and Cys1023 (3.1 fold increase) and Cys1115 (2.1 fold increase).  
 
 The cysteine residues involved in disulfide linkage with chaetocin have been 
highlighted in red in Figure 49. It is apparent that only one of the cysteine residues 
involved in bonding with chaetocin is actually present in the active site of G9a 
(Cys1115) and it is the least significant change (2.1-fold). Notably, the other cysteine 
residues are not in the active site of G9a but in the pre-SET domain and are believed 
to coordinate structural zinc ions. 
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Figure 48 G9A (913-1193) sequence highlighting cysteine residues involved in chaetocin binding. Taken from 
Cherblanc et al.129 
All 20 cysteine residues are highlighted in boldface, and those cysteine residues involved in the formation of 
disulfide bonds with chaetocin are scaled according to their fold increase in carbamidomethyl labelling upon 
chaetocin treatment (the numbers above these residues represent the fold change observed relative to control). 
Singly and doubly underlined sequences indicate identified and quantitated peptides from the LC-MS/MS data, 
respectively. Shaded sequences highlight the SET domain, which is flanked on the left by the pre-SET domain and 
on the right by the post-SET domain. The arrows and twists represent β sheet and α helical secondary structural 
elements, respectively, as identified by RSCB PDB accession number 2O8J. 
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Figure 49 Cysteine residues of G9a involved in bonding with chaetocin. 
Generated from the pdb structure 2O8J (G9a co-crystallised with SAH); the 5 cysteine residues identified by MS 
experiment are labelled and coloured in red. The grey balls represent zinc ions. 
 
 This data demonstrated that several cysteine residues reacted with chaetocin to 
form mixed disulfides. This clearly illustrated that chaetocin does not bind to a 
defined site of G9a and further confirmed that the interaction between the compound 
and the protein is nonspecific. 
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Conclusions 
 
Importance of the disulfide moiety for HKMT inhibition 
 Measuring the inhibitory activity of chaetocin and its structurally important 
analogues clearly shed light onto the requirement of the disulfide bridge of ETP 
compounds for their HKMT inhibitory activity, in definite opposition with the 
hypothesis postulated by Greiner et al..74 In particular, the structurally simple ETP-
containing molecule 6 retained substantial inhibitory activity, while the unreactive 
thioether derivative 4 displayed no activity whatsoever. As aforementioned, Sodeoka 
and co-workers have performed the first total synthesis of chaetocin (1), its unnatural 
enantiomer (ent-1) as well as sulfur-free analogues (5 and ent-5).84,104 Their synthetic 
chaetocin sample had similar inhibitory potency against G9a to the one we measured 
(IC50 of 2.4 and 1.7 µM for chaetocin and ent-chaetocin respectively). More 
importantly, the sulfur-free analogues, 5 and ent-5, were found to be totally inactive. 
These data are in very good agreement with our results on the requirement of the 
disulfide bridges for HKMT inhibition. 
The attempts described here toward the development of a SAR around 
chaetocin structure led us to uncover a structure–reactivity relationship as proposed 
by Rishton,144 whereby the activity observed is actually only a reflection of the 
reactivity of the compound evaluated toward the target. Here, the unreactive thioether 
(or the sulfur-free analogue synthesised by Sodeoka and co-workers) does not display 
any inhibitory activity while chaetocin, bearing the reactive disulfide linkage, does. 
This absence of SAR in a series of analogues from an original hit identified by HTS 
usually reflects that this series is not fit-for-purpose in terms of further development 
from a drug discovery perspective.145 Consequently, chaetocin is not a suitable 
starting point for the discovery of a specific HKMT inhibitor. 
 
Mechanism of action 
Having established that the inhibitory activity of chaetocin was entirely 
dependent on the reactive ETP disulfide, we next sought to identify the molecular 
mechanisms responsible for the inhibitory effect of this class of molecules.  
Firstly, the biological activities of ETP compounds have been reported to rely 
on their ability to redox cycle and generate reactive oxygen species (ROS).85 Since 
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the generation of H2O2 under the assay conditions was not observed, we considered 
that this mechanism is unlikely to account for the HKMT inhibitory activity of ETP 
compounds in our cell free system. 
Secondly, another mechanism proposed for inhibition by ETP compounds is 
cross linking with cysteine residues, potentially followed by formation of internal 
disulfide bridge.94,146 The time-dependent nature of the HKMT inhibition gave the 
first hint of such a mechanism. In particular, the time-dependency was accentuated in 
absence of reducing agent (here DTT). The reversibility test corroborated nicely this 
observation. Indeed, the inhibition of G9a by ETP-containing compounds (chaetocin 
(1) or ETP compound 6) was clearly irreversible in absence of reducing agent while 
fully reversible in presence of DTT. These biochemical observations suggested that 
cross-linking between the ETP functionality and the HKMT via a disulfide linkage 
(which can be reduced in presence of DTT) was central to the inhibition mechanism. 
Thirdly, the mass spectrometric data, obtained by an orthogonal approach, 
further validated the biochemical conclusions. We first identified an adduct formation 
between chaetocin and G9a in the absence of reducing agent, while such adduct could 
not be observed in the presence of DTT, once again pointing at a disulfide linkage. 
Furthermore, by in depth LC-MS/MS analysis, we identified the cysteine residues 
involved in such bonding. Importantly, this data shows that more than one cysteine 
residues are involved in disulfide bond formation upon chaetocin treatment. It is 
therefore apparent that chaetocin does not exhibit specificity towards a single cysteine 
residue, which would be expected for a targeted covalent inhibitor.147 Additionally, 
our SAM competition studies are in opposition with the conclusions of Greiner et al. 
who suggested that chaetocin binds to the co-factor binding cleft.74 Our biochemical 
and mass spectrometric data refute such competitive binding and, in conjunction with 
literature data, strongly suggest that chaetocin does not bind to a defined pocket. 
Indeed, the fact that a structurally simple ETP compound 6 is able to significantly 
inhibit HKMT activity, not only supports the critical role of the ETP core for 
inhibition, but also suggests much of the rest of the complex structure of chaetocin to 
be superfluous. In addition to this, Sodeoka and co-workers showed that the two 
enantiomers of chaetocin they prepared inhibited the target equally effectively,104 
which clearly exposes the fact that the three dimensional structure of chaetocin is not 
involved in the binding to the HKMT target. On top of this, a number of structurally 
unrelated ETP compounds (including gliotoxin, chetomin and 
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11,11’-dideoxyverticillin, Figure 8) were shown to also inhibit G9a.148,149 In 
combination, these results clearly show that the framework and three dimensional 
structure of chaetocin (or of any ETP compounds) are not essential for binding or 
inhibitory activity, the reactive disulfide bridge is the only required moiety. This 
prevents chaetocin from being classed as a targeted covalent inhibitor. Indeed, for a 
covalent inhibitor to be viable from a drug development perspective, the reactivity of 
the compound needs to be accompanied by specific shape complementarity with the 
biological target:147 a variety of interactions between target and inhibitor (like with 
the more conventional reversible inhibitor) needs to precede the covalent attachment. 
In the case of ETP-containing compounds, this does not appear to be the case: our 
mass spectrometry experiment revealed that five different cysteine residues reacted 
with chaetocin. Furthermore, in opposition with other natural products containing 
electrophilic moieties,150 the disulfide bridge of the ETP compound seems too 
reactive to be tuned towards HKMT selectivity: our data and that of other groups 
clearly show that upon modification of the disulfide bridge, all biological activity is 
abolished, which also points out the absence of binding interactions. 
Finally, protein denaturation by ETPs has been observed previously by a 
number of techniques including circular dichroism and NMR studies.142,143 The 
increased inhibitory activity of chaetocin observed in the presence of urea is also 
supportive that broad nonspecific protein denaturation is at least in part responsible 
for the observed inhibitory activity of ETP compounds. The adduct formation process, 
as identified by mass spectrometry, is likely to be responsible for the protein 
denaturation over time. 
 
Observed HKMT selectivity 
Our MS data showed that cysteine 994, 1017, 1021 and 1023 exhibit the 
largest reactivity towards chaetocin. These residues are located in the pre-SET 
domain of G9a and have been shown to be implicated in the binding of zinc atoms, 
which is thought to have a structural function in stabilising the SET domain.151  
Interestingly, we observed some adduct formation with cysteine 1115, which 
is part of a highly conserved region in the SET domain. This region is involved in 
hydrogen bonding interactions with SAM and adduct formation with this cysteine 
may have some direct inhibitory effect.151 While specific interaction with this cysteine 
residue would yield a promising covalent inhibitor, it has to be pointed out that only a 
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2.1-fold increase in labelling was observed at this residue, which is not as significant 
as for the other cysteine residues (3.1 and 4.8-fold). In addition, we did not observe 
any increased labelling at any of the other SET domain cysteine residues. This, 
together with the competition studies showing that chaetocin is not competitive with 
SAM, suggest that bonding with this cysteine is probably not the most significant 
interaction of chaetocin with G9a. 
 
Based on our MS data, we propose that the sensitivity of a given HKMT to 
chaetocin’s inhibition is related to the presence of a cysteine rich pre-SET and 
possibly post-SET domain (although we observe no binding of chaetocin to the post-
SET domain in G9a), through mixed disulfide formation with the ETP functionality. 
Notably, the three conserved cysteine residues in the post-SET domain within DIM5 
have been shown to be essential for HKMT activity.152 Indeed, while Greiner et al. 
claimed that chaetocin was selective for HKMT in the SUV39 family, namely 
dSU(VAR)3-9, SUV39H1, G9a, DIM5,74 our data suggests instead that the apparent 
selectivity is solely related to the presence of a pre-SET (and potentially post-SET) 
domain containing conserved cysteine clusters coordinating zinc ions.63 Importantly, 
SET7/9 and PR-SET7, which do no have any cysteine clusters, were not inhibited by 
chaetocin. The Drosophila enhancer-of-zest (dE(z)) complex was not targeted by 
chaetocin,74 although it has a pre-SET domain (with ~15 cysteine residues), but no 
post-SET domain. We also assayed chaetocin against the human orthologue EZH2 (in 
the assay kit described in chapter IV) and discovered that the natural product could 
also inhibit this enzyme (80% inhibition at 20 µM). Both dE(z) and EZH2 are active 
methyltransferases only as part of the Polycomb complex and as such can be causing 
difficulties in biochemical assays (e.g. purification, complex reconstitution).39,153 We 
believe that Greiner’s result on dE(z) should be interpreted with caution in light of the 
discrepancy with our results against EZH2. The reliability on the presence of a 
cysteine rich domain for ETP inhibition was again recently supported as gliotoxin and 
other ETP natural products have been reported to have a similar effect, inhibiting G9a 
and SU(VAR)3-9 but not SET7/9.148,149 Therefore instead of a protein binding site 
conferring an authentic HKMT selectivity to chaetocin, we believe any apparent in 
vitro selectivity is related to a given protein’s sensitivity to the ETP reactive disulfide, 
most likely concurrent with the presence of accessible cysteine residues.  
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Furthermore, ETP compounds have been shown to target numerous 
structurally, functionally, and evolutionary unrelated enzymes.84,85 This could have 
appeared as an early hint of non-specific effects. For example, chaetocin has already 
been shown to inhibit thioredoxin reductase by acting as a competitive substrate,95 
and also to disrupt the binding of p300 to hypoxia-inducible factor-1α (HIF-1α).93 In 
the case of gliotoxin, the most studied member of the ETP family, the list of 
biological effects and identified targets is extraordinarily long. Waring et al. 
previously reviewed this area 16 years ago and various new activities have been 
identified since then, including inhibition of G9a and inactivation of muscle creatine 
kinase.92,94,149 Notably, most of the studies looking at various ETP compounds show 
that they share the same targets, with very little (if any) selectivity, as exemplified by 
the disruption of the binding of p300 to HIF-1α which is efficiently achieved by 
chetomin, chaetocin, gliotoxin and a wide range of small synthetic ETPs.93,143 This, in 
addition to the data aforementioned, stresses the fact that it is highly unlikely that the 
ETP-containing compounds bind in a specific way to their biological target. 
 
Toxicity and epigenetic cell-based assay of ETP-containing compounds  
With this in mind, cellular evaluation of the effects of ETP compound appears 
highly challenging. Nevertheless, the effect of chaetocin on histone methylation in 
cells has been observed in several studies.74,154-156 Although one plausible explanation 
for this result is indeed direct inhibitory effects on HKMTs, an alternative possibility 
is that the observations are a result of the toxicity of ETP-containing molecules,85 
together with their important off-target effects. The complex effect of compound 
treatment on histone methylation may instead be an indirect readout of on-going cell 
death. In particular, the release of histones from nucleosomes during apoptosis is well 
established,157 and a variety of changes in histone modifications have been observed 
during the apoptotic process.158 These general effects on histones during apoptosis 
make it difficult to separate histone changes due to HKMT inhibition from changes 
due to cell death effects. In addition, the concentrations used in cell-based assay of 
ETP-containing compounds are much lower (50 – 200 nM) due to cytotoxicity than 
the IC50 values derived from biochemical assays (0.5 – 3 µM) which is highly unusual 
and strongly suggests that the effects observed in cells are inconsistent with inhibition 
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of the target enzyme and are probably mediated by other mechanisms, most likely 
unspecific apoptosis-related effects.139 
 
Final remarks on chaetocin and ETP-containing compounds 
Structurally diverse inhibitors are critically needed to improve medicinally 
relevant chemical space, and HTS remains one of the most efficient ways to identify a 
new molecular starting point. Nevertheless, the drug discovery community and 
particularly academia should be more thorough in the validation of hits against new 
targets. Mechanism of action as well as basic SAR studies should be routinely 
performed to assess the authenticity of a new inhibitor to ensure that only fit-for-
purpose molecules are used in further biological testing. Indeed, the use of chaetocin 
as a specific and selective H3K9-methylase inhibitor in a cell-based assay is highly 
arguable in light of all the other enzymes it targets and its known reactivity. We 
strongly believe that chaetocin has no potential to be developed into a selective 
HKMT inhibitor. 
 However, it is possible than ETP compounds find applicability in a non target-
selective approach. In particular, chaetocin was shown to induce apoptosis selectively 
in myeloma and leukaemia cell lines via imposition of oxidative stress, to which they 
are more sensitive than normal cell lines.132,133 Chaetocin was later shown to produce 
oxidative damage in myeloma cells by inhibiting the antioxidant enzyme thioredoxin 
reductase,95 by acting as a competitive substrate. Further studies will hopefully reveal 
if chaetocin or a related ETP-containing compound has the potential to be developed 
into an anti-myeloma or leukaemia therapeutic. 
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Chapter III 
 
Stereochemistry of ETP 
desulfurisation 
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Introduction 
 
It is crucial to know the stereochemistry of compounds used for biological 
applications, as enantiomers can sometimes display strongly different activities. Since 
natural biomolecules (e.g. enzymes) are chiral, the two enantiomers of a molecule will 
interact differently with a given target.159 In most cases, only one of the enantiomers 
displays the desired biological effect while the opposite enantiomer may be inactive 
or even responsible for adverse effects, as illustrated by the unfortunate example of 
thalidomide.160 
As outlined in Chapter II, analogues of the natural product chaetocin (1) have 
been prepared and biologically evaluated to characterise further the inhibitory activity 
of this class of compounds against HKMTs. Amongst these, monosulfide 3, obtained 
from desulfurisation of chaetocin (1), was a key analogue as it retains the bicyclic 
structure of the ETP core. Should the product be obtained with retention of 
configuration, monosulfide 3 would have a similar three-dimensional structure to that 
of the parent natural product. The stereochemistry of monosulfide 3 was however not 
straightforward to assign (Scheme 19). 
 
 
Scheme 19 
 
Since our various attempts at growing a crystal of analogue 3 suitable for 
X-ray diffraction were unsuccessful, we decided to carefully review stereochemical 
assignments for similar desulfurisation reactions in the literature. 
The desulfurisation of organic linear disulfides into the corresponding sulfides 
by treatment with phosphines has been reported as early as 1935,161 and a number of 
reagents have been proposed to mediate this transformation.162,163 Safe and Taylor 
reported the first example of desulfurisation of ETP-containing natural products in 
1969.110 In their work, dehydrogliotoxin (21) was converted to its monosulfide 
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counterpart (22) by treatment with triphenylphosphine (Scheme 20). Comparison of 
the electronic circular dichroism (ECD) spectra of the monosulfide derivative 22 and 
that of the parental natural product 21 suggested opposite stereochemistry.110,164 
Indeed, the sign of the Cotton effects of the desulfurised product’s ECD curve was 
opposite to those of the natural product.164 The reaction was thus reported to lead to 
inversion of stereochemistry at the bridgehead carbon atoms. 
 
 
Scheme 20 
 
 However, Sammes argued that the inversion of configuration was 
“mechanistically unfeasible”, and that the curves were not comparable,165 based on 
detailed circular dichroism studies performed on the natural product gliotoxin 
(Figure 8).166 In an ECD spectrum, each Cotton effect corresponds to the differential 
absorption of left- and right-polarised light by a given electronic transition of a 
chromophore. A chromophore is defined as a molecular moiety, responsible for one 
or more electronic transitions, associated with absorption bands in the UV-visible 
range (typically a functional group or a combination of several groups with a more or 
less extended π electron system).167 In the case of gliotoxin, it has been showed that 
the chromophoric disulfide moiety interferes with that of the diene, thus leading to a 
Cotton effect of the opposite sign to those found for similar diene system.166 
Importantly, the ECD curve of a sulfur-free analogue of gliotoxin did exhibit a Cotton 
effect of the expected sign for this type of diene, thus corroborating the proposed 
chromophore interaction theory. Sammes postulated that a similar scenario could be 
happening between dehydrogliotoxin and its monosulfide analogue: as the disulfide 
moiety is no longer present to interact with the other chromophores in the 
monosulfide derivative, it can be anticipated that an inversion of the sign of some 
Cotton effects could be observed without being related to a change in the product’s 
stereochemistry.165 Hence, the assignment of the stereochemistry of monosulfide 22 
may not be highly reliable. 
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 Sato and Hino, in subsequent studies on the reaction of a synthetic ETP 
derivative 23 with triphenylphosphine, observed monosulfide 24 en route to dimeric 
species for which they postulated an SN1-type mechanism (Scheme 21). This implied 
that the monosulfide should be obtained with retention of configuration at the 
bridgehead carbon atoms.168 
 
 
Scheme 21 
 
 The problem of the stereochemical course of this reaction appeared to have 
found its definite solution in 1979, when Ottenheijm and co-workers published a 
detailed study of the triphenylphosphine-mediated desulfurisation of a synthetic 
analogue of natural product gliotoxin 25 (Scheme 22).169  
 
 
Scheme 22 
 
The (R,R) ETP 25 was desulfurised to give the (S,S) monosulfide 26, with inversion at 
both stereocentres. The stereochemistry of the product was unambiguously assigned 
by X-ray diffraction using the anomalous dispersion of the sulfur atom.170 ECD 
curves of the desulfurised product and parental ETP were also found to have opposite 
signs of most Cotton effects.169 The authors therefore drew the conclusion that 
comparison of the ECD curves was actually a suitable way to determine relative 
stereochemistry. 
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 Nevertheless, a few years later, Barbier and co-workers reported their study on 
the stereochemical course of the desulfurisation of sirodesmin PL (27) into its 
monosulfide derivative 28 (Scheme 23). Based on chemical derivatisation evidence 
together with X-ray analysis of a diacetyl derivative, the authors showed that the 
reaction proceeded with retention of configuration.171  
 
 
Scheme 23 
 
Importantly, they also reported that the ECD curves of the natural product 27 
and its desulfurised derivative 28 exhibited Cotton effects of opposite signs although 
the reaction was found to proceed with retention of stereochemistry. They therefore 
warned against the correlative use of ECD data as an approach to determine the 
absolute configuration of the bridgehead carbon atoms in molecules with similar 
framework. 
 
 Three different mechanisms have been proposed to account for the observed 
stereochemistries.168,169,171 
 The first mechanism was proposed by Sato and Hino and is depicted in 
Scheme 24: nucleophilic attack of triphenylphosphine lead to the cleavage of the 
disulfide bond of ETP 29 to give phosphonium salt 30; the lone pair of the nitrogen of 
the diketopiperazine was then suggested to displace triphenylphosphine sulfide to 
give iminium 31, which then undergoes ring closing by nucleophilic attack of the 
thiolate onto the iminium to give monosulfide 32a with retention of 
stereochemistry.168 
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To account for the observed inversion of stereochemistry, Ottenheijm and 
co-workers suggested instead that phosphonium salt 30 is stable to elimination 
(Scheme 25), and that the thiolate centre can epimerise via ring opening of the 
diketopiperazine ring, conformational rearrangement and ring closing 
(30→33→33’→34), followed by SN2-type displacement of the triphenylphosphine 
sulfide leaving group by the thiolate to give monosulfide 32b with inversion of 
stereochemistry. 
 
 
Scheme 25 
 
Finally, Barbier and co-workers proposed a mechanism leading to retention of 
stereochemistry but invoking the participation of the substituent of the 
diketopiperazine ring in order to explain the discrepancies observed with 
Ottenheijm’s results.171 In particular, when the substituent is a hydroxymethyl like in 
sirodesmin PL (27, Scheme 26), it is plausible that the triphenylphosphine sulfide 
leaving group is displaced by the hydroxyl group via SN2-type displacement (35→36), 
followed by an additional SN2-type displacement of the oxirane by the thiolate anion 
(36→37). This double inversion mechanism would eventually result in net retention 
of stereochemistry. 
 
 
Scheme 26 
 
 In light of these conflicting results, it was not possible to assign the 
stereochemistry of chaetocin monosulfide 3 by analogy with known examples. As 
chaetocin presents a similar pendant alcohol as sirodesmin PL (27), it was expected 
that this natural product would most likely be desulfurised with retention of 
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configuration but we felt additional proof was needed. It was thus decided to record a 
variety of chiroptical spectra and to compare the experimentally obtained data with 
their simulated counterparts for the possible stereoisomers. 
 Chiroptical spectroscopy refers to the optical techniques using refraction, 
absorption or emission of anisotropic radiation that can be employed for identifying 
the relative and absolute stereochemistry of a substance. In this work, three different 
techniques have been used: optical rotation (at a fixed wavelength, here at 589 nm (D 
line of sodium), referred to as [α]D), electronic circular dichroism (ECD) and 
vibrational circular dichroism (VCD). Optical rotation and ECD have been used 
extensively for the determination of stereochemistry primarily via correlative 
approach, whereby the acquired spectra are compared to those of a related molecule 
of known stereochemistry. Examples of such correlative approaches based on ECD 
spectroscopy were outlined above and will be further discussed in this chapter. More 
recently, comparing experimental chiroptical spectra to ab initio simulations has 
become an increasingly common approach for the determination of absolute 
configuration and a number of examples have been recently reported.167,172-174 The 
increased computer power allowed for more advanced quantum chemical calculations 
and enhanced the reliability of the predicted spectra.172 Although the use of VCD in 
stereochemical assignment for natural products is less common, it is emerging as a 
highly useful technique.175 VCD is an extension of ECD to the infrared and near-
infrared regions of the spectrum where vibrational transitions occur within the ground 
electronic state of the molecule.172 This technique does not require the presence of a 
chromophore in the molecule, which represents a major advantage over ECD. In 
addition, VCD has the important benefit of addressing all 3N-6 vibrational modes (i.e. 
stretching, bending, scissoring, rocking and twisting, N=number of atoms: 3 degrees 
of freedom for each atom minus the displacements and rotations of the whole 
molecule), thereby offering more information-rich spectra (large number of bands), 
while ECD is based on the relatively few electronic transitions.176 
 The simulations of optical rotation, ECD and VCD spectra were carried out by 
Prof. Rzepa (Chemistry Department, Imperial College London) assisted by an 
undergraduate student, Ya-Pei Lo, using Gaussian 09.177 The simulated spectra were 
visually compared with the experimental data in terms of sign, magnitude and 
wavelength of the maxima. The VCD measurements were performed by the European 
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Centre for Chirality and, in addition to visual inspection, a mathematical algorithm 
was used to assess the adequacy of the manual stereochemical assignments in light of 
previous successful assignments (implemented in the CompareVOA program178).179 
This algorithm allowed us to establish a confidence level for the absolute 
configuration assignment made by visual interpretation. Briefly, a similarity measure 
Σ, expressing the degree of agreement between theory and experiment, is computed 
for both enantiomers and lies between 0 and 1. The enantiomeric similarity index Δ 
gives the difference between the values of Σ for both enantiomers of a given 
stereoisomer. Hence, Δ is a measure for the discriminative power of a VCD analysis 
and therefore a high quality VCD spectrum is characterised by a high absolute value 
of Δ. These quantities, Σ and Δ, are then compared to a database of previous 
successful assignments to calculate a confidence level. 
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Results and Discussion 
 
Chaetocin 
 
 As aforementioned, we needed to assign the absolute configuration of 
chaetocin monosulfide 3 and for this purpose we decided to use three different 
chiroptical techniques and to compare the experimental data to the simulated ones. 
Given chaetocin’s symmetry, there are three different diastereoisomers one could 
envisage after desulfurisation: one where both ETP centres (i.e. the stereochemistry at 
C11/C15 and C11’/C15’; see chaetocin numbering Scheme 19) had undergone 
retention (S,S S,S–structure 3a, Figure 50); one where one ETP centre had undergone 
retention and one inversion (R,R S,S–structure 3b, Figure 50) or one where both ETP 
centres had undergone inversion (R,R R,R–structure 3c, Figure 50). Desulfurisation of 
chaetocin could result in hybrid structure 3b if two mechanisms, one leading to 
inversion and one leading to retention of stereochemistry, were in competition. 
 We first started our investigation with optical rotation measurement and 
calculations. The measured optical rotation for analogue 3 was +484 (c 0.0039, 
CHCl3, 25 ˚C). The optical rotations for the three possible stereoisomers were 
calculated at the ωB97XD/6-311G(d,p) level of theory and were +467 for 3a, +357 
for 3b, and +259 for 3c. The predicted values showed a significant difference, which 
gave us confidence for an efficient assignment. In particular, the calculated value for 
3a was very close to the experimental measurement, which suggested the reaction had 
proceeded with retention of stereochemistry at the bridgehead carbon atoms. 
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Figure 50 Possible stereoisomers for chaetocin desulfurised analogue calculated using Gaussian 09177 at the 
ωB97XD/6-311++G(d,p) level of theory. Adapted from Cherblanc et al.180. 
 
To further confirm the assignment, we undertook the ECD studies of 
monosulfide 3. We first wanted to confirm the ability of the computational method to 
predict ECD spectra for the chaetocin framework, and we therefore simulated the 
ECD spectrum of the parental molecule 1 at the ωB97XD/6-311++G(d,p) level of 
theory. The simulated spectrum of chaetocin was in good agreement with the 
experimental spectrum with a similar pattern of Cotton effects (large positive (235 –
 240 nm), small negative (265 – 274 nm) then small positive (285 – 305 nm) 
(Figure 51). This analysis was in strong agreement with the established 
stereochemistry of the natural product and provided high confidence on the validity of 
our approach. 
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Figure 51 ECD spectra of chaetocin (1) 
Black line: experimental results for 1 in methanol (left y axis); Red line: calculated spectra (right y axis). The 
calculations were performed at ωB97XD/6-311++G(d,p) level of theory; the predicted curves were shifted by +20 
nm, convoluted line width 0.30 eV. 
 
The ECD spectra for monosulfide 3 were likewise computed at the 
ωB97XD/6-311++G(d,p) level of theory for the three possible stereoisomers and 
compared with the experimental ECD curve (Figure 52). The experimental ECD 
curve of chaetocin monosulfide 3 exhibited one negative (222 nm) then two positive 
(250, 305 nm) Cotton effects. The ECD curve of 3c displays a negative Cotton effect 
around 280 nm, in clear opposition with the experimental data. This diastereoisomer 
could thus be excluded with high confidence based on this observation. The ECD 
curve for 3b had a clear pattern of negative (222 nm), positive (246 nm), negative 
(272 nm), positive (289 nm) Cotton effects and therefore could be excluded with good 
confidence due to the presence of an additional negative Cotton effect not observed in 
the experimental spectrum. Finally, the predicted ECD curve for 3a had one negative 
(233 nm) followed by two positive (247, 288 nm) Cotton effects, in good agreement 
with the experimental data. 
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Figure 52 ECD spectra of chaetocin monosulfide 3. Adapted from Cherblanc et al.180 
Black line: experimental results for 3 in methanol (left y axis); Blue: calculated S,S S,S–structure 3a, Green: 
calculated R,R S,S–structure 3b, Red: calculated R,R R,R–structure 3c (right y axis); The calculations were 
performed at ωB97XD/6-311++G(d,p) level of theory; the predicted curves were shifted by +20 nm and 
convoluted with a line width 0.24 eV.  
 
The ECD analysis appeared consistent with the reaction proceeding with 
retention of ETP stereochemistry, in agreement with the conclusions drawn from the 
optical rotation study. 
 
Lastly, a VCD analysis was performed to further confirm our assignment. The 
experimental and theoretical IR and VCD spectra of chaetocin monosulfide 3 are 
shown in Figure 53 and Figure 54. Both IR and VCD spectra were recorded at the 
European Centre for Chirality and our collaborators also performed the detailed 
analysis described here.  
 
Simulated IR/VCD spectra are commonly scaled with a factor which usually 
lies between 0.96 and 1.00181 in a way that the simulated IR spectrum gives 
acceptable visual agreement with the experimental one. This was done for all three 
diastereoisomers separately and a decent agreement for the IR spectra is apparent for 
each one (Figure 53). 
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Figure 53 Comparison of the experimental IR spectra of compounds 3 (black) with calculated (ωB97XD/6-
311G(d,p)) spectra for 3a (blue), 3b (green) and 3c (red). Adapted from Cherblanc et al.180 
 
 
Figure 54 Comparison of the experimental VCD spectra of compounds 3 (black) with calculated (ωB97XD/6-
311G(d,p)) spectra for 3a (blue), 3b (green) and 3c (red). Adapted from Cherblanc et al.180 
 
Notably, the spectrum of 2a was the only one that reproduced the strong absorption at 
ν=1320 cm-1 (number 4). The simulated VCD spectra were scaled using the same 
scale factors determined for the IR spectra. Seven important peaks in the VCD 
spectrum, numbered 1–7 in Figure 53 and Figure 54 were correlated with peak in the 
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IR spectrum. Features 1 and 2 are not predicted for any of the three diastereoisomers. 
Only structure 3a shows a good prediction of the remaining features (3–7). A poor 
agreement is observed for 3b and 3c. Feature 6 for example is negative for 3b and 3c 
while it is positive in the experimental spectrum. Importantly, a mirror-image 
relationship (negative vs. positive features) is meaningless here as it would imply that 
the enantiomer of the predicted stereoisomer was obtained, which is obviously 
impossible since this would involve the unnatural stereochemistry of the chaetocin 
core at C2/C3 and C2’/C3’ (Scheme 19). Structure 3a clearly showed the most 
satisfactory agreement and the visual VCD analysis was therefore also supportive that 
desulfurisation occurred with retention of stereochemistry. We subsequently used the 
algorithm mentioned earlier to assess the quality of the manual assignment in light of 
previous successful assignments (Figure 55).179 The results of the analysis for 
compound 3a, 3b and 3c are shown in Table 8. For 3b and 3c, Δ was found negative 
which means that the enantiomeric form of 3b and 3c have a higher similarity score 
than respectively 3b and 3c. As mentioned above however, this is chemically 
impossible as it implies inversion of stereochemistry at C2/C3 and C2’/C3’, and 3b 
and 3c can thus be excluded. More importantly, the confidence level for the 
assignment for 3a is computed to be very high (94%) in comparison with previous 
successful assignment (Figure 55, Table 8). 
 
Table 8 Calculated quantities describing the similarity between calculated and experimental IR and VCD spectra. 
Molecule Optimal scaling factor IR similarity (%) 
Σ for best 
enantiomer Δ 
Confidence 
level (%) 
3a 0.966 84.9 59.4 39.8 94% 
3b 0.960 81.2 74.7 –57.1 99% 
3c 0.961 84.7 54.1 –12.9 50% 
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Figure 55 Positioning of 3a in the Compare VOA database of previous assignments.  
 
 Since VCD analysis was in agreement with optical rotation and ECD analysis, 
the stereochemistry of the monosulfide chaetocin 3 could thus be assign with high 
confidence to that of structure 3a, that is, retention of configuration of the bridgehead 
carbon atoms. This work has been published in Chemistry – A European Journal in 
September 2011.180 
This assignment was in agreement with that of the monosulfide analogue of 
Sirodesmin PL 28 (Scheme 23), which also bears a pendent alcohol on the ETP core 
that has been suggested by Barbier and co-workers to be involved in the mechanism 
leading to retention of configuration (Scheme 26). Dehydrogliotoxin 21 (Scheme 20) 
however did not seem to follow the same trend and we thus decided to reconsider its 
stereochemical assignment. 
 
 
Dehydrogliotoxin 
 
 Dehydrogliotoxin (21) has been reported to be desulfurised with inversion of 
configuration at the bridgehead carbon atoms to give the (S,S) monosulfide 22 
(Scheme 20). As mentioned above, this assignment was solely based on the 
observation that the ECD spectrum of the desulfurised product 22 was approximately 
the mirror-image of that of the parent ETP 21.164 As the use of this correlative 
approach for absolute configuration determination has been cautioned,165 we felt it 
was important to verify this assignment. The ECD spectrum of dehydrogliotoxin (21) 
was therefore simulated at the ωB97XD/6-311++G(d,p) level of theory and was 
compared to the reported experimental spectrum (Figure 56).164 The two spectra were 
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in good agreement, displaying a strong negative Cotton effect around 230 nm and a 
positive one near 275 – 280 nm, therefore corroborating the accepted (R,R) 
stereochemistry for ETP 21 and the ability of the computational method to efficiently 
predict the ECD curve for this framework. 
 
 
Figure 56 ECD spectra of dehydrogliotoxin (21) 
Black line: literature spectra of 21 in 1,4-dioxane164; Red line: calculated spectra calculated at the ωB97XD/6-
311++G(d,p) level of theory, scaled by 1.8 and shifted by +15 nm, convoluted with a line width 0.25 eV. 
 
The ECD spectrum of dethiodehydrogliotoxin (22), was then simulated at the 
ωB97XD/6-311++G(d,p) level of theory for the reported (S,S) stereochemistry but 
this time however, the spectrum did not match at all (Figure 57). Strikingly, the 
simulated spectra for (R,R)-dethiodehydrogliotoxin (mirror-image of the (S,S) 
stereoisomer) was in very good agreement with the reported literature spectra.164 Our 
data suggests that the assignment of stereochemistry by Safe and Taylor was therefore 
incorrect and in fact dethiodehydrogliotoxin (22) has the opposite stereochemistry 
(R,R) to that of structure 22 in Scheme 20 (i.e. ent-22). Consequently, the 
desulfurisation of dehydrogliotoxin (21) proceeded also with retention at both carbon 
centres, in opposition with Safe and Taylor conclusions.164 The origin of this 
erroneous assignment will be discussed later. This work was also included in our 
publication in Chemistry – A European journal.180 
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Figure 57 ECD spectra of dethiodehydrogliotoxin (22). Adapted from Cherblanc et al.180 
Black: literature spectra164 of 22 recorded in 1,4-dioxane; Red: calculated S,S-dethiodehydrogliotoxin (22); Blue: 
calculated R,R-dethiodehydrogliotoxin (ent-22). The calculations were done at ωB97XD/6-311++G(d,p) level of 
theory; scaled by 5 and shifted by +15 nm, convoluted with a line width 0.25 eV. 
 
 
Gliotoxin analogue 
 
At this stage, there remained only one example where ETP desulfurisation was 
reported to occur with inversion of configuration: the desulfurisation of synthetic 
gliotoxin analogue 25 into monosulfide 26, reported by Ottenheijm and co-workers 
(Scheme 22).169 As aforementioned, the stereochemical assignment of monosulfide 26 
was based on anomalous dispersion X-ray crystallography. Ottenheijm and co-
workers validated their stereochemistry assignment with a suitable R-factor test. This 
test is a simple and powerful approach that gives a measure of the agreement between 
the crystallographic model and the experimental X-ray diffraction data. 
Although Ottenheijm and co-workers reported a mechanistic scenario to 
support the apparent inversion of configuration (Scheme 25),169 we decided to 
computationally study the mechanistic course of this reaction, in collaboration with 
Prof. Henry Rzepa, by first calculating the energies along the retention pathways 
initially suggested by Sato and Hino (Figure 58, Scheme 24).164,168,177 
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Figure 58 Energy barriers (in kcal/mol) for the desulfurisation of gliotoxin analogue 25 along the pathway leading 
to retention of stereochemistry (Scheme 24). 
Indicated transition states and energy barriers were all located at the ωB97Xd/6-311G(d,p) level with inclusion of 
a continuum solvent model for THF (scale 1.5 cm = 4 kcal/mol). Triphenylphosphine or triphenylphosphine 
sulfide (SPPh3) were included in the energy calculation throughout. 
 
The initial bimolecular step involves nucleophilic attack of the 
triphenylphosphine on the β sulfur atoms of ETP 25 (TS1, Figure 58 and Scheme 27) 
with a calculated barrier ΔG298‡ of 19.6 kcal/mol relative to 25. Attack on the α sulfur 
atom has a higher barrier of 27.7 kcal/mol due to the hindrance from the methyl 
groups. Consequently, only attack of the β sulfur corresponds to a room temperature 
reaction. Importantly, this regiochemical outcome is corroborated by the experimental 
trapping of a key intermediate (Int2) by methanol and isolation of compound 38 
reported by Ottenheijm and co-workers (Scheme 27).169  
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The second unimolecular step via TS2 is the elimination of 
triphenylphosphine sulfide from Int1 to form the zwitterionic intermediate Int2. The 
barrier for elimination of Ph3PS from Int1 is predicted to be very low; 
ΔG298‡ = 2.2 kcal/mol (TS2) relative to Int1. This energy is much lower than the one 
for TS1 and hence this second step is not rate determining. At this stage, it is worth 
pointing out that the inversion mechanism proposed by Ottenheijm and co-workers 
involved ring opening of the diketopiperazine, bond rotation and subsequent ring 
closure, prior to elimination of Ph3PS (Scheme 25).169 The very low activation barrier 
for Ph3PS elimination from Int1 (2.2 kcal/mol) strongly suggests that this 
intermediate is highly transient and therefore the mechanism proposed by Ottenheijm 
appears extremely unlikely. Int2 itself is also computed to be 4.5 kcal/mol lower than 
Int1 (Figure 58). The mechanism then involves re-closure of the zwitterionic species 
Int2 to reform the sulfur bridge, with a barrier of 10.6 kcal/mol (TS3, Figure 58). 
Here again, the activation barrier is significantly lower in energy than the one leading 
to TS1. This suggests that, for this pathway, attack by triphenylphosphine (TS1) is 
rate determining, with the remainder of the pathway being energetically downhill.  
 The energy profile of this reaction sequence strongly suggests that 
desulfurisation of ETP compound 25 occurs with retention of configuration. The 
mechanism proposed by Ottenheijm and co-workers leading to highly stereospecific 
inversion of both stereogenic centres requires that PPh3S would be stable from 
elimination in Int1,169 which does not seem realistic in light of the calculated energies. 
 This computational study thus brought into further questioning the 
observations of Ottenheijm and co-workers. Consequently, we decided to prepare 
ETP 25 and to investigate its desulfurisation in our own hands. Racemic ETP 25 was 
prepared in seven steps from commercially available material. Indolenine 39 was 
prepared following literature procedure (Scheme 28):182 Addition of iPrMgCl to 
diethyl oxalate gave the product of monoalkylation 40 in high yield (90%). This was 
condensed with phenyl hydrazine to afford arylhydrazone 41 in good yield (77%), 
which was then cyclised by refluxing in ethanolic HCl to give the desired indolenine 
39 in good yield (67%) in a Fischer-type reaction. 
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Scheme 28183 
 
Indolenine 39 was reduced to indoline 42 in excellent yield (94%) by treatment with 
NaBH3CN (Scheme 29).184 NaBH4 was used as a safer alternative for scaled-up 
synthesis and afforded the product in similar yield. Indoline 42 was directly treated 
with 2-chloropropanoyl chloride to afford the acylated product 43 (Scheme 29).185 
Refluxing acylated indoline 43 with methylamine in THF/MeCN gave 
diketopiperazine 44.185 Both compound 43 and 44 were obtained as a mixture of 
diastereoisomers but separation was not necessary, as the two chiral centres will lose 
their stereochemical information in the final step.  
 
 
Scheme 29183 
 
The sulfenylation of diketopiperazine 44 was performed using the method recently 
described by Nicolaou and co-workers (Scheme 29 and 30).100,102 The reaction of 
NaHMDS and elemental sulfur (S8) is postulated to give N,N’-tetrathiobis-
trimethylsilyl (45, Scheme 30). Deprotonation of the diketopiperazine ring with 
NaHMDS formed an enolate which reacted with the tetrasulfide species 45 to lead to 
the formation of the first sulfur-carbon bond. Subsequent alpha deprotonation and 
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intramolecular attack of the enolate to the tetrasulfide moiety led to the formation of 
the second sulfur-carbon bond and the installation of the tetrasulfide bridge. The latter 
was then reduced with NaBH4 to the dithiolate and final oxidation with KI3 led to the 
desired ETP 25. 
 
 
Scheme 30 Postulated mechanism for the general formation of the ETP core from the corresponding 
diketopiperazine. Adapted from 100,102 
 
ETP (±)-25 was thus obtained in low to medium yield (15 – 42%). Attempts at 
improving the yield of this reaction by varying the conditions (temperature, base, 
order of addition, reaction time) did not lead to significant improvement. A trisulfide 
analogue (46, Scheme 31) was consistently observed in 5 – 10% yield. In addition to a 
slight change in chemical shifts from the disulfide analogue, the NMR spectra of 
trisulfide 46 exhibited duplicated signals. This has been observed for a number of 
natural and synthetic products containing the epitrisulfide functionality and it is 
commonly accepted that the compound actually exists as two conformers 
(Scheme 31).96,186,187 The trisulfide 46 could also be desulfurised to the monosulfide 
26, via the disulfide 25, to limit loss of material.96 
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Scheme 31 The two conformers of the trisulfide derivative 46 
 
The enantiomers of ETP 25 were then separated using semi-preparative HPLC 
on a chiral stationary phase. The first ETP enantiomer eluted from the HPLC column 
had an optical rotation and an ECD spectrum in agreement with those of the starting 
material used by Ottenheijm and co-worker in their desulfurisation studies, assigned 
to have (R,R) stereochemistry by qualitative comparison with the ECD spectra of 
gliotoxin.169,188 Since we and others showed that correlative methods can lead to 
important errors,165,179,180 we sought to confirm this assignment by ab initio 
calculations as described above. 
The optical rotation of (R,R)-25 was first investigated. At the 
M062X/6-311++G(d,p) level of theory, the optical rotation of (R,R)-25 was predicted 
to be −498. Ottenheijm et al. had reported a value of −502 (c 2.345, CHCl3),188 and 
we recorded a value of −335 (c 2.00, CHCl3). The strong negative sign of the optical 
rotation was in agreement with the configuration of this stereoisomer to be (R,R). The 
ECD spectra were likewise experimentally measured and computationally simulated 
at the M062X/6-31++G(d,p) level of theory for (R,R)-25. Figure 59 shows the 
experimental ECD spectra recorded by us and the one reported by Ottenheim et al.,188 
together with the predicted one. The two experimental spectra are comparable with 
three negative Cotton effects around 230, 250 and 280 nm. The Cotton effects at 230 
and 250 nm are observed in the simulated spectra but the one at 280 nm is of the 
opposite sign. While the simulation of (R,R)-25 is undoubtedly closer to the 
experimentally obtained spectra than the simulated spectrum for its enantiomer 
((S,S)-25, mirror image of that shown in Figure 59), the calculations were unable to 
correctly predict all three negative Cotton effects. 
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Figure 59 ECD spectra of ETP 25. Adapted from Cherblanc et al.183 
Black: Experimental data for 25 in dichloromethane (right y axis); Red: Data from Ottenheijm and co-workers188 
for 25 (left y axis, reported as Δε), Blue: Calculated data for (R,R)-25 at M062X/6-31++G(d,p) 
(solvent=dichloromethane) (left y axis, rescaled by 0.385, shifted by +25 nm, and convoluted with a line width 
0.24 eV). 
 
 VCD analysis was therefore undertaken to further validate the assignment of 
ETP 25. The experimentally measured and computationally simulated IR and VCD 
spectra for (R,R)-25 are depicted in Figure 60. Analogously to our work on chaetocin, 
a scaling factor (0.968) derived from the IR similarity measure was used to rescale the 
VCD spectrum.179 Visual examination of the data showed an excellent agreement 
between calculated and experimental spectra: most bands observed in the IR and/or 
VCD spectra were predicted by the calculations. The agreement was further 
confirmed by the similarity measures Σ (describing the level of agreement between 
the experimental VCD spectra with the theoretical data derived for each enantiomer). 
The resulting values were ΣRR=75.5 and ΣSS=6.9. Combination of the enantiomeric 
similarity index Δ (the difference between the Σ value of each enantiomer) and the 
spectral database in the CompareVOA program179 computed a confidence level of 
100% for the (R,R) stereochemistry. Since all three chiroptical techniques used were 
supportive of the (R,R) assignment of ETP 25, we were therefore confident in the 
stereochemistry reported by Ottenheijm and co-workers.169,188 
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Figure 60 IR and VCD Spectra of ETP 25. Taken from Cherblanc et al.183 
The top panels show the calculated IR and VCD spectra for (R,R)-25 obtained at M062X/6-311++G(d,p) 
(solvent=chloroform). The bottom panels show the experimental IR and VCD spectra for 25 obtained for a 
solution in CDCl3. The theoretical spectra were obtained by using a scale factor of 0.968. The thin black line given 
in the bottom right panel refers to the noise spectrum supplementing the measured VCD data. 
 
  ETP (R,R)-25 was desulfurised with triphenylphosphine in dioxane as 
described by Ottenheijm and co-workers.169 A 93:7 enantiomeric ratio (e.r.) of the 
monosulfide product 26 (Scheme 22) was observed by chiral HPLC. Similarly, ETP 
(S,S)-25 afforded a 2:98 e.r. of monosulfide 26; the major isomer being the 
enantiomer to that obtained with (R,R)-25. Semi-preparative chiral HPLC was also 
performed on racemic mixtures of product 26 (obtained from the desulfurisation of 
racemic ETP 25) to access larger and enantiopure quantities of monosulfide 26. 
The enantiomer of 26 of shorter retention time by chiral HPLC had an optical 
rotation in agreement with that reported by Ottenheijm and co-workers [−47.5 (c 1.12, 
CH2Cl2) and −53 (c 1.13, CH2Cl2),169 respectively]. At the M062X/6-311++G(d,p) 
level of theory, the calculated optical rotation of (R,R)-26 was −169. Although this 
predicted value was qualitatively different from the experimental ones, the strong 
negative sign of the rotation suggests that this enantiomer is of a (R,R) configuration. 
Since this enantiomer was the major product obtained by desulfurisation of (R,R)-25, 
this indicates that the reaction proceeded with retention of configuration, in 
opposition with Ottenheijm’s conclusions.  
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To further validate our results, the ECD spectra of the supposed (R,R)-26 were 
recorded (Figure 61). Our spectrum was in good agreement with that of Ottenheijm 
and co-workers,169 with two positive Cotton effects (around 220 and 250 – 260 nm) 
followed by a negative one (280 – 290 nm) and finally a positive one (320 nm). The 
ECD spectrum of (R,R)-26 was simulated at the M062X/6-31++G(d,p) level of theory  
but it did not compare well with the experimental data (Figure 61). The ECD 
spectrum for (S,S)-26 would be the mirror image of the spectrum depicted in 
Figure 61 and would not be in good agreement with the experimental data either. 
 
 
Figure 61 ECD spectra of monosulfide 26. Adapted from Cherblanc et al.183 
Black: Measured data for 26 (enantiomer 1) (right y axis); Red: Data from Ottenheijm and co-workers169  for 26 
(left y axis, reported as Δε), Blue: Calculated data for (R,R)-26 at M062X/6-31++G(d,p) 
(solvent=dichloromethane) (left y axis, rescaled by 0.167, shifted by +25 nm, and convoluted with a line width 
0.24 eV). 
 
We therefore decided to turn our attention to VCD spectroscopy as this 
technique gave satisfactory results for the parent molecule 25, although the simulated 
ECD spectrum was also in moderate agreement with the experimental spectra. The IR 
and VCD spectra of supposed (R,R)-26 and the corresponding simulated spectra are 
shown in Figure 62.  
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Figure 62 IR and VCD Spectra of monosulfide 26. Taken from Cherblanc et al.183 
The top panels show the calculated IR and VCD spectra for (R,R)-26 obtained at M062X/6-311++G(d,p) 
(solvent=chloroform). The bottom panels show the experimental IR and VCD spectra for 26 obtained for a 
solution in CDCl3. The theoretical spectra were obtained by using a scale factor of 0.976. The thin black line given 
in the bottom right panel refers to the noise spectrum supplementing the measured VCD data. 
 
Gratifyingly, experimental and calculated spectra were in excellent agreement. 
The similarity measures were calculated for both enantiomers: ΣRR=66.5 and ΣSS=4.2. 
The derived enantiomeric similarity index Δ in combination with the spectral database 
in CompareVOA179 computed a confidence level of 99% for the (R,R) 
stereochemistry for 26. Since this enantiomer was obtained by desulfurisation of 
(R,R)-25, the VCD results, together with the optical rotation comparison, strongly 
advocates that the reaction proceeded with retention of configuration. 
 
 While VCD and optical rotation were clearly supportive of this assignment, 
the results obtained for the ECD comparison were unsatisfying and we therefore felt 
that an additional method would strengthen the reliability of our assignment. We 
reasoned that a non-spectroscopic approach would be particularly relevant and we 
therefore decided to use the method of chemical derivatisation that Barbier and co-
workers employed to determine the stereochemistry of the desulfurisation of 
Sirodesmin PL 27.171 The natural product 27 (Scheme 23), of (R,R) configuration, as 
determined by X-ray crystallography analysis, was stereospecifically converted to a 
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thioacetal. In parallel, monosulfide 28, isolated from the desulfurisation of the parent 
ETP 27, was converted to the same thioacetal. Therefore, if the bridgehead carbon 
atoms in the thioacetal have the same stereochemistry when obtained from ETP 27 or 
from monosulfide 28, then the desulfurisation reaction proceeded with retention of 
configuration at these centres. The validity of this approach has been confirmed by 
Barbier and co-worker by X-ray crystallography of an acetylated derivative of 
monosulfide 28 and appeared therefore as a suitable method for determining the 
relative stereochemistry of parent ETP and corresponding monosulfide. A summary 
of this approach, applied to the substrates of interest (ETP 25 and monosulfide 26) for 
the formation of thioacetal 47, is shown in Scheme 32. 
 
 
Scheme 32 Derivatisation strategy applied to ETP 25 and monosulfide 26. Ar– = (CH3OPh)–;  
–X = –[CH(p-CH3OPh)S]2–BF3. Adapted from171,183 
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 We therefore prepared thioacetal 47 from ETP (R,R)-25 and monosulfide 26 
of suggested (R,R) stereochemistry. The reactions were first attempted on the racemic 
starting material. ETP (±)- and (R,R)-25 were reduced to the dithiol by treatment with 
sodium borohydride, and converted directly into thioacetal 47 by treatment with 
anisaldehyde in presence of boron trifluoride. Thioacetal 47 was obtained in modest 
yield as a mixture of diastereoisomers, with the syn product (with respect to the 
anisaldehyde and polycyclic residues171, Scheme 32) as a major product (43% from 
(±)-25, 13% from (R,R)-25) and only traces of the anti product (observed by TLC and 
LCMS of the crude but not isolated from (±)-25, 6% from (R,R)-25). The assignment 
of the syn diastereoisomers was based on a NOESY NMR experiment, which showed 
a correlation between the signal at 5.10 ppm (CH of the thioacetal carbon) and the 
signal at 3.27 ppm (CH3 on the nitrogen atom of the diketopiperazine ring) 
(Figure 63). This correlation was absent from the NOESY NMR of the anti 
diastereoisomer. 
 
 
Figure 63 NOESY correlation observed for the syn diastereoisomer of 47 
 
Concomitantly, thioacetal 47 could be obtained from the racemic and 
enantiopure (proposed to be (R,R) stereochemistry) monosulfide 26 by treatment with 
the trithiane derivative of anisaldehyde 48 (Scheme 32). This trithiane 48 was 
prepared following a recent literature procedure by reaction of anisaldehyde with 
SiCl4 and Na2S in acetonitrile (Scheme 33).189  
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N
S
S
N
O
O
O
H
H
H
H
*
O
H
O
SiCl4, Na2S
MeCN, RT, 16 h O
H
S
S
S
S
O
OO 48
 	  
131	  
	  
	   	  
Interestingly, in CDCl3 both the α and β conformer of trithiane 48 (Figure 64) 
could be observed with the ratio of α increasing with temperature. In d6-DMSO only 
the β isomer, the most stable chair conformation, was observed.190 The acidity of 
chloroform may be responsible for the inter-conversion observed via opening of the 
6-membered ring. 
 
 
Figure 64 The α and β conformers of the trithiane of anisaldehyde 48, Ar– = (CH3OPh)–.190 
 
The thioacetal 47 was also obtained as a mixture of diastereoisomers readily 
separable by column chromatography (anti : syn ratio of 70:30 from (±)-26 and 40:60 
from (R,R)-26) in medium to low yields (anti: 56% from (±)-26, 17% from (R,R)-26; 
syn: 25% from (±)-26, 25% (R,R)-26). 
The syn diastereoisomers isolated had identical spectra (1H-NMR, 13C-NMR, 
HSQC and NOESY) to the ones obtained as major products from reaction of (±)- and 
(R,R)-25. Importantly, the optical rotations of the syn thioacetal 47 obtained from ETP 
(R,R)-25 and monosulfide (R,R)-26 were comparable: −66 (c 0.20, CHCl3) from ETP 
25 via pathway A and −40 (c 0.20, CHCl3) from monosulfide 26 via pathway B. Final 
confirmation was obtained by analytical HPLC on a chiral stationary phase. Indeed, 
the thioacetal products obtained from enantiopure compounds by the two different 
pathways were found to be the same enantiomer as only one peak was observed upon 
spiking (mixing) (Figure 65). As a control, Figure 66 shows the trace obtained by 
spiking the thioacetal syn-47 obtained by reaction of (±)-25 and the one obtained by 
reaction of (±)-26, and it is clearly apparent that the two enantiomers are very well 
separated (approximately 40 min). 
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Figure 65 Thioacetal 47 obtained by reaction of (R,R)-25 spiked with thioacetal 47 obtained by reaction of 
(R,R)-26, (syn diastereoisomer) (Hexane – Isopropanol, 98:2) 
 
  
 
Figure 66 Thioacetal 47 obtained by reaction of (±)-25 spiked with thioacetal 47 obtained by reaction of (±)-26, 
(syn diastereoisomer) (Hexane – Isopropanol, 98:2) 
 
The same enantiomer of thioacetal 47 was obtained via either pathway and we 
could therefore conclude that the stereochemistry of ETP 25 and monosulfide 26 was 
the same, i.e. (R,R).  
Our data, obtained by two orthogonal methods, strongly advocates that 
desulfurisation of ETP (R,R)-25 occurred with retention of stereochemistry at the 
bridgehead carbon atoms contrary to the original report.169 This work has been 
accepted for publication in the Journal of Organic Chemistry in October 2013.183 
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 Nevertheless, we are still not in a position to identify the origin of 
Ottenheijm’s misassignment, validated by an X-ray crystal structure. We still felt that 
obtaining a crystal structure of our samples would definitely ensure the accuracy of 
the results obtained by chemical derivatisation and by analysis of chiroptical spectra. 
 We thus tried to crystallise both starting material (R,R)-25 and monosulfide 
(R,R)-26 using various techniques such as slow evaporation from various solvents 
including dichloromethane as reported,169 chloroform, methanol; solvent diffusion 
whereby the sample was dissolved in dichloromethane and a layer of n-octane was 
carefully added on top of it; vapour diffusion (combinations of dichloromethane, 
water, methanol, diethylether) but we could not obtained any crystals of suitable 
quality for X-ray analysis. The racemic starting material ETP 25 did crystallise from 
dichloromethane in the triclinic crystal system, of space group P1 (centrosymmetric, 
achiral) and the unit cell contained two independent molecules (See crystallographic 
data). Ottenheijm and co-workers also reported the crystal structure of the racemic but 
not of the enantiopure ETP 25.188 Interestingly, racemic ETP 25 crystallised (from 
methanol–water) in a different crystal system (monoclinic, space group C2/c). The C-
S-S torsion angles and the S–S bond length are however comparable in both structures. 
 Encouraged by the crystallisation of the racemic mixture of ETP 25, we 
envisaged that mixing the (R,R)-25 with the “opposite” enantiomer of a highly similar 
compound could potentially trigger the crystallisation of this “pseudo-racemic” 
mixture (Scheme 34). X-ray crystallography could then confirm the stereochemistry 
of the two different molecules. We selected a fluorinated analogue of ETP 25 (49, 
abbreviated F-ETP, Scheme 34), with the fluorine atom on the phenyl ring, far from 
the ETP moiety in order to keep the disruption of the three-dimensional structure and 
hopefully the packing to a minimum. Upon desulfurisation of F-ETP 49 into the 
corresponding monosulfide 50 and mixing with “opposite” enantiomer, we reasoned 
that this strategy may allow us to obtain crystal structures of both enantiopure ETP 25 
and monosulfide 26 (Scheme 34). 
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Scheme 34 Strategy of the “pseudo-racemic” mixture preparation 
 
The synthesis of F-ETP 49 was carried out following the same route described 
for ETP 25 (Scheme 28 and 29) except using 4-fluorophenylhydrazine to form the 
dihydroindole core (See Experimental Details, compounds 49 to 55). The yields were 
similar throughout except the sulfenylation step tended to give better yield. This 
observation is most likely related to the electron-withdrawing inductive effect of the 
fluorine atom, which would decrease the pKa of the hydrogen α to the amide moiety. 
Racemic F-ETP 49 crystallised readily in the flask and an X-ray crystal structure was 
obtained (see crystallographic data). Once again, the unit cell contained two 
independent molecules, and F-ETP 49 crystallised in the same triclinic crystal system, 
space group P1 (centrosymmetric), as ETP 25. Consequently, the enantiomers of a 
fraction of F-ETP 49 were separated using semi-preparative HPLC on a chiral 
stationary phase. Their stereochemistry was assigned by comparison with ETP 25 and 
based on the sign of their optical rotation and their order of elution. As extra 
precaution, the optical rotation were also calculated (at the ωB97XD/6-311+G(d,p) 
level of theory) and the optical rotation of (R,R)-49 was predicted to be −448, in close 
agreement with the value we measured (−419 (c 1.05, CHCl3)). Consequently, ETP 
(R,R)-25 was mixed in a 1:1 ratio with F-ETP (S,S)-49 (and the opposite enantiomers 
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too, Scheme 34). Various solvent and techniques were attempted for crystallisation, 
but unfortunately no suitable crystals could be obtained. 
F-ETP (±)-49 was desulfurised to the monosulfide 50 by treatment with 
triphenylphosphine as described before in medium yield (50%) (Scheme 34). A 
crystal structure of the racemic fluorinated monosulfide 50 could be obtained 
(monoclinic crystal system, P21/n space group, see crystallographic data). The angles 
and bond lengths observed were comparable to the one described by Tijhuis and co-
workers for monosulfide 26 although the crystal system was different 
(orthorhombic).170 In particular, we observed a much more pronounced boat 
conformation compared to the parent ETP 49 due to the presence of the highly 
strained monosulfide bridge. 
Encouraged by the crystallisation of the racemic fluorinated monosulfide 50, 
the enantiomers were also separated using semi-preparative HPLC on a chiral 
stationary phase. The stereochemical assignment was done by comparison with 
monosulfide 26 and the optical rotation was calculated (at the ωB97XD/6-311+G(d,p) 
level of theory). The optical rotation of (R,R)-50 was predicted to be −124, and we 
measured −32.2 (c 1.01, CHCl3). The same difference in predicted and experimental 
values has been observed for monosulfide 26 (calculated: –131, measured: −47.5 (c 
1.12, CH2Cl2)). The strong negative sign of the predicted value and the agreement 
between the two experimental values (fluorinated and non-fluorinated monosulfide) 
were in strong support of a correct assignment. The samples were then mixed with the 
“opposite” enantiomer of the non-fluorinated monosulfide (Scheme 34). 
Unfortunately again, after a number of attempts, no suitable crystals were obtained. 
In summary, although a wide range of methods were attempted, we were 
unable to crystallise our sample of monosulfide (R,R)-26. It is worth noting that 
Ottenheijm and co-workers also struggled to obtain crystals, as judged by their 
comment: “after numerous attempts one suitable crystal could be prepared for the X-
ray analysis”.169  
Nevertheless, even if we had managed to obtain a crystal structure confirming 
the (R,R) stereochemistry of monosulfide 26, we would still be unable to identify the 
origin of its incorrect stereochemical assignment by Ottenheijm and co-workers.169 As 
mentioned earlier, they did obtain an X-ray crystal structure of monosulfide (S,S)-26 
and we can only speculate on the origin of this data (e.g. error in the labelling of the 
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ETP starting materials or in the monosulfide samples). Also, it should be noted that 
re-analysis (optical rotation or ECD) of the crystal used for the crystallographic 
studies was not performed; this would have ensured that its absolute configuration 
matched that of the bulk material. 
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Conclusions 
 
 Through the comparison of simulated and experimental chiroptical spectra, we 
have managed to unambiguously assign the stereochemistry of an analogue of the 
natural product chaetocin, monosulfide 3, the biological activity of which is described 
elsewhere in this thesis (Chapter II). 
This led us to re-assess the stereochemical course of the desulfurisation of 
ETP-containing compounds. Indeed, the various assignments prior to our work were 
often contradictory (see Scheme 20 to 23) and no unified mechanism could be 
proposed. In particular, the pendent alcohol present in a number of natural products 
(including sirodesmin PL (27) and chaetocin (1)) was proposed by Barbier et al. to 
potentially influence the course of the reaction and to favour a double inversion 
mechanism, ultimately leading to net retention of stereochemistry at the bridgehead 
carbon atoms (Scheme 26).171 This was proposed in light of Ottenheijms’s 
assignment169 (inversion of stereochemistry) and was in agreement with our findings 
but was inconsistent with the assignment proposed for dehydrogliotoxin (21), which 
was proposed to be desulfurised with inversion of stereochemistry based on the 
comparison of the ECD curves of the product and that of the ETP starting material. 
Our studies on the monosulfide derivative of dehydrogliotoxin 22 allowed us to shed 
light on the misassignment of its stereochemistry, by simulating the ECD spectra of 
the two enantiomers and comparison with the reported one. Finally, gliotoxin 
analogue 25 remained the last example in the literature of an inversion of 
stereochemistry upon desulfurisation. Computational and chiroptical studies coupled 
with chemical derivatisation allowed us to re-assign this compound: all our data 
strongly support the fact that ETP 25 is also desulfurised with retention of 
stereochemistry. 
We thus propose that all chiral ETP compounds are desulfurised with retention 
of stereochemistry at the bridgehead carbon atoms, likely via a unified mechanism 
depicted in Scheme 24 and Figure 58. 
 
In broader terms, it is important to highlight that some of the incorrect 
stereochemical assignments of desulfurised ETP compounds in the literature stemmed 
from the use of correlative methods, particularly ECD spectroscopy. Our study, 
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coupled with literature examples, clearly shows that the sign of a given Cotton effect 
is not characteristic for ETP or monosulfide stereochemistry. In this case, although 
differing by only one sulfur atom, the ECD spectrum of an ETP compound is not 
comparable with that of its monosulfide analogue because different molecular orbitals 
are involved for the transitions in each molecule. In addition, the interference between 
the different chromophores present in a given molecule (e.g. the disulfide and the 
diene functionalities in the study on gliotoxin166) appear to have a significant impact 
on the resulting ECD spectra and any changes in chromophore may lead to important 
changes in the spectrum which are not necessarily related to the absolute 
configuration of the molecule.165 Overall, correlative methods whereby the 
stereochemistry of a compound is assigned by comparison of its ECD curve to that of 
a related (but different) molecule should definitely be discarded, regardless of how 
structurally similar the two molecules are. 
In conclusion, the exploitation of chiroptical data for stereochemistry 
assignment should not be performed solely by analogy with similar molecules but 
should always be accompanied by simulations, allowed by the computational power 
available today. It is also good practice to use several techniques where possible to 
validate an assignment with confidence.191 Indeed, in the case of monosulfide 26, the 
simulated ECD spectrum did not correlate well with the experimental one, while 
optical rotation and VCD gave a clear answer. 
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Introduction  
 
As outlined in Chapter I, epigenetic therapy holds important promise for the 
future of targeted chemotherapy in cancer.40 Research in epigenetics over the past two 
decades has uncovered a number of new targets for the drug discovery community, 
including the various enzyme classes described above (e.g. DNMTs, HDACs, 
HKMTs).192  
HKMTs have only recently been recognised as new promising targets, and of 
those enzymes, Enhancer of Zest Homologue 2 (EZH2) is possibly one of the most 
therapeutically relevant for cancer therapy.39 EZH2 is the catalytic subunit of the 
Polycomb Repressive Complex 2 (PRC2) and it trimethylates H3K27, thereby 
inducing the silencing of genes involved in critical processes such as differentiation, 
and proliferation.193 To date, only EZH2 (and in some cases the closely related EZH1) 
was found able to perform trimethylation of H3K27.194 Mono and dimethylation of 
H3K27 have been reported to be also mediated by G9a (primarily a H3K9 
dimethylase) both in vitro and in vivo, but trimethylation was not observed.195 This 
absence of redundancy in the enzyme able to install H3K27me3 is distinctive amongst 
the histone methylating enzymes. For example, H3K9 can be methylated by several 
enzymes including G9a, GLP and SUV39H1/2.13 This unique feature of the 
H3K27me3 mark has important implications in terms of its pharmacologic disruption: 
the inhibition of EZH2 (and EZH1) should be sufficient to lead to a decrease of 
H3K27me3, since no other enzyme is able to install this mark. 
Over the past decade, a large number of studies have demonstrated that EZH2 
is a highly promising target for epigenetic therapy. Firstly, EZH2 was found to be 
overexpressed in numerous tumour types including breast and prostate cancer, where 
its level of expression has been linked to the aggressiveness of the disease and poor 
patient outcome (See also Table 1, Chapter I).57,58,196,197 Furthermore, genetic 
disruption of EZH2 (siRNA) was found in a number of independent studies to result 
in a reduction of cancer cell growth.39,198-200 
Secondly, a number of mutations in cancer have recently been identified that 
affect levels of the H3K27me3 mark. Inactivating mutations of the H3K27 
demethylase UTX were found at significant levels in various cancer types.201,202 The 
only other H3K27me3 demethylase known, JMDJ3, was found to be expressed at low 
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level in cancer cells.203 Inactivation of H3K27 demethylases would result in higher 
level of H3K27me3. More recently, mutations in EZH2 have also been discovered. 
Recurrent mutations of tyrosine 641 of EZH2 were found in 7% and 22% of follicular 
lymphomas and diffuse large B-cell lymphoma respectively.204 While this was first 
believed to be an inactivating mutation, further studies uncovered an unprecedented 
coordinated activity of wild type and mutant EZH2. It was shown that the mutant 
enzyme displayed poor ability to methylate an unmethylated lysine residue (reaction 
from H3K9 to H3K9me) but enhanced catalytic efficiency for the subsequent 
methylation reactions (H3K9me to me2 and then me3).205 The mutant enzyme thus 
relies on the presence of wild-type EZH2 to perform the first methylation step. A 
similar mutation of EZH2 (A677G) in lymphoma cell lines was found to lead to 
distinct substrate specificity.206 This EZH2 mutant demonstrated nearly equal 
efficiency for all three substrates (H3K27, H3K27me1 or H3K27me2). An additional 
point mutation in EZH2 (A687V) was also recently found to alter the pattern of 
substrate efficiency and to greatly favour methylation of the H3K27me1 state over 
other H3K27 forms.207 It has not yet been confirmed if this mutation would also lead 
to H3K27 hyper-trimethylation (via a potential coupling with wild-type EZH2 
activity). Nonetheless, both mutations (Tyr641 or A677) lead to increased level of 
H3K27me3 in lymphoma cell lines, which further implicates EZH2 as an oncogene 
and strongly suggests that H3K27me3 is implicated in the aberrant silencing of 
tumour suppressor genes in lymphoma. 
However, a number of studies have reached contrasting conclusions, 
highlighting the potential role of EZH2 as a tumour suppressor gene in malignant 
myeloid diseases (i.e. disorders of haematopoietic stem cells or progenitors of red 
blood cells, granulocytes, and platelets, such as myelodysplastic syndromes (MDSs), 
myeloproliferative disorder (MPD), and acute myeloid leukaemia (AML)).208 Three 
important studies reported that deletions or inactivation of the EZH2 gene are 
common in MDSs and in certain MPDs. The loss of the methyltransferase activity has 
also been demonstrated in some cases.209-211 Furthermore, inactivating mutations of 
EZH2 in MDSs and some types of MPD have been shown to predict poor 
survival.212,213 Likewise, inactivating mutations of EZH2 concurrent with reduced 
level of the H3K27me3 mark have also been found to be sufficient to cause T-acute 
lymphoblastic leukaemia (T-ALL).214 Subsequently, mutations in PRC2 complex 
(EZH2, EED or SUZ12) were discovered to be very frequent in T-ALL, and 
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alterations were found at even higher levels in a pediatric subtype.215,216 These studies 
clearly established EZH2/PRC2 as an important tumour suppressor gene in T-ALL as 
well as in a range of malignant myeloid diseases and that the loss of EZH2 activity 
(i.e. H3K27 trimethylation) might lead to the de-repression of oncogenic pathways. 
Taken together, these results show the crucial importance of H3K27 
methylation in a wide range of cancers. On top of this, the histone residue itself has 
been found to be recurrently mutated in aggressive brain tumours, including a lysine 
to methionine change found in 78% of the cases in specific pediatric gliomas.217,218 In 
a recent study, it was reported that histones bearing this K27M mutation were able to 
inhibit EZH2 and lead to lower H3K27me3 levels in cells.219  
It is therefore of the highest importance to further study the regulation of 
H3K27 methylation in cancer. The development of modulators of this mark holds 
promise for the treatment of a variety of cancer types. However, as described above, 
changes in H3K27 methylation level may have contrasting effects depending on the 
cancer in question, and it will thus be crucial to prove the validity of targeting the 
enzyme installing the mark (EZH2 or EZH1) or removing it (UTX, JMJD3) in a tissue 
specific manner. Likewise, the success of clinical trials will most likely depend upon 
the identification of reliable biomarkers (e.g. mutations) and subsequent patient 
stratification.  
This project proposed to address such need. In particular, our main objective is 
to identify molecules that reduce H3K27 trimethylation and concomitantly lead to re-
expression of silenced EZH2 target genes. As mentioned above, the re-activation of 
pathways aberrantly silenced by EZH2 is expected to induce apoptosis of cancer cells.  
At the time this project was initiated, no direct EZH2 inhibitor had been 
publicly disclosed. One compound, 3-Deazaneplanocin A (DZNep, Figure 67) had 
been reported to selectively inhibit H3K27me3 and H4K20me3 in cells as well as to 
induce apoptosis in cancer cells by depleting cellular level of PRC2 proteins (at least 
in part by proteasome-mediated protein degradation), while not affecting their mRNA 
level.220  
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Figure 67 Structure of DZNep 
 
However, DZNep was previously identified as a SAH hydrolase inhibitor and 
would thus be expected to indirectly inhibit (through increasing concentration of 
SAH) all of the SAM-dependent enzymes (HKMT, PRMT, DNMT, and various non-
epigenetic methyltransferases).221,222 Jones and co-workers subsequently 
demonstrated that DZNep globally inhibited histone methylation and does not display 
any HKMT selectivity.223 While these studies further confirmed that disruption of the 
PRC2 complex effectively induced apoptosis in cancer cells, this compound was not a 
suitable starting point for our project in light of its poor selectivity and obscure 
mechanism of action. 
Rational design of SAM analogues that display EZH2 selectivity would be one 
potential option. Although SAM binding pockets are highly conserved between 
HKMTs,63 careful crystallographic studies can guide the design of inhibitors and 
specificity could be achieved, as recently illustrated by the development of a highly 
specific DOT1L inhibitor (Figure 6, Chapter I).73 However, in the case of EZH2, this 
approach was impeded by the absence of a crystal structure to lead the medicinal 
chemistry effort in a rational way. 
We instead focused our interest on a small molecule inhibitor reported to 
inhibit another HKMT, the H3K9 dimethylase G9a. BIX-01294 (2, Figure 7) was 
identified through HTS (125,000 compounds) to inhibit the HKMT G9a.75 The 
specificity of the compound was assessed against a number of histone 
methyltransferases, including an arginine methyltransferase (PRMT1) and additional 
lysine methyltransferases specific for other residues such as SET7/9 (H3K4me) or the 
hyper active SUV39H1 (H320R) mutant, but excluding EZH2. BIX-01294 
specifically inhibited G9a (IC50 = 1.7 µM) and to a lesser extent the closely related 
GLP (G9a-like protein) (IC50 = 38 µM). No inhibition of the other histone 
methyltransferases was observed at the tested concentrations (up to 45 µM). 
BIX-01294 was shown to act in an uncompetitive manner with SAM, which 
N
N
N
NH2
OHOH
HO
DZNep
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suggested that it could only bind to the enzyme-cofactor complex. Furthermore, when 
cells were treated with BIX-01294, a reduction of 20% of H3K9me2 mark was 
observed by mass spectrometry, together with a comparable increase of the 
unmethylated state. The other methylation states of H3K9 (H3K9me and H3K9me3) 
were not significantly altered, nor were the other lysine residues (H3K27, H3K36, 
H4K20).75 Analyses of microarrays of G9a null mouse ES cells compare to wild-type 
identified a number of G9a target genes and six of those were investigated by 
chromatin immunoprecipitation (ChIP) experiments. Upon treatment with BIX-01294, 
ChIP confirmed a pronounced decrease of the H3K9me2 mark at their promoter 
regions.75 However, the reduction of the repressive chromatin mark H3K9me2 only 
resulted in increased gene expression for two target genes out of the six tested.75 
Finally, it was shown that the level of H3K9me2 was fully restored after washing of 
the inhibitor. BIX-01294 was thus able to transiently modify the H3K9me2 repressive 
mark in cells but its effect on gene re-expression was limited. 
 Two years later, the crystal structure of the catalytic SET domain of GLP in 
complex with BIX-01294 and SAH was reported.65 GLP was preferred since a crystal 
structure of GLP in complex with SAH and an H3 peptide substrate was already 
available. Moreover, the two enzymes are highly similar: GLP shares around 80% 
sequence identity with G9a in their SET domains. Furthermore, when assayed under 
different reaction conditions, BIX-01294 inhibited GLP better than G9a 
(IC50 = 1.9 µM for G9a, IC50 = 0.7 µM for GLP).65 Importantly, it was shown that the 
inhibitor bound in the histone peptide groove thereby preventing the substrate from 
binding (Figure 68).  
Based on the structural information provided by the co-crystal structure, SAR 
studies have been performed around the BIX-01294 scaffold. A number of analogues 
with increasing potency towards G9a (and GLP) and physicochemical properties have 
been reported. Figure 69 summarises the achievement of different groups.  
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Figure 68 Ternary complex of GLP with SAH and BIX-01294 (2) (PDB: 3FPD, left) or H3 peptide (PDB:2RFI, 
right). BIX-01294 and the H3 peptide are shown with green carbons and SAH with purple carbons for clarity. 
 
 
Figure 69 SAR development around BIX-01294 scaffold against G9a and GLP224-228 
 
Cheng and co-workers designed a number of analogues bearing one or two 
lysine mimics (e.g. E72, Figure 69).224 The lysine mimic was shown to extend into the 
lysine-binding channel and rationalised the observed increased affinity of the 
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compound for the enzyme. Jin and co-workers reported an extensive SAR study 
summarised in Figure 69.225-228 Efforts to improve the cellular potency of this class of 
compounds through increasing lipophilicity led to the discovery of a couple of 
optimised analogues, including the highly potent UNC0638 (Figure 69).225,228  
 From the in-depth work of Jin and co-workers, the BIX-01294 scaffold proved 
to be amenable for the rapid synthesis of a large number of analogues to generate a 
suitable SAR study. Upon careful manipulation of the physicochemical properties of 
the analogues it was possible to generate cell-penetrant, highly active tool compounds 
for cell-based studies.  
Whilst the BIX-01294 studies focused on G9a (and GLP) inhibition, there 
were a number of reasons we felt we could use this molecule as a starting point for the 
reversal of H3K27-mediated gene silencing. 
Although the main activity of G9a is the dimethylation of H3K9me2, G9a has 
also been shown to contribute to H3K27 methylation.195 Furthermore, sequence 
alignment clearly showed that the H3 sequence around lysine 9 and lysine 27 are 
appreciably similar (Figure 70),24 and therefore the binding pockets accommodating 
the respective histone region in G9a and EZH2 would likely be similar. We therefore 
anticipated that upon derivatisation of the BIX-01294 scaffold, it might be possible to 
expand the biological activities of the parent compound and gain EZH2 inhibitory 
activity. 
 
H3K9  KQTARKSTGGKA 
H3K27 TKAARKSAPATG 
 
Figure 70 Sequence of histone peptides24 
 
It is worth stating that H3K9 dimethylation, mediated by G9a, is a 
transcriptionally repressive mark. In light of the epigenetic crosstalk mentioned 
above, it may be necessary to develop agent targeting several histone-modifying 
enzymes to eventually reach a more permissive chromatin state. Consequently, 
molecules leading to a reduction of both H3K9 and H3K27 methylation may be more 
efficient at killing cancer cells than compounds targeting a single enzyme. Dual or 
polypharmacology might be a desirable feature in the field of epigenetics. 
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 In late 2012, a number of pharmaceutical companies disclosed the structure of 
their EZH2 inhibitors (Figure 71). Epizyme developed the first highly potent EZH2-
selective inhibitor, EPZ005687, which displays a Ki of 24 nM and a selectivity greater 
than 500-fold against 15 methyltransferases (50-fold against EZH1).77 The compound 
reduced H3K27 trimethylation in cells without altering the methylation state at other 
histone residues. Furthermore, it killed lymphoma cells bearing an EZH2 mutation 
(Tyr641 or Ala677) selectively, while having little effect on cell lines containing 
wild-type EZH2. These data suggested that EZH2 mutant-bearing lymphoma cells 
critically depend on EZH2 activity for proliferation and survival.77 Very recently, 
Epizyme reported another EZH2 inhibitor, EPZ-6438, which showed dose-dependent 
regression of malignant rhabdoid tumours (rare and highly malignant childhood 
neoplasm, originally of the kidney).229 Shortly after, GSK, Novartis and Jin and 
co-workers disclosed the structure of their EZH2 inhibitors (GSK343/126, EI1 and 
UNC1999 respectively, Figure 71).78-81 Highly similar to EPZ005687, the molecules 
contain an indazole or indole core bearing a pyridone side chain connected via an 
amide linkage at position 4 (indole numbering). Side chains at position 6 principally 
differentiate the molecules. All compounds display nanomolar potency and high 
selectivity in biochemical assays and were competitive with SAM. Jin and co-workers 
reported that UNC1999 was inhibiting both EZH2 and EZH1, which was expected to 
inhibit further H3K27 methylation compared with EZH2 specific inhibitors. In 
addition, their compound was orally bioavailable and therefore could be employed 
conveniently in animal studies. Importantly, all the compounds reported were able to 
kill lymphoma cell harbouring the Tyr641 point mutation but had little effect on cells 
with wild-type EZH2. 
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Figure 71 Current specific inhibitors of EZH2 
 
 In light of the fact that overexpression of wild-type EZH2 is observed in a 
variety of cancers, there is still a need for small molecules able to kill cancer cells 
harbouring high levels of wild-type EZH2. Indeed, the discovery of potent inhibitors 
displaying selectivity for cancer cells with mutated EZH2 was a great advance, but 
the use of such compounds will be limited to a very defined patient group, (e.g. the 
Tyr641 mutation is only present in ~ 7% of follicular lymphomas and 22% of diffuse 
large B-cell lymphoma). 
 
 This chapter will describe our approach for the identification and development 
of small molecules leading to the reversal of wild-type EZH2-mediated gene silencing 
in breast cancer cells, using BIX-01294 (2) as a chemical start point. 
The biological evaluation of preliminary BIX-01294 analogues was performed 
by collaborators in Prof. Robert Brown’s lab (Imperial College London). The initial 
analogue library used consisted of ~30 analogues provided by our collaborators Thota 
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Ganesh and James Snyder at Emory university, as well as compounds made by co-
workers in house. The compounds were first tested in an in vitro cell-free assay kit 
against EZH2 (using the PRC2 complex, specific for H3K27) and SUV39H1 (specific 
for H3K9), as described in Chapter II. None of the BIX-01294 analogues tested led to 
a reproducible decrease in EZH2 activity. In general, a flat response to many of the 
analogues was observed. Unexpectedly, some compounds led to an apparent 
increased activity for EZH2 and SUV39H1. A few compounds showed some 
inhibitory activity toward SUV39H1, and compound 56 (Figure 72) exhibited the 
most significant effect (65% inhibition at 20 µM).  
 
 
Figure 72 Structure of analogue 56 
 
The mechanism leading to the observed increased activity was unclear but we 
felt it was most likely an artefact of the assay setting, questioning the reliability of the 
commercial assay kit for this compound series. As an alternative assay, Prof. Brown 
and co-workers developed a cell-based assay (MDA-MB-231 breast cancer line) 
designed to monitor the ability of compounds to reverse H3K27me3 dependent gene 
silencing using a real-time reverse transcription polymerase chain reaction (RT-PCR) 
to examine mRNA levels of candidate genes.230 
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Result and discussion 
 
 Synthesis of BIX-01294 analogues 
 
In order to initiate the project, a focused library of analogues had to be 
synthesised to expand the biological activities of the BIX-01294 scaffold and 
hopefully gain EZH2 inhibition (and possibly specificity) as well as to develop a SAR 
around the quinazoline core. Three positions were to be explored: the nature of the 
amines at position 2 and 4 as well at the substituent at position O-7 (Figure 69). 
Unfortunately, as mentioned above, in the absence of EZH2 crystal structure, no 
structural information was available to guide our initial design.  
 
Derivatisation at position O-7 
 Since mainly analogues with a lysine mimic at O-7 have been reported 
(Figure 69), we felt that further exploration of this position using other side chains 
was warranted. Additionally, in light of the preliminary results obtained for 
compound 56 and the questioned reliability of the assay, we felt that re-synthesis of 
this compound in house was desirable to confirm the effect seen. 
To access derivatives with various ether side chains at this position, the core 
of the quinazoline had to be synthesised with a robust protecting group on the 
hydroxy moiety at position 7. For this purpose, the route developed by Liu et al. was 
adapted to access the quinazoline scaffold with a benzyl protecting group at 
position 7.226  
Protection of commercially available phenol 57 (Scheme 35) proceeded in 
quantitative yield with benzylbromide. Nitration of protected phenol 58 with nitric 
acid in acetic anhydride afforded nitro compound 59 in excellent yield (96%) as a 
single regioisomer. Reduction of the nitro moiety of compound 59 was initially 
performed with iron dust,226 but an alternative method using sodium dithionite turned 
out to be more convenient and afforded aniline 60 as a cleaner product by a simple 
acid/base extraction in excellent yield (97%).231 Quinazolinedione 62 was obtained in 
two steps from aniline 60 by formation of a methyl carbamate intermediate 61 and 
oxidative hydration of the nitrile group followed by spontaneous cyclisation in good 
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yield (62% over two steps). Chlorination of quinazolinedione 62 with phosphorus 
oxychloride afforded dichloroquinazoline 63 in excellent yield (97%). 
 
 
Scheme 35 
 
From the common dichloro intermediate 63, fully substituted compounds were 
four steps away: substitution at positions 2 and 4 with various amines, deprotection 
and finally O-alkylation under either Mitsunobu conditions or by treatment with alkyl 
halides (Scheme 36). 
 
 
Scheme 36 
 
The attempted synthesis of compound 56 is depicted in Scheme 37. 
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Scheme 37 
 
Treatment of dichloro compound 63 with the corresponding amine 64 under 
mild conditions resulted in selective substitution of the more reactive chloride, 
affording compound 65 in good yield (74%). The second displacement with amine 66 
required more forcing conditions (microwave irradiation at 160 ˚C) and the di-
substituted quinazoline 67 was obtained in low yield (30%), due to difficulties in the 
purification of this highly polar compound. Unexpectedly, the debenzylation of 
2,4-diaminoquinazoline 67 turned out to be quite problematic (Table 9). 
 
Table 9 Debenzylation conditions 
 
Conditions Observations 
5% Pd/C, H2, Ethanol, RT226 Unidentified products by 1H NMR and MS 
5% PdBaSO4, H2, THF, RT232 Unidentified products by 1H NMR and MS 
BF3•Et2O, EtSH, CH2Cl2, RT233 Starting Material 
 
Chang et al. reported the debenzylation of monochlorinated compound 65 
under standard conditions of hydrogenation (palladium on charcoal and hydrogen) 
and reported a 3:1 ratio of mono and di-debenzylated product, with the O-benzyl 
group being cleaved first. It was therefore assumed that careful monitoring of the 
reaction progress would allow for the selective cleavage of the O-benzyl group of 
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compound 67. However, similar reaction conditions for the debenzylation of 
compound 67 not only failed to selectively deprotect compound 68, but resulted in a 
complex mixture of products in which the main product could not be identified. A 
milder reductive method using a poisoned catalyst (Pd/BaSO4) was attempted but 
afforded results similar to the first hydrogenation.232 Alternatively, a Lewis acid 
mediated method (BF3•Et2O and EtSH)233 was explored but no reaction was observed. 
This difficult debenzylation lead to the consumption of all the benzyl protected 
compound 67.  
Consequently, it was decided that an alternative protecting group would be 
used. The allyl group was chosen for this purpose as numerous methods are known 
for its cleavage, and the N-benzyl group should not be affected under such 
deprotection conditions. Allyl-protected dichloroquinazoline 69 was thus prepared 
following the same route with comparable yields (Scheme 35). 
 
 
Scheme 38 
 
Mono-displacement of the most reactive chloride with amine 64 afforded 
substituted chloroquinazoline 75 in quantitative yield (Scheme 38). For the second 
chloro displacement however, microwave irradiation resulted in a Claisen 
rearrangement (Scheme 39). The two main products obtained by this method were the 
rearranged mono- and di-substituted quinazoline.  
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Scheme 39 
 
Milder conditions (in refluxing acetonitrile) afforded the expected product 76 
in very good yield (80%), without any rearrangement, but a long reaction time was 
required (3 days). Alternatively, refluxing compound 75 in neat amine 66 
(b.p. 133 ˚C) afforded the disubstituted quinazoline 76 in a shorter reaction time but 
with lower yield (45%) due to the formation of a minor amount of rearranged 
products. Unfortunately, deprotection of the allyl group of 76 also proved quite 
challenging. Several standard conditions were attempted (Table 10). 
 
Table 10 Conditions for cleavage of the allyl protecting group of 76 
 
Conditions Observations 
RhCl(PPh3)3, DABCO, Ethanol reflux234 Starting material 
Pd(PPh3)4, LiBH4, THF, RT235 Starting material 
Pd(PPh3)4, Et3SiH, AcOH, Toluene, RT236 No product detectable by NMR, 
traces in LC-MS 
NaBH4, I2, THF, RT237 Starting material 
Pd(PPh3)4, Morpholine, THF, RT238 Product detected by NMR / LC-MS, 
not isolated 
Pd(PPh3)4, K2CO3, MeOH, 50˚C239 Product isolated and confirmed by 
NMR and LC-MS 
 
 Palladium and rhodium complexes are believed to isomerise the double bond 
and lead to the formation of a vinyl ether via a π-allyl species, which can then be 
cleaved under various conditions.234,239,240 Vutukuri et al. developed a mild 
deprotection method involving potassium carbonate in methanol in the presence of 
palladium which was shown to be selective for the deprotection of aryl allyl ethers in 
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the presence of alkyl allyl ethers.239 The authors hypothesised that the carbonate anion 
acts as the nucleophile to react with the Pd-π-allyl species, although this has not been 
demonstrated. This methodology gave the most promising results for the deallylation 
of compound 76. However purification of free phenol 68 was not possible due to its 
high polarity and low solubility (1H NMR and HRMS were obtained on the crude 
material to confirm the identity of the product). A number of conditions were then 
attempted to alkylate crude phenol 68 (Table 11). Mesylate 77, prepared from alcohol 
78 in high yield (97%, Scheme 40), was first used as electrophile. The use of a mild 
base (Cs2CO3) resulted in traces amount of product and increasing the strength of the 
base ((CH3)3OK) did not lead to a significant increase in yield (from 2 to 9%). 
Mitsunobu conditions were attempted as an alternative method but no reaction was 
observed. Finally, an attempt was made to change the electrophile for iodide 79 
(prepared from mesylate 77, Scheme 40), but this did not lead to the desired product.  
 
Table 11 Conditions for alkylation of phenol 68 
 
Electrophile Conditions Observations 
Mesylate 77 Cs2CO3, DMF, 80 ˚C 2% yield 
Mesylate 77 (CH3)3OK, Acetone, 40 ˚C 9% yield 
Alcohol 78 DIAD, PPh3, THF, RT No reaction 
Iodide 79 
K2CO3, Acetone, RT, 
then (CH3)3OK, 60 ˚C 
No reaction (with K2CO3) then 
mixtures of unidentified 
products 
 
 
Scheme 40 
 
None of the conditions attempted afforded the final product 56 in an 
acceptable yield. It is still unclear if the low yields obtained are due to the poor 
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nucleophilicity or purity of phenol 68 or to the instability of the different electrophiles 
used (to competing elimination).  
It was therefore decided that an alternative route was needed to efficiently 
prepare a large number of derivatives. As it was likely that most of the issues 
encountered in the deprotection – alkylation steps were a results of the high polarity 
and rich electron density of the compounds we were dealing with, we envisaged that 
deprotection of the quinazoline core at an earlier stage might result in better yield. 
Chang et al. deprotected the benzyl on the quinazoline core before the introduction of 
the amine at position 2. Accordingly, a postdoctoral associate in the group, Dr. 
Thomas Moss, performed the benzylic ether deprotection of compound 65 with 
palladium on charcoal and could isolate phenol 80 in good yield (79%), which 
confirmed the significant influence of the second amino side chain. A sample of free 
phenol was supplied to complete the synthesis of butylphenyl analogue 56 
(Scheme 41). Phenol 80 was alkylated by treatment with mesylate 77 to afford 
compound 81 in medium yield (44%) and displacement of the second chlorine with 
the corresponding amine 66 led to final compound 56 in 36% yield. Performing the 
deprotection and alkylation at position 7 at an earlier stage allowed the synthesis to be 
completed with higher yields and the intermediates were easier to handle and purify 
due to their limited polarity. 
 
 
Scheme 41 
 
 A number of derivatives have been prepared by co-workers in the Fuchter 
group using this route (Figure 73). Derivatisation at position 7 was performed either 
by alkylation with corresponding halides or under Mitsunobu conditions, depending 
on the availability of the starting materials. 
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Dimethoxyquinazoline analogues 
Analogues with methoxy groups at position 6 and 7 were prepared in three 
steps from commercially available bis-methylated dicarbonyl compound 82 
(Scheme 42, applied to the synthesis of BIX-01294 (2)). The dichloroquinazoline core 
83 was obtained by treatment with POCl3 and two subsequent displacements with 
corresponding amines afforded the final compounds. Dr. Tomas Moss prepared large 
quantities of dichloroquinazoline 83 and kindly supplied a sample for the synthesis of 
BIX-01294 (2) which was to be used as a control molecule (Scheme 42). The first 
displacement with amine 64 afforded compound 84 in quantitative yield. The second 
displacement with the corresponding amine 85 was performed in toluene at reflux and 
afforded BIX-01294 (2) in medium yield (63%) for biological testing. 
 
 
Scheme 42 
 
A large number of derivatives have been synthesised by co-workers in the 
Fuchter group as well as at a contract synthesis company using this route, in order to 
access a large number of derivatives for SAR development. Figure 73 summarises the 
structure of the analogues synthesised in the Fuchter group for biological evaluation. 
 
 
Figure 73 Analogues prepared in the Fuchter group based on BIX-01294 scaffold for SAR exploration  
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Biological evaluation 
 
Biochemical assay against EZH2 and SUV39H1 
The library of new analogues was tested in the biochemical assay kit as 
described in Chapter II, against EZH2 and SUV39H1. However, the data obtained 
frequently contained significant well-to-well variability. Furthermore, the batch of 
newly synthesised analogue 56 was assessed but its inhibitory activity against 
SUV39H1 could not be reproduced (this effect was observed for a number of 
compounds). 
While the origin of the discrepancy of the data remains obscure, the 
commercial assay kit was therefore considered non reliable for our needs and its use 
was abandoned. 
 
Cell-based assay 
The focused library of BIX-01294 analogues was screened in order to identify 
compounds which induce the reactivation of PRC2 silenced genes. Cells were treated 
with compounds at a concentration of 10 µM and mRNA levels of two EZH2 target 
genes (KRT17 and FBXO32) were monitored by real-time RT-PCR. 
Three compounds were found to up-regulate KRT17 and FBXO32 RNA levels, 
and were identified as hit compounds (Figure 74). The RT-PCR data for these 
compounds is displayed in Table 12 (Entry 1–3). 
 
Figure 74 Structure of the hits identified in the cell-based assay 
 
Compound 56 was also assessed in this assay. Since cell death was observed at 
10 and 5 µM, the concentration was dropped to 1 µM for RT-PCR measurement. It is 
of particular importance in such cell-based assay to monitor cell death as it can lead to 
changes in histone marks and can thus interfere with the assay reading (See discussion 
in Chapter II). As seen in Table 12 (Entry 5), no effect on gene expression was 
observed at 1 µM. 
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Table 12 Effects on gene expression of compounds in cell-based screen 
Entry Compound KRT17 FBXO32 
1 86 4.1 3.7 
2 87 4.3 29.4 
3 88 7.0 33.3 
4 2 1.1 3.3 
5 56* 1.2 1.1 
Average qRT-PCR data for single concentration (10 µM, except *, 1 µM) dose treated in triplicate, for 48 h. RNA 
levels for target genes are normalised against the housekeeping gene GAPDH and shown is the fold increase 
compared to the untreated sample. 
 
The G9a/GLP inhibitor, BIX-01294 (2) was also tested in this assay (Entry 4). 
Although closely related to our hits from a chemical structure perspective, such 
G9a/GLP selective compound displayed a different effect on gene expression profile 
and did not significantly up-regulate KRT17, but did up-regulate FBXO32. Within 
our focused library, the majority of compounds had little or no effect on both KRT17 
and FBXO32.  
 
AlphaLISA assay against G9a 
 In light of the obvious similarity of the structures of the identified hits with 
that of known G9a inhibitors, we sought to assess whether our compounds retained 
some G9a inhibitory activity. The hit compounds were tested in the G9a AlphaLISA 
assay described in Chapter II, and BIX-01294 (2) was used as control. As shown in 
Table 13, the hit compounds exhibited some moderate G9a activity, ~ 5 to 10 µM. 
 
Table 13 G9a inhibitory activity of the hits and negative compounds 
 
86 87 88 2 
Mean pIC50 (SD) -5.244 (0.038) -5.017 (0.096) -5.050 (0.067) -5.775 (0.033) 
IC50 (µM) 5.70 9.62 8.91 1.68 
pIC50 are average of three independent experiments run as duplicate (standard deviation). Assay conditions: G9a at 
1 nM, H3 peptide at 100 nM, SAM at 15 µM, 30 min reaction time.  
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Conclusions 
 
The synthetic route towards BIX-01294 analogues allowing late-stage 
derivatisation at position O-7 has been investigated. While the synthesis of 
compound 56 presented some challenges, an alternative route was developed to 
efficiently access analogues with diverse side-chains at position 7 (Figure 73). The 
library of compounds generated within the Fuchter group was initially evaluated in 
biochemical assays, however the results were found to be irreproducible. Evaluation 
of the compounds in a cell-based assay identified three hits able to reverse 
EZH2-mediated gene silencing. 
Assessment of the three hits in the G9a biochemical assay described in 
Chapter II revealed that the hits retained some modest G9a inhibitory activity (5 to 
10 µM). We can therefore hypothesise that our compounds lead to gene re-expression 
by targeting a panel of HKMTs with some selectivity toward the ones involved in 
repressive chromatin remodeling (G9a and EZH2). As mentioned above, the substrate 
binding site of G9a and EZH2 may be significantly similar and our initial data is 
consistent with the dual inhibition of G9a and EZH2, possibly with binding of the 
compound in the peptide binding groove. Further work is on-going in the Fuchter and 
Brown groups to test this hypothesis. For example, mass spectrometry experiments 
are on-going to monitor global changes in histone marks and the dynamics of the 
H3K27 trimethylation mark upon compound treatment. Additionally, probes for 
affinity based protein profiling have been designed based on our hit compounds in 
order to pull-out the proteins involved in hit binding. 
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The importance of epigenetic regulation is now well established and it is 
crucial to develop tools to study in depth these important mechanisms. The work 
presented in this thesis initially aimed at developing the SAR around two histone 
lysine methyltranseferase inhibitors previously reported: chaetocin (1) and 
BIX-01294 (2). 
Our work on chaetocin shed light onto the poor characteristics of this 
compound as a specific HKMT inhibitor. The absolute requirement of the reactive 
disulfide bridge led to the establishment of a very steep SAR, therefore impeding the 
progression of such compound through the next steps of drug development. This also 
stressed the importance of the proper validation of hits discovered through high 
throughput screen, tedious but fundamental task often underrated especially in 
academia. We also established the mode of action of chaetocin: biochemical and mass 
spectrometric data are concordant to suggest that the ETP core reacts with available 
cysteines to form covalent adducts which ultimately leads to protein inactivation. 
Although covalent inhibitors can be interesting in drug discovery, we do not believe 
that the reactivity of ETP compounds can be tuned in order to achieve selectivity and 
as such, we do not envision that chaetocin, or any ETP-containing compounds, could 
be used as specific HKMT inhibitors. 
The preparation of the monosulfide analogue of chaetocin (3) took us a bit 
off-track of our initial medicinal chemistry effort. The establishment of the 
stereochemistry of monosulfide 3 was required, however. In light of the 
inconsistencies in the literature, we proposed an alternative approach relying on the 
comparison of experimental and simulated data for three chiropotical properties: 
optical rotation, ECD and VCD. The method was also used, in parallel with chemical 
derivatisation, to correct the assignment of two additional compounds, and led us to 
conclude that all ETPs are desulfurised by triphenylphosphine with retention of 
configuration at the carbon bridgehead atoms. This approach is an additional and 
potent tool for absolute configuration determination but is relatively recent in the 
literature. We foresee that such method is bound to expand in the near future due to 
the ease with which it can be performed (should the spectrometer be available) and 
the increasing computational power leading to ever more accurate and reliable 
simulations. 
The project presented in the last chapter of this thesis aimed at expanding the 
biological activities of the known G9a inhibitor, BIX-01294 (2), and especially to 
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achieve EZH2 inhibition. Chemical derivatisation of the original lead was anticipated 
to lead to this additional activity, but the absence of crystallographic data precluded 
rational design. The cell-free assay available at the time turned out to be unreliable 
and a more sophisticated cell-based assay was therefore developed by our 
collaborators and used as the primary assay. Three analogues have been identified to 
re-express EZH2 target genes and were also found to retain some G9a inhibitory 
activity. We suspect that our hit compounds act as dual inhibitor and a number of 
additional studies are ongoing in our labs to validate our assumption and increase the 
potency of our compounds. Undeniably, EZH2 represents a very promising epigenetic 
target as illustrated by the number of pharmaceutical companies working on this 
HKMT and the proof of concept should soon be available since clinical trials of 
EZH2 inhibitors are now commencing. 
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Compound synthesis 
 
Materials and methods 
 
All reagents and solvents were supplied from commercial sources, and used as 
supplied unless otherwise indicated. Reactions requiring anhydrous conditions were 
conducted in heat-dried glassware (heat gun), under an inert atmosphere (argon), and 
using anhydrous solvents. CH2Cl2, toluene, triethylamine, pyridine and MeOH were 
distilled over CaH2. THF and Et2O were distilled over Na/benzophenone. Toluene 
was distilled over Na. N,N-dimethylformamide, acetonitrile and ethanol were 
obtained as dry or anhydrous from Aldrich Chemical Company, Other solvents and all 
reagents were obtained from commercial suppliers (Fluka; Aldrich Chemical 
Company; Lancaster Chemicals) and were used as obtained if purity was >98%. 
Reactions were performed under an atmosphere of N2 unless otherwise stated. All 
organic extracts were dried over magnesium sulfate.  
Specific rotation [α]!!  was recorded on a Perkin-Elmer 241 polarimeter at 589 nm (Na 
D-line) with a path length of 0.5 dm. Concentrations (c) are quoted in g/100 mL and 
specific rotations are quoted in units of deg.dm−1.cm3.g−1 at the indicated temperature 
(in ˚C). 
Infrared spectra were recorded neat on Perkin-Elmer Paragon 1000 Fourier transform 
spectrometer with automated background subtraction. Only selected absorptions are 
reported and are of strong or medium strength unless stated otherwise and given in 
wavenumbers (cm-1). 
1H NMR spectra were recorded on a Bruker DRX-400 spectrometer operating at 400 
MHz. 13C NMR spectra were recorded on a Bruker DRX-400 spectrometer operating 
at 100 MHz. Chemical shifts (δ) are quoted in units of parts per million (ppm) 
downfield from tetramethylsilane and are referenced to a residual solvent peak. 
(CDCl3 (δH: 7.26, δC: 77.0)). Coupling constants (J) are quoted in units of Hertz  (Hz). 
The following abbreviations are used within 1H NMR analysis: s = singlet,  
d = doublet, t = triplet, q = quartet, quint = quintuplet, sept = septuplet, m = multiplet. 
Spectra recorded at 400 MHz (1H NMR) and 100 MHz (13C NMR) were carried out 
by the Imperial College London Department of Chemistry NMR Service. Low and 
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high resolution mass spectrometry (EI, CI, FAB) were recorded by the Imperial 
College London Department of Chemistry Mass Spectrometry Service using a 
Micromass Platform II and Micromass AutoSpec-Q spectrometer. 
All flash column chromatography was carried out on BDH silica gel 60, particle size 
0.040 – 0.063 mm unless otherwise stated.  
Thin layer chromatography (TLC) was performed on pre-coated aluminium backed 
(Merck Kieselgel 60 F254), and visualised with ultraviolet light (254 nm) or potassium 
permanganate (KMnO4), vanillin, ninhydrin or phosphomolybdic acid (PMA) stains 
as deemed appropriate. 
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Synthetic procedures and compound characterisation  
 
Chapter II Design, synthesis and biological evaluation of chaetocin analogues 
 
2-Chloro-2-oxoethane-1,1-diyl diacetate (7)108 
 
Compound 7 was prepared as follows:108 Glyoxylic acid (21.5 mL of a 75% w/w in 
water, 175.0 mmol), acetic anhydride (175.0 mL, 1.8 mol) and glacial acetic acid 
(40.0 mL, 0.7 mol) were mixed and heated under reflux for 3 h. The solvents were 
rotary evaporated and the remaining volatiles were removed as an azeotrope with 
toluene. The residual brown oil was dissolved in a mixture of CH2Cl2 (120 mL) and 
SOCl2 (45 mL, 0.6 mol) and heated under reflux for 0.5 h. The mixture was rotary 
evaporated to afford acyl chloride 7 as a brown oil that was used in the next step 
without further purification (30.5 g, 89%): IR (neat) 1767, 1373, 1185, 1042 cm-1; 1H 
NMR (400 MHz, CDCl3) δ 6.91 (s, 1H), 2.21 (s, 6H); 13C (100 MHz, CDCl3) δ 168.1 
(2C), 167.5, 87.8, 20.3 (2C); MS (CI) m/z 195 (M+H)+, 212 (M+NH4)+; HRMS (CI) 
m/z calc. for C6H11NO5Cl 212.0326, found: 212.0331. 
 
Ethyl 2-(benzylamino)-2-((4-methoxybenzyl)thio)acetate (9)109 
 
Compound 9 was prepared as follows:109 Benzylamine (13.8 mL, 126 mmol) was 
added to a solution of ethyl glyoxalate (25.0 mL of a 50% solution in toluene, 126 
mmol) in toluene (200 mL). After 2 min, p-methoxybenzylmercaptan (17.5 mL, 126 
mmol) was added and the resulting white solution was allowed to stir for 2.5 h at 
room temperature. The solvent was rotary evaporated and the resulting oil was 
purified by flash column chromatography (EtOAc : Hexanes, 1 : 2) to afford the title 
compound 9 as a yellow oil (21.2 g, 49%): IR (neat) 1729, 1611, 1511, 1243, 1172, 
1032, 699 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.30 – 7.24 (m, 7H), 6.84 (d, J = 
AcO
AcO O
Cl
O
S
HN
O
OEt
 	  
172	  
	  
	   	  
8.8 Hz, 2H), 4.35 (s, 1H), 4.22 (q, J = 7.2 Hz, 2H), 3.87 (d, J = 13.0 Hz, 1H), 3.81 (s, 
3H), 3.76 (d, J = 3.2 Hz, 2H), 3.72 (d, J = 13.0 Hz, 1H), 1.32 (t, J = 7.2 Hz, 3H); 13C 
(100 MHz, CDCl3) δ 169.9, 158.7, 138.7, 130.0 (3C), 128.5 (2C), 128.4 (2C), 127.2, 
114.0 (2C), 63.6, 61.4, 55.3, 49.2, 33.2, 14.1; MS (ESI) m/z 346 (M+H)+; HRMS 
(ESI) m/z calc. for C19H24NO3S 346.1477, found: 346.1489. 
 
2-(Benzyl(2-ethoxy-1-((4-methoxybenzyl)thio)-2-oxoethyl)amino)-2-oxoethane-
1,1-diyl diacetate (13)93 
 
Compound 13 was prepared as follows:93 Acyl chloride 7 (4.23 g, 21.8 mmol) in 
CH2Cl2 (30 mL) was added dropwise to a biphasic mixture of amine 9 (7.52 g, 
21.8 mmol) in CH2Cl2 (100 mL) and NaHCO3 (1.83 g, 21.8 mmol) in water (50 mL) 
at room temperature. The resulting biphasic solution was allowed to stir vigorously 
for 3 h. The organic phase was separated and the aqueous layer was extracted with 
CH2Cl2 (2 × 100 mL). The combined organic layers were dried (MgSO4), filtered and 
rotary evaporated. Flash column chromatography (EtOAc : Hexanes, 1 : 2) afforded 
the title compound 13 as a colourless oil (8.31 g, 76%): IR (neat) 1770, 1743, 1684, 
1513, 1246, 1192, 1028 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.35 – 7.22 (m, 7H), 
6.98 (s, 1H), 6.85 (d, J = 8.8 Hz, 2H), 5.91 (s, 1H), 4.93 (d, J = 17.6 Hz, 1H), 4.64 (d, 
J = 17.6 Hz, 1H), 4.09 – 3.99 (m, 2H), 3.81 (s, 3H), 3.78 (s, 2H), 2.04 (s, 3H), 2.02 (s, 
3H), 1.21 (t, J = 7.1 Hz, 3H); 13C (100 MHz, CDCl3) δ 168.6, 168.3, 167.1, 165.7, 
158.9, 135.7, 130.2 (2C), 128.7, 128.5 (2C), 127.6, 126.8 (2C), 114.0 (2C), 84.0, 62.2, 
61.7, 55.2, 48.7, 35.5, 20.4, 20.2, 13.7; MS (ESI) m/z 504 (M+H)+, 526 (M+Na)+; 
HRMS (ESI) m/z calc. for C25H30NO8S 504.1692, found: 504.1674. 
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1,4-dibenzyl-3,6-bis((4-methoxybenzyl)thio)piperazine-2,5-dione (14) 
 
Compound 14 was prepared as follows:93,103 Benzylamine (1.3 mL, 11.7 mmol), 
followed by p-methoxybenzyl mercaptan (0.8 mL, 5.8 mmol) were added to a 
solution of ester 13 (2.00 g, 3.9 mmol) in MeCN (50 mL). The resulting mixture was 
allowed to stir for 2 min before adding TFA (85 µL, 1.1 mmol) and then heated at 
reflux for 20 h. The formed precipitate was recovered by filtration and rinsed with 
EtOAc to give the protected dithiodiketopiperazine 14 (1.02 g, 44%) as a white solid 
that was used in the next step without further purification: m.p. 172 – 174 ˚C; IR 
(neat) 1668, 1609, 1511, 1440, 1238, 1172, 1035 cm-1; 1H NMR (400 MHz, CDCl3) δ 
7.36 (d, J = 8.6 Hz, 4H), 7.22 – 7.11 (m, 6H), 6.88 (d, J = 8.6 Hz, 4H), 6.65 (d, J = 
7.2 Hz, 4H), 5.13 (d, J = 14.5 Hz, 2H), 4.39 (s, 2H), 3.99 (d, J = 14.0 Hz, 2H), 3.85 (s, 
6H), 3.82 (d, J = 14.0 Hz, 2H), 3.57 (d, J = 14.5 Hz, 2H); 13C (100 MHz, CDCl3) δ 
165.1 (2C), 159.2 (2C), 134.9 (2C), 130.8 (4C), 128.9 (2C), 128.6 (4C), 128.5 (4C), 
127.8 (2C), 114.2 (4C), 57.5 (2C), 55.3 (2C), 46.1 (2C), 36.4 (2C); MS (ESI) m/z 599 
(M+H)+, 621 (M+Na)+; HRMS (ESI) m/z calc. for C34H35N2O4S2 599.2038, found: 
599.2024. 
 
5,7-Dibenzyl-2,3-dithia-5,7-diazabicyclo[2.2.2]octane-6,8-dione (6)93 
 
Compound 6 was prepared as follows:93 BBr3 (160 µL, 1.68 mmol) was added 
dropwise to a solution of diketopiperazine 14 (250 mg, 0.42 mmol) in CH2Cl2 (10 
mL) at −78 ˚C. The solution was allowed to stir at this temperature for 45 min and 
then for 30 min at room temperature. After the addition of sat. aq. NH4Cl (20 mL), the 
biphasic mixture was allowed to stir for 10 min and iodine was added portionwise 
until the red colour persisted. The resulting mixture was allowed to stir for 3 min, 
time after which solid sodium thiosulfate was added, until the colour of iodine 
disappeared. The mixture was allowed to stir for 10 min and then diluted with CH2Cl2 
(10 mL) and water (20 mL). The organic layer was separated and the aqueous layer 
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was extracted with CH2Cl2 (2 × 20 mL). The combined organic extracts were dried 
(MgSO4), filtered and rotary evaporated. Purification by column chromatography 
(EtOAc : Hexanes, 1 : 3) furnished the title compound 6 as a white solid (110 mg, 
74%): IR (neat) 1673, 1496, 1422, 1246, 1167, 730, 696 cm-1; 1H NMR (400 MHz, 
CDCl3) δ 7.41 – 7.28 (m, 10H), 5.24 (s, 2H), 4.86 (d, J = 14.8 Hz, 2H), 4.50 (d, J = 
14.8 Hz, 2H); 13C (100 MHz, CDCl3) δ 163.8 (2C), 134.1 (2C), 129.2 (4C), 128.7 
(2C), 128.5 (4C), 64.7 (2C), 47.7 (2C); MS (CI) m/z 357 (M+H)+, 374 (M+NH4)+; 
HRMS (CI) m/z calc. for C18H20N3O2S2 374.0997, found: 374.0996. 
 
2,5-Dibenzyl-7-thia-2,5-diazabicyclo[2.2.1]heptane-3,6-dione (15) 
 
Compound 15 was prepared as follows:111 PPh3 (40 mg, 0.15 mmol) was added to a 
solution of ETP 6 (50 mg, 0.14 mmol) in CH2Cl2 (10 mL). The mixture was allowed 
to stir for 16 h at room temperature. The solvent was then removed and column 
chromatography (CH2Cl2 : MeOH, 95 : 5) afforded the monosulfide derivative 15 
(26.6 mg, 60%) as a white solid: m.p. 84 – 86 ˚C; IR (neat) 1699, 1357, 1190,  
696 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.39 – 7.24 (m, 10H), 4.79 (d, J = 15.2 Hz, 
2H), 4.72 (s, 2H), 4.27 (d, J = 15.2 Hz, 2H); 13C (100 MHz, CDCl3) δ 172.6 (2C), 
134.6 (2C), 128.9 (4C), 128.3 (2C), 128.2 (4C), 66.4 (2C), 47.4 (2C); MS (CI) m/z 
325 (M+H)+, 342 (M+NH4)+; HRMS (CI) m/z calc. for C18H20N3O2S 342.1276, 
found: 342.1275. 
 
1,4-Dibenzyl-3,6-bis(methylthio)piperazine-2,5-dione (16)93 
 
Compound 16 was prepared as follows:111 NaBH4 (9.4 mg, 0.24 mmol) was added to 
a solution of ETP 6 (11.2 mg, 0.03 mmol) in CH2Cl2 (3 mL) and MeOH (1 mL) at 
0 ˚C. The reaction mixture was allowed to stir for 0.5 h. MeI (2.0 mL, 32 mmol) was 
added and the resulting mixture was allowed to stir for 16 h. The solution was then 
washed with 10% aq. HCl (2 mL). The aqueous layer was extracted with CH2Cl2 (2 × 
3 mL). The organic layers were combined, dried (MgSO4) and rotary evaporated to 
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afford methylthioether 16 as a brown oil (7.4 mg, 60%) that was used in the next step 
without further purification: IR (neat) 1667, 1429, 1241, 1168, 727, 695 cm-1; 
1H NMR (400 MHz, CDCl3) δ 7.37 – 7.26 (m, 10H), 5.36 (d, J = 15.0 Hz, 2H), 4.51 
(s, 2H), 4.14 (d, J = 15.0 Hz, 2H), 2.33 (s, 6H); 13C (100 MHz, CDCl3) δ 164.3 (2C), 
134.7 (2C), 129.1 (4C), 128.7 (4C), 128.4 (2C), 62.0 (2C), 46.9 (2C), 16.7 (2C); MS 
(CI) m/z 387 (M+H)+, 404 (M+NH4)+; HRMS (CI) m/z calc. for C20H26N3O2S2 
404.1466, found: 404.1471. 
 
1,4-Dibenzylpiperazine-2,5-dione (18)241 
 
Compound 18 was prepared as follows:115 Nickel (II) chloride hexahydrate (267 mg, 
1.12 mmol) was added to a solution of ETP 6 (40 mg, 0.11 mmol) in EtOH (5 mL). 
At 0 ˚C, a solution of NaBH4 (127.5 mg, 3.37 mmol) in water (5 mL) was added 
dropwise to the reaction mixture which subsequently darkened. The mixture was 
allowed to stir at reflux for 16 h and was then extracted with CH2Cl2 (3 × 10 mL). The 
combined organic layers were washed with water (20 mL), dried (MgSO4) and rotary 
evaporated. Column chromatography (CH2Cl2 : MeOH, 95 : 5) afforded the title 
compound 18 as a white solid (24.5 mg, 75%): IR (neat) 1648, 1483, 1333, 1254, 718, 
699 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.35 – 7.26 (m, 10H), 4.58 (s, 4H), 3.93 (s, 
4H); 13C (100 MHz, CDCl3) δ 163.2 (2C), 134.9 (2C), 128.9 (4C), 128.5 (4C), 128.2 
(2C), 49.3 (2C), 49.2 (2C); MS (ESI) m/z 295 (M+H)+, 336 (M+MeCN+H)+; HRMS 
(ESI) m/z calc. for C18H19N2O2 295.1447, found: 295.1445. 
 
Chaetocin (1) Production96 
 
A conidial suspension of Chaetomium virescens var. thielavioideum was 
plated on solid complete media, containing 0.5% yeast extract (w/v), 1% vitamin 
solution, 1% (w/v) glucose as carbon source and 5 mM ammonium tartrate as 
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nitrogen source. The pH was adjusted to 6.5 with 10 M aq. NaOH. The plates were 
incubated during 5 days at 37 ˚C. A mycelia inoculum of Chaetomium virescens var. 
thielavioideum was prepared by dissecting agar surfaces of cultures grown on 
complete media and was inoculated into ten 1 L bottles half-filled with solid complete 
media. 
After three weeks of incubation at room temperature, the culture media were extracted 
with CH2Cl2 (2 × 500 mL per bottle) for 24 h and 48 h with orbital shaking. The 
resulting mixtures were then filtered, dried over MgSO4, and rotatory evaporated. The 
extracts were then purified by column chromatography (CH2Cl2 : MeOH, 98 : 2). The 
resulting solid was further purified by trituration in hexanes with sonication to afford 
210 mg of chaetocin (1):   α !!" + 542 (c 0.82, CHCl3); CD (MeOH) Δ!!" (nm): +434 
(237), 0 (263), −42 (272), 0 (284), +78 (304), +1 (350); IR (neat) 3383, 3336, 1670, 
1066, 749 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.42 (d, J = 7.5 Hz, 2H), 7.25 (t, J = 
7.5 Hz, 2H), 6.92 (t, J = 7.5 Hz, 2H), 6.74 (d, J = 7.5 Hz, 2H), 5.25 (s, 2H), 5.24 (br s, 
2H), 4.25 (dd, J = 12.5, 6.0 Hz, 2H), 4.17 (dd, J = 12.5, 9.4 Hz, 2H), 3.83 (d, J = 15.0 
Hz, 2H), 3.28 (dd, J = 9.4, 6.0 Hz, 2H), 3.08 (s, 6H), 2.74 (d, J = 15.0 Hz, 2H); 13C 
(100 MHz, CDCl3) δ 165.6 (2C), 162.8 (2C), 149.1 (2C), 130.4 (2C), 127.4 (2C), 
125.1 (2C), 120.4 (2C), 110.7 (2C), 80.5 (2C), 75.7 (2C), 73.3 (2C), 60.6 (2C), 59.8 
(2C), 39.2 (2C), 27.3 (2C); LCMS: Rt = 5.62 min, MS (ESI) m/z 697 (M+H)+; HRMS 
(ESI) m/z calc. for C30H29N6O6S4 697.1031, found: 697.1021. 
 
Chaetocin monosulfide derivative (3)96 
 
Compound 3 was prepared as follows:111 PPh3 (28 mg, 0.11 mmol) was added to a 
solution of chaetocin (1, 20 mg, 0.03 mmol) in CH2Cl2 (5 mL) and the resulting 
mixture was allowed to stir for 2 h at room temperature. The solvent was rotatory 
evaporated and the resulting pink solid was purified by column chromatography 
(CH2Cl2 : EtOAc, 60 : 40) to afford monosulfide 3 (17 mg, 93 %) as a white solid: 
m.p. 210 – 212 ˚C (dec.); α !!" + 484 (c 0.0039, CHCl3); UV λmax (CHCl3) (A): 243.4 
(0.49), 298 (0.21) nm; CD (MeOH) Δ!!" (nm): 0 (217), −43.7 (223.5), 0 (230), +184.9 
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(248.5), +59.5 (285), +81.6 (304), +0.8 (350); IR (neat) 3388, 2921, 1712, 1468, 1322, 
753 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.47 (d, J = 7.8 Hz, 2H), 7.22 (td, J = 7.8, 
0.7 Hz, 2H), 6.91 (td, J = 7.8, 0.7 Hz, 2H), 6.74 (d, J = 7.8 Hz, 2H), 5.46 (s, 2H), 4.89 
(s, 2H), 4.17 (dd, J = 13.1, 5.2 Hz, 2H), 4.09 (dd, J = 13.1, 8.2 Hz, 2H), 3.63 (d, J = 
14.9 Hz, 2H), 3.00 (s, 6H), 2.81 (dd, J = 8.2, 5.2 Hz, 2H), 2.49 (d, J = 14.9 Hz, 2H); 
13C (100 MHz, CDCl3) δ 174.9 (2C), 173.5 (2C), 149.2 (2C), 130.2 (2C), 128.1 (2C), 
124.9 (2C), 120.3 (2C), 110.6 (2C), 80.7 (2C), 79.4 (2C), 78.5 (2C), 63.6 (2C), 59.1 
(2C), 31.6 (2C), 28.3 (2C); LCMS: Rt = 4.77 min; MS (ESI) m/z 633 (M+H)+; HRMS 
(ESI) m/z calc. for C30H29N6O6S2 633.1590 found: 633.1598. 
 
Chaetocin methylthioether derivative (4)96 
 
Compound 4 was prepared as follows:111 NaBH4 (16 mg, 0.42 mmol) was added to a 
solution of chaetocin (1, 20 mg, 0.03 mmol) in CH2Cl2 / MeOH (6 mL / 2 mL) at 0 ˚C. 
After 30 min, MeI (1 mL, excess) was added dropwise to the solution. It was allowed 
to stir for 16 h and then treated with 1 N aq. HCl (5 mL). The organic layer was 
separated, the aqueous layer was extracted with CH2Cl2 (2 × 5 mL) and the combined 
organic layers were dried (MgSO4), rotary evaporated and purified by column 
chromatography (CH2Cl2 : MeOH, 99 : 1) to afford the methylated compound 4 
(10 mg, 47 %) as a white solid: m.p. 130 – 132 ˚C (dec.); α !!" + 175 (c 0.002, 
CHCl3); UV λmax (CHCl3) (A): 238.6 (1.07), 303.3 (0.44) nm, CD (MeOH) Δ!!" (nm): 
+180 (258), +53 (280), +126 (306), 0 (332); IR (neat) 3369, 2922, 2852, 1656, 1420, 
1385 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.48 (d, J = 7.6 Hz, 2H), 7.20 (t, J = 7.6 Hz, 
2H), 6.85 (t, J = 7.6 Hz, 2H), 6.63 (d, J = 7.6 Hz, 2H), 5.73 (s, 2H), 4.90 (br s, 2H), 
4.65 (br s, 2H), 4.29 (d, J = 10.7 Hz, 2H), 3.78 (d, J = 10.7 Hz, 2H), 3.09 (s, 6H), 2.64 
(d, J = 15.2 Hz, 2H), 2.44 (d, J = 15.2 Hz, 2H), 2.19 (s, 6H), 1.87 (s, 6H); 13C (100 
MHz, CDCl3) δ 166.5 (2C), 165.4 (2C), 150.9 (2C), 129.7 (2C), 128.7 (2C), 125.1 
(2C), 119.1 (2C), 110.1 (2C), 80.5 (2C), 77.2 (2C), 69.2 (2C), 64.6 (2C), 60.6 (2C), 
43.7 (2C), 28.6 (2C), 15.8 (2C), 12.8 (2C); LCMS: Rt = 5.58 min; MS (ESI) m/z 779 
(M+Na)+; HRMS (ESI) m/z calc. for C34H40N6O6S4Na 779.1790, found: 779.1777.  
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Chapter III  Stereochemistry of ETP desulfurisation 
 
Ethyl 3-methyl-2-oxobutanoate (40)182 
 
Compound 40 was prepared as follows:182 Isopropyl magnesium chloride (2 M in 
THF, 50 mL, 100 mmol) was added dropwise to a solution of diethyl oxalate (6.8 mL, 
50 mmol) in dry THF (50 mL) at −78 ˚C. The solution was allowed to stir at −78 ˚C 
for 1 h, then poured into a allowed to stir suspension of ice (40 g), Et2O (50 mL) and 
conc. aq. HCl (3.6 mL). The mixture was extracted with Et2O (3  × 50 mL). The 
organic layer was washed with water, dried (MgSO4), filtered through celite and 
rotatory evaporated to afford the title compound 40 as a yellow oil (3.310 g, 46%) that 
was used in the next step without further purification: 1H NMR (400 MHz, CDCl3), δ 
4.31 (q, J = 7.2 Hz, 2H), 3.25 (sept, J = 6.8 Hz, 1H), 1.35 (t, J = 7.2 Hz, 3H), 1.14 (d, 
J = 6.8 Hz, 6H); 13C (100 MHz, CDCl3) δ 198.2, 161.8, 62.2, 36.9, 17.1 (2C), 14.0; 
MS (CI) m/z 162 (M+NH4+); HRMS (CI) m/z calc. for C7H16NO3 162.1130, found: 
162.1128. 
 
(Z)-Ethyl 3-methyl-2-(2-phenylhydrazono)butanoate (41)182 
 
Compound 41 was prepared as follows:182 A solution of keto-ester 40 (3.25 g, 
22.6 mmol) and phenylhydrazine (3.4 mL, 33.9 mmol) in toluene was heated at 60 ˚C 
for 1 h under N2. The solvent was rotatory evaporated and the crude product was 
purified by column chromatography (EtOAc : Hexanes, 5 : 95) to afford hydrazone 41 
as a yellow oil (4.11 g, 78%): 1H NMR (400 MHz, CDCl3) δ 12.02 (br s, 1H), 7.26 – 
7.32 (m, 2H), 7.19 – 7.21 (m, 2H), 6.93 – 6.97 (m, 1H), 4.29 (q, J = 7.1 Hz, 2H), 3.02 
(sept, J = 6.8 Hz, 1H), 1.36 (t, J = 7.1 Hz, 3H), 1.19 (d, J = 6.8 Hz, 6H); 13C NMR 
(100 MHz, CDCl3) δ 163.6, 143.9, 133.0, 129.2 (2C), 121.4, 113.5 (2C), 60.4, 30.9, 
21.2 (2C), 14.2; MS (ESI) m/z 235 (M+H+); HRMS (ESI) m/z calc. for C13H19N2O2 
235.1447, found 235.1444. 
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Ethyl 3,3-dimethyl-3H-indole-2-carboxylate (39)182 
  
Compound 39 was prepared as follows:182 A solution of 34% HCl in EtOH was 
prepared by adding acetyl chloride to EtOH at 0 ˚C. Hydrazone ester 41 (4.11 g, 
17.6 mmol) was added to the ethanolic HCl (150 mL) and the mixture was heated to 
reflux for 10 min. The solvent was then rotatory evaporated to afford a residue that 
was taken up in Et2O (100 mL) and treated with 5% aq. Na2CO3. The organic phase 
was separated and the aqueous layer was extracted with Et2O (3  × 50 mL), and the 
combined organic layers were washed with water until neutral, dried (MgSO4) and 
concentrated under reduced pressure. Purification by column chromatography 
(EtOAc : Hexanes, 1 : 9) afforded indolenine 39 (2.57 g, 67%) as light yellow solid: 
1H NMR (400 MHz, CDCl3) δ 7.83 – 7.81 (m, 1H), 7.33 – 7.38 (m, 3H), 4.44 (q, J = 
7.1 Hz, 2H), 1.51 (s, 6H), 1.44 (t, J = 7.1 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 
175.5, 161.6, 151.9, 147.5, 128.4, 128.0, 123.5, 121.3, 61.7, 54.2, 22.6 (2C), 14.2; MS 
(ESI) m/z 218 (M+H+); HRMS (ESI) m/z calc. for C13H16NO2 218.1181, found 
218.1184. 
 
Ethyl 3,3-dimethylindoline-2-carboxylate (42)182  
  
Compound 42 was prepared as follows:184 To a solution of indolenine 39 (615 mg, 
2.83 mmol) in 12 mL of MeOH and 2.5 mL of AcOH was added sodium 
cyanoborohydride (232 mg, 3.69 mmol). The reaction mixture was allowed to stir at 
room temperature for 18 h, time after which the reaction was quenched by addition of 
12 N aq. HCl (0.5 mL). Removal of the solvent under reduced pressure gave a residue 
which was treated with 5% aq. Na2CO3 (15 mL) and the resulting solution was 
extracted with CH2Cl2 (3 × 50 mL). The combined organic extracts were dried 
(MgSO4) and evaporated to give indoline 42 a colourless oil (640 mg, 98%) that was 
used in the next step without further purification: 1H NMR (400 MHz, CDCl3) δ 7.06 
(td, J = 7.8, 1.3 Hz, 1H), 7.01 (dd, J = 7.5, 1.3 Hz, 1H), 6.79 (td, J = 7.3, 0.9 Hz, 1H), 
6.71 (app-d, J = 7.9 Hz, 1H), 4.32 – 4.22 (m, 2H), 4.19 (br s, 1H), 4.16 (s, 1H), 1.53 
(s, 3H), 1.33 (t, J = 7.2 Hz, 3H), 1.16 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 172.2, 
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148.1, 137.2, 127.7, 121.9, 119.7, 110.4, 71.5, 60.9, 45.8, 27.7, 24.4, 14.3; MS (ESI) 
m/z 220 (M+H)+; HRMS (ESI) m/z calc. for C13H18NO2 220.1338, found: 220.1337. 
 
Ethyl 1-(2-chloropropanoyl)-3,3-dimethylindoline-2-carboxylate (43) 
  
Compound 43 was prepared as follows:185 2-Chloropropionyl chloride (0.35 mL, 3.56 
mmol) was added dropwise to a solution of triethylamine (0.46 mL, 3.29 mmol) and 
indoline 42 (600 mg, 2.70 mmol) in chloroform (50 mL) at 0 ˚C. The mixture was 
allowed to warm to room temperature and stir for a further 4 h. After that time, the 
reaction mixture was poured into ice-water, and extracted with CH2Cl2 (3 × 50 mL). 
The combined organic extracts were washed with brine, dried (MgSO4), filtered and 
rotatory evaporated. The residue was purified by column chromatography (Hexanes : 
EtOAc, 95 : 5) to afford the title compound 43 as two diastereoisomers as colourless 
oil (combined mass 731 mg, 87%): IR (neat) 2972, 1747, 1673, 1598, 1483, 1409, 
1199, 752 cm-1; Diastereoisomer 1: 1H NMR (500 MHz, CDCl3) δ 8.22 (br s, 1H), 
7.28 – 7.24 (m, 1H), 7.10 – 7.08 (m, 2H), 4.86 (s, 1H), 4.26 – 4.11 (m, 3H), 1.73 (br d, 
J = 6.4 Hz, 3H), 1.42 (s, 3H), 1.40 (s, 3H), 1.26 (t, J = 7.2 Hz, 3H); 13C NMR (100 
MHz, CDCl3) δ 169.8, 166.1, 141.2, 138.7, 128.3, 124.9, 121.6, 117.5, 72.0, 61.7, 
51.6, 45.1, 32.0, 22.7, 20.3, 14.2; MS (CI) m/z 310 (M+H+); HRMS (ESI) m/z calc. 
for C16H21NO3Cl 310.1210, found: 310.1213; Diastereoisomer 2: 1H NMR (500 MHz, 
DMSO) δ 8.05 (br d, J = 7.8 Hz, 1H), 7.28 – 7.24 (m, 2H), 7.10 (br t, J = 7.5 Hz, 1H), 
5.09 (br s, 1H), 5.02 (br q, J = 6.2 Hz, 1H), 4.10 (q, J = 7.0 Hz, 2H), 1.78 (br d, J = 
6.2 Hz, 3H), 1.33 (br s, 3H), 1.31 (br s, 3H), 1.17 (t, J = 7.0 Hz, 3H); 13C NMR (100 
MHz, DMSO) δ 169.2, 166.8, 141.4, 139.6, 127.6, 124.6, 122.1, 116.7, 71.0, 60.9, 
51.5, 44.6, 31.2, 21.8, 21.2, 13.9; MS (CI) m/z 310 (M+H+); HRMS (ESI) m/z calc. 
for C16H21NO3Cl 310.1210, found: 310.1215. 
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2,3,10,10-tetramethyl-2,3,10,10a-tetrahydropyrazino[1,2-a]indole-1,4-dione (44) 
  
Compound 44 was prepared as follows:185 Potassium carbonate (218 mg, 1.7 mmol) 
and an excess of methylamine (5.5 mL of a 2M solution in THF, 11.0 mmol) were 
added to a solution of acylated indoline 43 (340 mg, 1.1 mmol) in MeCN (10 mL) in a 
sealed tube. After refluxing for 18 h, the reaction mixture was filtered, concentrated 
and the residue was purified by column chromatography (Hexanes : EtOAc, 1 : 1) to 
afford the title compound 44 as a mixture of non-separable diastereoisomers as a 
colorless oil (190 mg, 67%): IR (neat) 2969, 1666, 1602, 1483, 1426, 1402, 1290, 755 
cm-1; Diastereoisomer 1 (cis): 1H NMR (400 MHz, CDCl3) δ 8.03 (app-d, J = 7.6 Hz, 
1H), 7.28 – 7.13 (m, 3H), 4.38 (d, J = 1.6 Hz, 1H), 4.16 (dq, J = 7.1, 1.6 Hz, 1H), 
3.05 (s, 3H), 1.70 (s, 3H), 1.67 (d, J = 7.1 Hz, 3H), 1.16 (s, 3H); 13C NMR (100 MHz, 
CDCl3) δ 164.6, 163.8, 140.4, 138.8, 127.5, 125.4, 121.6, 116.9, 68.5, 57.3, 44.5, 30.9, 
24.0, 23.1, 18.0; Diastereoisomer 2 (trans): 1H NMR (400 MHz, CDCl3) δ 8.04 (app-
d, J = 7.8 Hz, 1H), 7.28 – 7.13 (m, 3H), 4.34 (s, 1H), 4.02 (q, J = 7.1 Hz, 1H), 3.01 (s, 
3H), 1.70 (s, 3H), 1.54 (d, J = 7.1 Hz, 3H), 1.19 (s, 3H); 13C NMR (100 MHz, CDCl3) 
δ 165.1, 164.8, 140.8, 138.7, 127.9, 125.6, 121.9, 116.9, 68.2, 60.2, 45.1, 31.7, 24.9, 
24.3, 17.4; MS (ESI) m/z 259 (M+H+); HRMS (ESI) m/z calc. for C15H19N2O2 
259.1447, found: 259.1462.  
 
2,3,10,10-Tetramethyl-2,3-dihydro-1H-3,10a-epithiopyrazino[1,2-a]indole-
1,4(10H)-dione 11-sulfide – ((±)-25)242 
 
Compound 25 was prepared as follows:100,102 NaHMDS (6.4 mL of a 0.6 M solution 
in PhMe, 3.84 mmol) was added dropwise to a solution of elemental sulfur (328 mg, 
10.24 mmol) in dry THF (40 mL) at room temperature. The solution was allowed to 
stir for 1 min, time after which diketopiperazine 44 (330 mg, 1.28 mmol) in THF 
(6 mL) was added dropwise. The solution was allowed to stir for 1 min and additional 
NaHDMS (4.3 mL of a 0.6 M solution in PhMe, 2.56 mmol) was added. The resulting 
orange / light brown mixture was allowed to stir for 30 min at room temperature. The 
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solution was then quenched with aq. sat. NH4Cl and extracted with CH2Cl2 (3 × 
50 mL). The combined organic layers were dried (MgSO4), filtered and concentrated 
to give a dark green residue which was taken up in a degassed mixture of THF – 
EtOH (1:1, 26 mL) and cooled to 0 ˚C. Sodium borohydride (1.210 g, 32 mmol) was 
then added in small portions and the resulting mixture was allowed to warm up to 
room temperature and to stir for 45 min. The solution was subsequently cooled to 
0 ˚C and quenched by addition of aq. sat. NH4Cl. The mixture was extracted with 
EtOAc (3 × 50 mL) and the combined organic extracts were then treated with an 
aqueous solution of KI3 (1.4 M), until the dark purple colour persisted. The mixture 
was allowed to stir for 10 min and quenched with 5% aq. Na2S2O3 solution until 
disappearance of the dark purple colour. The resulting mixture was extracted with 
EtOAc (3 × 50 mL) and the combined organic layers were dried (MgSO4), filtered 
and concentrated. The residue was purified by column chromatography (Hexanes : 
EtOAc, 90 : 10) to afford the racemic title compound 25 as a yellow solid (100 mg, 
24%) which was recrystallised from CH2Cl2 to afford white crystals: m.p. 104 – 
106 °C; IR (neat) 1690, 1460, 1357, 1174 cm-1; 1H NMR (400 MHz, CDCl3) δ 8.02 (d, 
J = 8.0 Hz, 1H), 7.37 – 7.33 (m, 1H), 7.28 – 7.25 (m, 2H), 3.12 (s, 3H), 2.10 (s, 3H), 
1.79 (s, 3H), 1.59 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 164.3, 162.4, 139.1, 136.1, 
128.8, 126.1, 121.3, 115.9, 82.6, 74.3, 49.2, 28.7, 27.3, 20.5, 18.2; MS (CI) m/z 321 
(M+H)+, 257 (M−S2+H)+; HRMS (CI) m/z calc. for C15H17N2O2S2 321.0731, found: 
321.0745. The obtained enantiomers could be separated by chiral HPLC (OD+ 
semiprep column, Hexane : Isopropanol, 1 : 1). First peak: α !!"  −335 (c 2.00, 
CHCl3), Second peak: α !!" +394 (c 2.05, CHCl3). 
 
2,3,10,10-Tetramethyl-2,3-dihydro-1H-3,10a-epithiopyrazino[1,2-a]indole-
1,4(10H)-dione - ((±)-26)242 
  
To a solution of ETP 25 (33 mg, 0.10 mmol) in dioxane (8 mL) was added PPh3 
(33 mg, 0.16 mmol) and the resulting mixture was allowed to stir overnight at room 
temperature. The solvent was then removed under reduced pressure and the pink 
residue was purified by column chromatography (Hexanes : EtOAc, 100 : 0 to 95 : 5) 
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to afford the racemic title compound 26 as colourless oil (19 mg, 64%), which was 
recrystallised from CH2Cl2 to give a white solid: m.p. 58 – 60 ˚C; IR (neat) 1720, 
1456, 1387, 1288, 1134 cm-1; 1H NMR (400 MHz, CDCl3) δ 8.54 (app-d, J = 7.8 Hz, 
1H), 7.25 (td, J = 7.8, 1.0 Hz, 1H), 7.20 (dd, J = 7.8, 1.0 Hz, 1H), 7.13 (td, J = 7.8, 1.0 
Hz, 1H), 2.96 (s, 3H), 1.83 (s, 3H), 1.75 (s, 3H), 1.48 (s, 3H); 13C NMR (100 MHz, 
CDCl3) δ 172.5, 172.0, 139.7, 138.1, 128.1, 124.7, 122.4, 113.6, 86.6, 75.1, 43.5, 27.2, 
26.3, 25.7, 13.3; MS (CI) m/z 289 (M+H)+, 306 (M+NH4)+; HRMS (CI) m/z calc. for 
C15H17N2O2S 289.1011, found: 289.1026. The obtained enantiomers could be 
separated by chiral HPLC (OD+ semiprep column, Hexane : Isopropanol, 90 : 10): 
First peak: α !!" −47.5 (c 1.12, CH2Cl2), Second peak α !!" +34.4 (c 1.12, CH2Cl2). 
 
2-(4-methoxyphenyl)-4,11,11,13-tetramethyl-4H-4,11a-
(epiminomethano)[1,3,5]dithiazepino[5,4-a]indole-5,12(11H)-dione (47) 
and  
From ETP 25: NaBH4 (4.5 mg, 0.117 mmol) was added to a solution of racemic ETP 
25 (15.0 mg, 0.047 mmol) in degassed MeOH : THF (1:1, 5 mL)  at 0 ˚C. Once 
complete (monitored by TLC), a few drops of 0.1 N aq. HCl were added and the 
solvent was removed under reduced pressure. The residue was taken up with CH2Cl2 
(5 mL), dried (MgSO4) and the solvent was removed under reduced pressure. The 
residue obtained was dried under vacuum and then dissolved in dry CH2Cl2 (5 mL). p-
anisaldehyde (7 µL, 0.056 mmol) and boron trifluoride etherate (9 µL, 0.073 mmol) 
were added and the reaction was allowed to stir for 16 h under N2. The solvent was 
then removed under reduced pressure and the residue was purified by column 
chromatography (Hexanes : EtOAc, 80 : 20) to afford the title compound as a mixture 
of diastereoisomers as a colorless oil (Diastereoisomer 1: only traces observed by 
TLC and LCMS of the crude but not isolated; Diastereoisomer 2: 9 mg, 43%;). 
Diastereoisomer 2: IR (neat) 1682, 1606, 1511, 1483, 1372, 1257 cm-1; 1H NMR (400 
MHz, CDCl3) δ 8.18 (d, J = 7.9 Hz, 1H), 7.35 – 7.31 (m, 1H), 7.28 (app-d, J = 8.8 Hz, 
2H), 7.19 (d, J = 4.2 Hz, 2H), 6.80 (app-d, J = 8.8 Hz, 2H), 5.10 (s, 1H), 3.76 (s, 3H), 
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3.27 (s, 3H), 1.98 (s, 3H), 1.72 (s, 3H), 1.34 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 
165.5, 162.2, 160.4, 139.5, 137.5, 130.6 (2C), 128.4, 126.8, 125.9, 121.5, 117.4, 114.2 
(2C), 82.1, 68.8, 55.3, 52.0, 49.2, 28.0, 27.6, 22.3, 21.8; A NOESY experiment 
showed a correlation between the signal at 5.1 ppm (CH of the thioacetal carbon) and 
the signal at 3.27 ppm (CH3 on the nitrogen atom of the ETP ring) thus suggesting 
that this diastereoisomer is the syn. MS (ES) m/z 441 (M+H)+; HRMS (ES) m/z calc. 
for C23H25N2O3S2 441.1307, found: 441.1316. 
The 2 enantiomers could be observed by chiral HPLC (OD+ analytical column, 
Hexane : Isopropanol, 98 : 2, 1 mL/min) around 60 min and 100 min. The reaction 
was repeated on a single enantiomer of ETP 25 (first peak by HPLC separation) and 
the product was also obtained as mixture of diastereoisomers (13% of diastereoisomer 
2, and 6% of diastereoisomer 1). Diastereoisomer 2 was obtained as a single 
enantiomer eluting with a comparable retention time as the first peak of the racemic 
(around 70 min).   α !!" −66 (c 0.20, CHCl3) 
 
From monosulfide (26): 
The trithiane derivative of p-anysaldehyde 48 was prepared as follows:189,190 A 
mixture of Na2S (390 mg, 5 mmol) and SiCl4 (1.15 mL, 10 mmol) in MeCN (7.5 mL) 
was allowed to stir for 15 min. After that time, p-anysaldehyde (304 µL, 2.5 mmol) 
was added and the mixture was allowed to stir for 16 h at room temperature. Ice-cold 
water (50 mL) was then added and the resulting mixture was extracted with EtOAc (2 
× 100 mL), dried (MgSO4) and the solvent was removed under reduced pressure. The 
solid obtained was recrystallised from acetic acid to afford the trithiane derivative of 
p-anysaldehyde 48 as a pink solid (41 mg, 4%). 
In DMSO, only the Beta conformer was observed243: 1H NMR (400 MHz, d-DMSO) 
δ 7.36 (d, J = 8.7 Hz, 3 × 2H), 6.96 (d, J = 8.7 Hz, 3 × 2H), 5.68 (s, 3 × 1H), 3.75 (s, 3 
× 3H); 13C NMR (100 MHz, DMSO) δ 159.4 (3 × 1C), 130.2 (3 × 1C), 129.1 (3 × 2C), 
114.4 (3 × 2C), 56.4 (3 × 1C), 55.2 (3 × 1C); In CDCl3, alpha/beta ratio243 varied as a 
function of the temperature (1:10 at 25 ˚C versus 1:5 at 40 ˚C). Alpha conformer: 1H 
NMR (400 MHz, CDCl3) δ 7.80 (d, J = 8.8 Hz, 2H), 7.38 (d, J = 8.7 Hz, 2 × 2H), 6.97 
(d, J = 8.8 Hz, 2H), 6.88 (d, J = 8.7 Hz, 2 × 2H), 5.69 (s, 1H), 5.40 (s, 2 × 1H), 3.86 (s, 
3H), 3.80 (s, 2 × 3H); 13C NMR (100 MHz, CDCl3) δ 174.4, 160.0 (2 × 1C), 130.4 (2 
× 1C), 130.3, 130.1 (2 × 1C), 129.2 (2 × 2C), 114.4 (2 × 2C), 114.3 (1 × 2C), 55.4, 
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55.3 (2 × 1C), 52.8, 51.2 (2 × 1C); MS (CI) m/z 153 (1/3M+H)+; HRMS (CI) m/z calc. 
for C8H9OS 153.0369, found: 153.0422. 
A solution of the racemic monosulfide 26 (21 mg, 0.073 mmol) in CH2Cl2 (10 mL) 
was treated with the trithiane derivative of p-anysaldehyde 48 (17 mg, 0.036 mmol) 
and boron trifluoride etherate (15 µL, 0.117 mmol). The mixture was allowed to stir 
at 40 ˚C for 5 h and then additional boron trifluoride etherate (2 × 30 µL, 0.234 
mmol) was added. The mixture was subsequently absorbed on silica gel and purified 
by column chromatography (Hexanes : EtOAc, 85 : 15) and title compound 47 was 
obtained as a mixture of two diastereoisomers as colourless oils (56% of 
diastereoisomer 1 and 25% of diastereoisomer 2, 7:3): Diastereoisomer 1: IR (neat) 
1682, 1606, 1510, 1481, 1459, 1372, 1254 cm-1; 1H NMR (500 MHz, CDCl3) δ 8.23 
(d, J = 8.0 Hz, 1H), 7.37 – 7.33 (m, 1H), 7.24 (app-d, J = 8.7 Hz, 2H), 7.27 – 7.21 (m 
2H), 6.78 (app-d, J = 8.7 Hz, 2H), 4.98 (s, 1H), 3.76 (s, 3H), 3.14 (s, 3H), 2.00 (s, 3H), 
1.74 (s, 3H), 1.33 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 166.0, 161.7, 160.4, 140.0, 
136.6, 130.6 (2C), 128.2, 126.7, 126.5, 122.2, 116.8, 114.2 (2C), 77.8, 71.3, 55.3, 
51.6, 50.4, 28.5, 27.6, 22.7, 19.5; A NOESY experiment did not show any correlation 
between the signal at 5.1 ppm (CH of the thioacetal carbon) and the signal at 3.37 
ppm (CH3 on the nitrogen atom of the ETP ring) thus suggesting that this 
diastereoisomer is the trans. MS (ES) m/z 441 (M+H)+; HRMS (ES) m/z calc. for 
C23H25N2O3S2 441.1307, found: 441.1308; 
Diastereoisomer 2 matched the data of the compound obtained by reaction of the ETP 
25 (IR, 1H, 13C, HSQC and NOESY). MS (ES) m/z 441 (M+H)+; HRMS (ES) m/z calc. 
for C23H25N2O3S2 441.1307, found: 441.1318; The two enantiomers could be 
observed by chiral HPLC (OD+ analytical column, Hexane : Isopropanol, 98 : 2, 1 
mL/min) at 52 min and 80 min. 
The reaction was repeated on a single enantiomer of monosulfide 26 (first peak by 
HPLC separation) and diastereoisomer 2 was obtained as a single enantiomer α !!" −40 (c 0.20, CHCl3) eluting with the comparable retention time as the first peak 
of the racemic (around 70 min), and importantly with the same retention time as the 
thioacetal obtained from ETP 25 (as confirmed by spiking). 
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Ethyl 2-(2-(4-fluorophenyl)hydrazono)-3-methylbutanoate (51) 
  
Compound 51 was prepared as follows:182 Keto-ester 40 (2.000 g, 13.87 mmol) was 
added to a solution of the hydrochloride salt of 4-fluorophenylhydrazine (3.384 g, 
20.81 mmol) and triethylamine (2.9 mL, 20.81 mmol) in toluene and the resulting 
mixture was heated at 60 ˚C for 1 h. The solvent was rotatory evaporated and the 
crude product purified by column chromatography (EtOAc : Hexanes, 5 : 95) to 
afford hydrazone 51 as a yellow oil (3.250 g, 93%): IR (neat) 1727, 1683, 1551, 1510, 
1205, 1155 1092 cm-1; 1H NMR (400 MHz, CDCl3) δ 12.01 (br s, 1H), 7.13 – 7.10 (m, 
2H), 7.01 – 6.96 (m, 2H), 4.28 (q, J = 7.1 Hz, 2H), 3.01 (sept, J = 6.8 Hz, 1H), 1.36 (t, 
J = 7.1 Hz, 3H), 1.18 (d, J = 6.8 Hz, 6H); 13C NMR (100 MHz, CDCl3) δ 163.7, 158.0 
(d, J = 237 Hz, 1C), 140.3, 133.0, 115.8 (d, J = 22 Hz, 2C), 114.4 (d, J = 8 Hz, 2C), 
60.5, 30.8, 21.2 (2C), 14.2; 19F NMR (377 MHz, CDCl3) δ −123.05; MS (ESI) m/z 
253 (M+H+), 236; HRMS (ESI) m/z calc. for C13H18FN2O2 253.1352, found 253.1358. 
 
Ethyl 5-fluoro-3,3-dimethyl-3H-indole-2-carboxylate (52) 
  
 Compound 52 was prepared as follows:182 A solution of 34% HCl in EtOH was 
prepared by adding acetyl chloride to EtOH at 0 ˚C. Hydrazone ester 51 (3.250 g, 
12.88 mmol) was added to the ethanolic HCl (150 mL) and the mixture was heated to 
reflux for 10 min. The solvent was then rotatory evaporated to afford a residue that 
was taken up in Et2O (100 mL) and treated with 5% aq. Na2CO3. The organic phase 
was separated and the aqueous layer was extracted with Et2O (3  × 50 mL), and the 
combined organic layers were washed with water until neutral, dried (MgSO4) and 
rotatory evaporated. Purification by column chromatography (EtOAc : Hexanes, 1 : 9) 
afforded indolenine 52 (1.662 g, 55%) as a pale pink solid: m.p. 90 – 92 ˚C; IR (neat) 
1710, 1595, 1543, 1461, 1305, 1198, 1093, 1057 cm-1; 1H NMR (400 MHz, CDCl3) δ 
7.77 (dd, J = 8.4, 4.7 (JH-F) Hz, 1H), 7.09 – 7.02 (m, 2H), 4.44 (q, J = 7.1 Hz, 2H), 
1.51 (s, 6H), 1.44 (t, J = 7.1 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 175.3, 163.1 (d, 
J = 250.3 Hz, 1C), 161.3, 149.9 (d, J = 8.6 Hz, 1C) , 147.9, 124.6 (d, J = 9.7 Hz, 1C), 
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115.1 (d, J = 24.0 Hz, 1C), 109.1 (d, J = 24.9 Hz, 1C), 61.8, 54.7, 22.6 (2C), 14.2; 19F 
NMR (377 MHz, CDCl3) δ −111.64; MS (ESI) m/z 236 (M+H+); HRMS (ESI) m/z 
calc. for C13H15FNO2 236.1087, found 236.1107. 
 
Ethyl 5-fluoro-3,3-dimethylindoline-2-carboxylate (53) 
  
Compound 53 was prepared as follows:184 To a solution of indolenine 52 (1.445 g, 
6.14 mmol) in 28 mL of MeOH and 7 mL of AcOH was added sodium 
cyanoborohydride (502 mg, 7.98 mmol). The reaction mixture was allowed to stir at 
room temperature for 18 h. 12 N aq. HCl (2 mL) was then added. The solvent was 
rotatory evaporated and the obtained residue which was taken up in 5% aq. Na2CO3 
(50 mL). The solution was extracted with CH2Cl2 (3 × 50 mL) and the combined 
organic extracts were dried (MgSO4) and rotatory evaporated to afford title compound 
53 as a yellow oil (1.721 g, quant.) that was used in the next step without further 
purification: 1H NMR (400 MHz, CDCl3) δ 6.77 – 6.70 (m, 2H), 6.62 (dd, J = 8.3, 4.3 
(JH-F) Hz, 1H), 4.31 – 4.22 (m, 2H), 4.16 (s, 1H), 4.08 (br s, 1H), 1.50 (s, 3H), 1.33 (t, 
J = 7.1 Hz, 3H), 1.14 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 172.0, 157.8 (d, J = 
234.5 Hz, 1C), 143.9, 139.2 (d, J = 8.2 Hz, 1C), 113.8 (d, J = 23.7 Hz, 1C), 111.1 (d, 
J = 8.7 Hz, 1C), 109.4 (d, J = 24.1 Hz, 1C), 71.9, 61.1, 46.1, 27.5, 24.2, 14.3; 19F 
NMR (377 MHz, CDCl3) δ −124.62; MS (ESI) m/z 238 (M+H)+; HRMS (ESI) m/z 
calc. for C13H17FNO2 238.1243, found: 238.1248.  
 
Ethyl 1-(2-chloropropanoyl)-5-fluoro-3,3-dimethylindoline-2-carboxylate (54) 
 
Compound 54 was prepared as follows:185 2-Chloropropionyl chloride (0.774 mL, 
7.98 mmol) was added dropwise to a solution of triethylamine (1.027 mL, 7.37 mmol) 
and crude indoline 53 (1.721 g, 6.14 mmol) in chloroform (100 mL) at 0 ˚C. The 
mixture was allowed to warm to room temperature and stir for a further 4 h. After that 
time, the reaction mixture was poured into ice-water, and extracted with CH2Cl2 (3 × 
50 mL). The combined organic extracts were washed with brine, dried (MgSO4), 
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filtered and rotatory evaporated. The residue was purified by column chromatography 
(Hexanes : EtOAc, 95 : 5) to afford the title compound 54 as two diastereoisomers as 
colourless oils (combined mass 1.862 g, 92% over 2 steps): Diastereoisomer 1: IR 
(neat) 1741, 1674, 1487,1400, 1259, 1199, 1168 cm-1; 1H NMR (400 MHz, CDCl3) δ 
8.16 (br s, 1H), 6.94 (td, J = 9.0, 2.9 Hz, 1H), 6.80 (br d, J = 7.2 Hz, 1H), 4.88 (s, 1H), 
4.26 – 4.18 (m, 3H), 1.71 (br d, J = 6.1 Hz, 3H), 1.42 (s, 3H), 1.39 (s, 3H), 1.26 (t, J = 
7.1 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 169.6, 166.6, 160.2 (d, J = 248.6 Hz, 1C), 
140.9 (d, J = 4.8 Hz, 1C), 137.2, 118.5 (d, J = 7.7 Hz, 1C), 114.5 (d, J = 23.3 Hz, 1C), 
109.0 (d, J = 22,8 Hz, 1C), 72.2, 61.9, 51.3, 45.0, 31.7, 22.4, 20.3, 14.2; 19F NMR 
(377 MHz, CDCl3) δ −117.35; MS (ESI) m/z 328 (M+H+); HRMS (ESI) m/z calc. for 
C16H20FNO3Cl 328.1116, found: 328.1118; Diastereoisomer 2: IR (neat) 1740, 1665, 
1485,1399, 1257, 1196, 1167 cm-1; 1H NMR (500 MHz, CDCl3) δ 8.17 (br s, 1H), 
6.94 (td, J =8.7, 2.5 Hz, 1H), 6.81 (br s, 1H), 4.75 (m, 2H), 4.18 (q, J = 7.1 Hz, 2H), 
1.76 (br d, J = 4.5 Hz, 3H), 1.38 (br s, 6H), 1.24 (br unresolved t, 3H); 13C NMR (100 
MHz, DMSO) δ 168.8, 166.8, 160.1 (d, J = 240.6 Hz, 1C), 141.4, 137.4, 118.8, 114.4 
(d, J = 24.2 Hz, 1C), 109.1, 73.3, 61.7, 51.3, 44.8, 31.5, 21.8, 21.1, 14.1; 19F NMR 
(377 MHz, CDCl3) δ −117.27; MS (ESI) m/z 328 (M+H+); HRMS (ESI) m/z calc. for 
C16H20FNO3Cl 328.1116, found: 328.1117.  
 
8-Fluoro-2,3,10,10-tetramethyl-2,3,10,10a-tetrahydropyrazino[1,2-a]indole-1,4-
dione (55) 
  
Compound 55 was prepared as follows:185 Potassium carbonate (1.209 mg, 9.1 mmol) 
and an excess of methylamine (31 mL of a 2M solution in THF, 61.0 mmol) were 
added to a solution of acylated indoline 54 (2.000 g, 6.1 mmol) in MeCN (20 mL) in a 
sealed tube. After refluxing for 18 h, the reaction mixture was filtered, concentrated 
and the residue was purified by column chromatography (Hexanes : EtOAc, 1 : 1) to 
afford the title compound 55 as a mixture of non-separable diastereoisomers as a 
colorless oil (1.554 g, 92%): IR (neat) 1665, 1611, 1482, 1418, 1400 cm-1; 
Diastereoisomer 1 (cis): 1H NMR (400 MHz, CDCl3) δ 7.99 (dd, J = 8.6, 4.7 (JH-F) Hz, 
1H), 6.94 (app-td, J = 8.7 (JH-F and JH-H), 2.7 Hz, 1H), 6.89 (dd, J = 8.1 (JH-F), 2.6 Hz, 
1H), 4.40 (d, J = 1.7 Hz, 1H, cis coupling, confirmed by NOESY), 4.17 (qd, J = 6.7, 
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1.7 Hz, 1H, cis coupling, confirmed by NOESY), 3.05 (s, 3H), 1.68 (s, 3H), 1.67 (d, J 
= 6.7 Hz, 3H), 1.16 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 164.6, 163.9, 160.7 (d, J 
= 244.4 Hz, 1C), 143.0 (d, J = 7.8 Hz, 1C), 135.0, 118.5 (d, J = 8.8 Hz, 1C), 114.2 (d, 
J = 22.7 Hz, 1C), 109.5 (d, J = 23.8 Hz, 1C), 69.1, 57.6, 45.1, 31.3, 24.6, 23.2, 18.4; 
19F NMR (377 MHz, CDCl3) δ −115.58; Diastereoisomer 2 (trans): 1H NMR (400 
MHz, CDCl3) δ 8.00 (dd, J = 8.7, 4.7 (JH-F) Hz, 1H), 6.94 (app-td, J = 8.8 (JH-F and 
JH-H), 2.5 Hz, 1H), 6.89 (dd, J = 8.1 (JH-F), 2.7 Hz, 1H), 4.36 (s, 1H), 4.01 (q, J = 7.0 
Hz, 1H), 3.01 (s, 3H), 1.68 (s, 3H), 1.54 (d, J = 7.0 Hz, 3H), 1.19 (s, 3H); 13C NMR 
(100 MHz, CDCl3) δ 164.8, 164.6, 160.6 (d, J = 244.3 Hz, 1C), 143.0 (d, J = 7.4 Hz, 
1C), 134.7, 118.1 (d, J = 8.7 Hz, 1C), 114.3 (d, J = 23.4 Hz, 1C), 109.4 (d, J = 23.4 
Hz, 1C), 68.3, 60.0, 45.3, 31.7, 24.8, 24.1, 17.5; MS (ESI) m/z 277 (M+H+), 225, 214, 
206; HRMS (ESI) m/z calc. for C15H18FN2O2 277.1352, found: 277.1359.  
 
8-Fluoro-2,3,10,10-tetramethyl-2,3-dihydro-1H-3,10a-epithiopyrazino[1,2-
a]indole-1,4(10H)-dione 11-sulfide (49) 
  
 
Compound 49 was prepared as follows:100,102 NaHMDS (9.2 mL of a 0.6 M solution 
in PhMe, 5.48 mmol) was added dropwise to a solution of elemental sulfur (468 mg, 
14.62 mmol) in dry THF (73 mL) at room temperature. The solution was allowed to 
stir for 1 min, time after which diketopiperazine 55 (500 mg, 1.83 mmol) in THF 
(9 mL) was added dropwise. The solution was allowed to stir for 1 min and additional 
NaHDMS (6.1 mL of a 0.6 M solution in PhMe, 3.66 mmol) was added. The resulting 
orange / light brown mixture was allowed to stir for 30 min at room temperature. The 
solution was then quenched with aq. sat. NH4Cl and extracted with CH2Cl2 (3 × 50 
mL). The combined organic layers were dried (MgSO4), filtered and concentrated to 
give a dark green residue which was taken up in a degassed mixture of THF – EtOH 
(1:1, 36 mL) and cooled to 0 ˚C. Sodium borohydride (1.730 g, 45.70 mmol) was then 
added in small portions and the resulting mixture was allowed to warm up to room 
temperature and to stir for 45 min. After that time, the solution was cooled to 0 ˚C and 
quenched by addition of aq. sat. NH4Cl. The mixture was extracted with EtOAc (3 × 
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50 mL) and the combined organic extracts were then treated with an aqueous solution 
of KI3 (1.4 M), until the dark purple colour persisted. The mixture was allowed to stir 
for 10 min and quenched with 5% aq. Na2S2O3 solution until disappearance of the 
dark purple colour. The resulting mixture was extracted with EtOAc (3 × 50 mL) and 
the combined organic layers were dried (MgSO4), filtered and rotatory evaporated. 
The residue was purified by column chromatography (Hexanes : EtOAc, 90 : 10) to 
afford the racemic title compound 49 as a yellow solid (262 mg, 42%) which was 
recrystalised from CH2Cl2 to afford yellow crystals: m.p. 138 – 140 ˚C; IR (neat) 
1686, 1486, 1357, 1316, 1259, 1164 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.95 (dd, J 
= 8.8, 4.5 (JH-F) Hz, 1H), 7.01 (app-td, J = 8.8 (JH-F and JH-H), 2.6 Hz, 1H), 6.95 (dd, J 
= 7.9 (JH-F), 2.6 Hz, 1H), 3.10 (s, 3H), 2.07 (s, 3H), 1.74 (s, 3H), 1.57 (s, 3H); 13C 
NMR (100 MHz, CDCl3) δ 164.0, 162.2, 161.0 (d, J = 247.2 Hz, 1C), 141.2 (d, J = 
7.7 Hz, 1C), 132.03, 117.0 (d, J = 9.4 Hz, 1C), 115.3 (d, J = 23.5 Hz, 1C), 109.1 (d, J 
= 24.7 Hz, 1C), 82.8, 74.2, 49.2, 28.5, 27.3, 20.4, 18.1; 19F NMR (377 MHz, CDCl3) 
δ −115.00; MS (CI) m/z 356 (M+NH4)+, 339 (M+H)+, 275 (M-S2+H)+; HRMS (CI) 
m/z calc. for C15H16FN2O2S2 339.0637, found: 339.0631. The two enantiomers could 
be separated by chiral HPLC (OD+ semiprep column, Hexane : Isopropanol, 1 : 1): 
First peak: α !!" −419 (c 1.05, CHCl3), Second peak α !!" +300 (c 1.05, CHCl3). 
 
8-Fluoro-2,3,10,10-tetramethyl-2,3-dihydro-1H-3,10a-epithiopyrazino[1,2-
a]indole-1,4(10H)-dione (50) 
 
Compound 50 was prepared as follows:111 PPh3 (187 mg, 0.71 mmol) was added to a 
solution of F-ETP 49 (100 mg, 0.29 mmol) in CH2Cl2 (10 mL) and the resulting 
mixture was allowed to stir for 1 h at room temperature. The solvent was rotatory 
evaporated and the orange residue was purified by column chromatography 
(Hexanes : EtOAc, 97 : 3 to 93 : 7) to afford the title compound 50 as a white solid 
(45.5 mg, 50%): m.p. 126 – 128 ˚C; IR (neat) 1720, 1487, 1301, 1259, 1192 cm-1; 1H 
NMR (400 MHz, CDCl3) δ 7.48 (dd, J = 8.6, 4.5 (JH-F) Hz, 1H), 6.94 (app-td, J = 8.6 
(JH-F and JH-H), 2.5 Hz, 1H), 6.90 (dd, J = 8.1 (JH-F), 2.5 Hz, 1H), 2.96 (s, 3H), 1.83 (s, 
3H), 1.74 (s, 3H), 1.46 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 172.5, 171.7, 160.3 (d, 
N N
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J = 242.3 Hz, 1C), 141.6 (d, J = 8.0 Hz, 1C), 134.3, 114.7 (d, J = 24.5 Hz, 1C), 114.4 
(d, J = 9.7 Hz, 1C), 110.0 (d, J = 24.1 Hz, 1C), 86.8, 75.1, 43.7, 27.1, 25.8, 25.7, 13.2; 
MS (ESI) m/z 307 (M+H)+, 240; HRMS (ESI) m/z calc. for C15H16FN2O2S 307.0917, 
found: 307.0925. The obtained enantiomers could be separated by chiral HPLC (OD+ 
semiprep column, Hexane : Isopropanol, 90 : 10). First peak: α !!" −32.2 (c 1.01, 
CHCl3), Second peak α !!" +30.7 (c 1.03, CHCl3). 
  
 	  
192	  
	  
	   	  
Chapter IV Towards the discovery of novel EZH2 inhibitors 
 
4-Benzyloxy-3-methoxybenzonitrile (58)226 
 
Compound 58 was prepared as follows:226 To an ice-cooled solution of 4-hydroxy-3-
methoxybenzonitrile (57, 5.00 g, 33.5 mmol) in DMF (60 mL) were slowly added 
K2CO3 (6.95 g, 50.3 mmol) followed by benzylbromide (4.4 mL, 36.8 mmol). The 
solution was allowed to stir overnight at room temperature. Sat. aq. NaCl (100 mL) 
was then added and the resulting precipitate was filtered, washed with water and dried 
under vacuum to afford the title compound 58 as a white solid (7.74 g, 96%) that was 
used in the next step without further purification: IR (neat) 2223, 1595, 1512, 1267, 
1241, 1132, 984 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.43 – 7.31 (m, 5H), 7.21 (dd, J 
= 8.2, 1.9 Hz, 1H), 7.09 (d, J = 1.9 Hz, 1H), 6.90 (d, J = 8.2 Hz, 1H), 5.20 (s, 2H), 
3.90 (s, 3H); 13C (100 MHz, CDCl3) δ 151.9, 149.6, 135.7, 128.7 (2C), 128.2, 127.2 
(2C), 126.2, 119.2, 114.3, 113.2, 104.1, 70.8, 56.1; MS (CI) m/z 257 (M+NH4)+; 
HRMS (CI) m/z calc. for C15H17N2O2 257.1290, found: 257.1292. 
 
4-Benzyloxy-5-methoxy-2-nitrobenzonitrile (59) 
  
Compound 59 was prepared as follows:226 Benzonitrile 58 (7.00 g, 29.3 mmol) was 
dissolved in acetic anhydride (70 mL) and cooled to 0 ˚C. Nitric acid (4.9 mL of 69 
wt.% solution in water, 76.7 mmol) was added slowly and the reaction was allowed to 
stir overnight at room temperature. The mixture was then poured into ice-water and 
the resulting precipitate was filtered, washed with water and dried under vacuum to 
afford the title compound 59 (8.04 g, 96%) as a white solid that was used in the next 
step without further purification: m.p. 128 – 130 ˚C; IR (neat) 2228, 1572, 1533, 1517, 
1336, 1288, 1223, 1057 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.85 (s, 1H), 7.46 – 7.37 
(m, 5H), 7.21 (s, 1H), 5.27 (s, 2H), 4.01 (s, 3H); 13C (100 MHz, DMSO) δ 153.4, 
150.8, 142.1, 135.4, 128.6 (2C), 128.4, 128.1 (2C), 116.7, 115.7, 109.6, 99.8, 70.8, 
57.1; MS (CI) m/z 302 (M+NH4)+; HRMS (CI) m/z calc. for C15H16N3O4 302.1141, 
found: 303.1141. 
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2-Amino-4-benzyloxy-2-methoxybenzonitrile (60)226 
 
Compound 60 was prepared as follows:231 To a solution of nitrobenzonitrile 59 
(100 mg, 0.35 mmol) in CH2Cl2 (3 mL), tetrabutylammonium chloride monohydrate 
(68 mg, 0.24 mmol) was added, followed by the slow addition of a solution of sodium 
dithionite (367 mg, 2.11 mmol) in water (3 mL). The mixture was allowed to stir 
overnight at room temperature and then basified with 2 N aq. NaOH at 0 ˚C. The 
aqueous layer was extracted with CH2Cl2 (2 × 10 mL). A precipitate was obtained 
upon treatment of the combined organic layers with 1M HCl in Et2O. The white solid 
was filtered and dissolved in water. The aqueous layer was basified with 2N NaOH 
and extracted with EtOAc. The organic layer was dried (MgSO4) and concentrated to 
yield the title compound 60 (87 mg, 97%) as a white solid: IR (neat) 3440, 3352, 3243, 
2205, 1641, 1620, 1505, 1239, 1119, 985 cm-1; 1H NMR (400 MHz, DMSO) δ 7.44 – 
7.37 (m, 5H), 6.87 (s, 1H), 6.51 (s, 1H), 5.57 (s, 2H), 5.03 (s, 2H), 3.65 (s, 3H); 13C 
(100 MHz, CDCl3) δ 153.4, 148.2, 140.4, 136.2, 128.5 (2C), 128.1, 127.9 (2C), 116.6, 
114.3, 100.1, 83.9, 69.5, 56.2; MS (CI) m/z 272 (M+NH4)+; HRMS (CI) m/z calc. for 
C15H18N3O2 272.1399, found: 272.1402. 
 
Methyl (5-(benzyloxy)-2-cyano-4-methoxyphenyl)carbamate (61) 
  
Compound 61 was prepared as follows:226 To a solution of aniline 60 (50 mg, 
0.19 mmol) and DIEA (137 µL, 0.79 mmol) in DMA – CH2Cl2 (1 mL : 0.5 mL) at 
0 ˚C was added methyl chloroformate (23 µL, 0.29 mmol). The mixture was allowed 
to stir overnight at room temperature. Water (5 mL) was then added and the resulting 
precipitate was recovered and dried under vacuum to afford the title compound 61 
(47 mg, 79%) as a yellow solid that was used in the next step without further 
purification: IR (neat) 3329, 2223, 1716, 1595, 1510 1220, 1128, 996 cm-1; 1H NMR 
(400 MHz, DMSO) δ 9.55 (br s, 1H), 7.47 – 7.37 (m, 5H), 7.35 (s, 1H), 7.19 (s, 1H), 
5.14 (s, 2H), 3.80 (s, 3H), 3.67 (s, 3H); 13C (100 MHz, DMSO) δ 154.7, 151.7, 146.6, 
136.0, 135.2, 128.5 (2C), 128.2, 128.0 (2C), 117.1, 114.5, 110.8, 109.5, 70.1, 56.1, 
NC O
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52.1; MS (CI) m/z 330 (M+NH4)+; HRMS (CI) m/z calc. for C17H20N3O4 330.1454, 
found: 330.1462. 
 
7-(Benzyloxy)-6-methoxyquinazoline-2,4(1H,3H)-dione (62)226 
 
Compound 62 was prepared as follows:226 Carbamate 61 (1.088 g, 3.5 mmol) was 
added to a solution of H2O2 (10 mL of 35 wt.% solution in water, 110 mmol) and 
NaOH (1.28 g, 32 mmol) in ethanol (50 mL) and the resulting mixture was allowed to 
stir for 4 h under reflux. Water (70 mL) was added and the solution was allowed to 
cool to room temperature and then acidified with 1 N aq. HCl. The resulting 
precipitate was recovered, washed with water and dried under vacuum to afford the 
title compound 62 (609 mg, 64%) as a white solid that was used in the next step 
without further purification: IR (neat) 1718, 1649, 1618, 1512, 1267, 1107, 838 cm-1; 
1H NMR (400 MHz, DMSO) δ 11.12 (s, 1H), 10.94 (s, 1H), 7.50 – 7.38 (m, 5H), 7.30 
(s, 1H), 6.80 (s, 1H), 5.16 (s, 2H), 3.80 (s, 3H); 13C (100 MHz, DMSO) δ 163.1, 153.6, 
151.8, 144.7, 138.7, 136.1, 128.5 (2C), 128.1, 128.0 (2C), 107.3, 106.7, 100.1, 70.0, 
55.7; MS (ESI) m/z 299 (M+H)+; HRMS (ESI) m/z calc. for C16H15N2O4 299.1032, 
found: 299.1036. 
 
7-(Benzyloxy)-2,4-dichloro-6-methoxyquinazoline (63)226 
 
Compound 63 was prepared as follows:226 A mixture of quinazolinedione 62 
(282.2 mg, 0.95 mmol), N,N-diethylaniline (166 µL, 1.04 mmol) and POCl3 (2 mL) 
was allowed to stir under reflux for 3 h and then rotary evaporated. Sat. aq. NaHCO3 
(5 mL) was added and the resulting mixture was extracted with chloroform (2 × 
10 mL). The combined organic layer was dried (MgSO4), rotary evaporated and 
purified by column chromatography (EtOAc : Hexanes, 2 : 8) to afford the title 
compound 63 (248.4 mg, 78%) as a colourless oil: IR (neat) 1611, 1547, 1500, 1424, 
1237, 1149, 847 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.50 – 7.35 (m, 5H), 7.36 (s, 
1H), 7.30 (s, 1H), 5.31 (s, 2H), 4.06 (s, 3H); 13C (100 MHz, CDCl3) δ 160.1, 156.8, 
HN
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153.4, 151.9, 150.4, 134.8, 128.9 (2C), 128.6, 127.4 (2C), 117.9, 107.6, 102.8, 71.3, 
56.5; MS (ESI) m/z 335 (M+H)+; HRMS (ESI) m/z calc. for C16H13N2O2Cl2 335.0354, 
found: 335.0370. 
 
7-(Benzyloxy)-N-(1-benzylpiperidin-4-yl)-2-chloro-6-methoxy-quinazolin-4-
amine (65) 
 
Compound 65 was prepared as follows:226 A mixture of dichloroquinazoline 63 
(265 mg, 0.79 mmol), 4-amino-1-benzylpiperidine (64, 484 µL, 2.37 mmol) and 
DIEA (206 µL, 1.18 mmol) in THF (2 mL) was allowed to stir overnight at room 
temperature. The solution was then rotary evaporated and purified by column 
chromatography (MeOH : CH2Cl2, 5 : 95) to afford the title compound 65 (285 mg, 
74%) as a white solid: m.p. 108 – 110 ˚C; IR (neat) 1584, 1514, 1452, 1260,  
1218 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.32 – 7.20 (m, 10H), 7.05 (s, 1H), 7.03 (s, 
1H), 6.11 (d, J = 8.0 Hz, 1H), 5.14 (s, 2H), 4.24 – 4.20 (m, 1H), 3.81 (s, 3H), 3.48 (s, 
2H), 2.83 (br app-d, J = 12.0 Hz, 2H), 2.13 (br app-td, J = 12.0, 1.5 Hz, 2H), 2.01 (br 
app-d, J = 12.0 Hz, 2H), 1.57 (qd, J = 12.0, 3.6 Hz, 2H); 13C (100 MHz, CDCl3) δ 
159.2, 156.0, 153.8, 149.1, 147.6, 137.9, 135.3, 129.1 (2C), 128.6 (2C), 128.1 (3C), 
127.0 (3C), 108.4, 107.0, 100.5, 70.7, 62.8, 56.1, 52.1 (2C), 48.4, 31.9 (2C); MS 
(ESI) m/z 489 (M+H)+; HRMS (ESI) m/z calc. for C28H30N4O2Cl 489.2057, found: 
489.2047. 
 
7-(Benzyloxy)-N4-(1-benzylpiperidin-4-yl)-N2-(3-(dimethylamino)propyl)-6-
methoxyquinazoline-2,4-diamine (67) 
 
Compound 67 was prepared as follows:226 A mixture of chloroquinazoline 65 
(367 mg, 0.75 mmol), N,N-dimethyl-1,3-propanediamine (66, 189 µL, 1.50 mmol) 
and 4 M HCl in dioxane (375 µL, 1.50 mmol) in isopropanol (4 mL) was allowed to 
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stir for 20 minutes at 160 ˚C in a microwave reactor. The solution was then diluted 
with 10 mL of CH2Cl2 and washed with sat. aq. NaHCO3 (10 mL). The organic layer 
was dried (MgSO4), rotary evaporated and purified by column chromatography 
(CH2Cl2 : 7M NH3 in MeOH, 95 : 5) to afford the title compound 67 (124 mg, 30%) 
as an orange oil: IR (neat) 1581, 1505, 1450, 1249, 738 cm-1; 1H NMR (400 MHz, 
CDCl3) δ 7.45 – 7.27 (m, 10H), 6.91 (s, 1H), 6.77 (s, 1H), 5.20 (br s, 2H+1H), 4.18 – 
4.14 (m, 1H), 3.90 (s, 3H), 3.54 (s, 2H), 3.48 (app-q, J = 6.9 Hz, 2H), 2.86 (br app-d, 
J = 12.0 Hz, 2H), 2.37 (t, J = 6.9 Hz, 2H), 2.22 (s, 6H), 2.19 (br app-td, J = 12.0, 2.6 
Hz, 2H), 2.06 (br app-dd, J = 12.0, 4.4 Hz, 2H), 1.77 (quint, J = 6.9 Hz, 2H), 1.60 (qd, 
J = 12.0, 4.4 Hz, 2H); 13C (100 MHz, CDCl3) δ 159.0, 158.6, 153.2, 148.3, 145.3, 
138.2, 136.0, 128.9 (2C), 128.3 (2C), 128.0 (2C), 127.7, 127.0 (2C), 126.8, 106.5, 
103.8, 102.1, 70.2, 62.9, 57.7, 56.1, 52.5 (2C), 48.2, 45.4 (2C), 40.2, 31.9 (2C), 27.7; 
MS (ESI) m/z 555 (M+H)+; HRMS (ESI) m/z calc. for C33H43N6O2 555.3448, found: 
555.3441. 
 
4-Allyloxy-3-methoxybenzonitrile (70) 
 
Compound 70 was prepared as follows:226 To an ice-cooled solution of benzonitrile 
57 (2.00 g, 13.4 mmol) in acetone (150 mL) were slowly added K2CO3 (2.22 g, 
16.1 mmol), followed by allyl bromide (2.32 mL, 26.8 mmol). The solution was 
refluxed for 3 h, time after which it was quenched with water (100 mL) and extracted 
with Et2O (2 × 100 mL). The combined organic layers were dried (MgSO4), filtered 
and rotary evaporated to afford the title compound 70 (2.33 g, 92%) as a white solid 
that was used in the next step without further purification: m.p. 48 – 50 ˚C; IR (neat) 
2223, 1595, 1512, 1241, 1135, 1003 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.24 (dd, J 
= 8.4, 1.6 Hz, 1H), 7.08 (d, J = 1.6 Hz, 1H), 6.89 (d, J = 8.4 Hz, 1H), 6.10 – 6.00 (m, 
1H), 5.42 (app-dq, J = 17.4, 1.3 Hz, 1H), 5.36 (app-dq, J = 10.4, 1.3 Hz, 1H), 4.66 
(app-dt, J = 5.4, 1.3 Hz, 2H), 3.89 (s, 3H); 13C (100 MHz, CDCl3) δ 151.9, 149.5, 
132.0, 126.3, 119.3, 118.9, 114.2, 112.8, 104.0, 69.8, 56.2; MS (CI) m/z 207 
(M+NH4)+; HRMS (CI) m/z calc. for C11H15N2O2 207.1134, found: 207.1133. 
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4-Allylyloxy-5-methoxy-2-nitrobenzonitrile (71) 
 
Compound 71 was prepared as follows:226 Nitric acid (1.4 mL of 69 wt% solution in 
water, 21.14 mmol) was slowly added to a solution of benzonitrile 70 (2.00 g, 
10.57 mmol) in acetic anhydride (50 mL) at 0 ˚C. The reaction was allowed to stir for 
1 h at room temperature, time after which the mixture was poured into ice-water and 
the resulting precipitate was filtered, washed with water and dried under vacuum to 
afford the title compound 71 (2.216 g, 89%) as a pale yellow solid that was used in 
the next step without further purification: m.p. 156 – 158 ˚C; IR (neat) 2224, 1572, 
1507, 1334, 1224, 1058 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.79 (s, 1H), 7.21 (s, 1H), 
6.11 – 6.01 (m, 1H), 5.49 (app-dq, J = 17.2, 1.2 Hz, 1H), 5.41 (app-dq, J = 10.4, 1.2 
Hz, 1H), 4.75 (app-dt, J = 5.6, 1.2 Hz, 2H), 4.01 (s, 3H); 13C (100 MHz, CDCl3) δ 
153.6, 151.1, 142.6, 130.8, 120.0, 115.6, 115.5, 109.2, 100.9, 70.5, 56.9; MS (CI) m/z 
252 (M+NH4)+; HRMS (CI) m/z calc. for C11H14N3O4 252.0984, found: 252.0982. 
 
2-Amino-4-allyloxy-2-methoxybenzonitrile (72) 
 
Compound 72 was prepared as follows:231 To a solution of nitrobenzonitrile 71 
(2.21 g, 9.39 mmol) in CH2Cl2 (50 mL) was added tetrabutylammonium bromide 
(2.1 g, 6.57 mmol), followed by the slow addition of a solution of sodium dithionite 
(9.8 g, 56.3 mmol) in water (50 mL). The mixture was allowed to stir for 3 h at room 
temperature and then basified with 2 N aq. NaOH at 0 ˚C. The organic layer was 
recovered and the aqueous layer extracted with CH2Cl2 (2 × 100 mL). A precipitate 
was obtained upon treatment of the combined organic layer with 1M HCl in Et2O. 
The white solid was filtered and dissolved in water. The aqueous layer was basified 
with 2N NaOH and extracted with EtOAc (2 × 100 mL). The organic layer was dried 
(MgSO4) and rotary evaporated to give the title compound 72 (1.32 g, 69%) as a 
white solid that was used in the next step without further purification: m.p. 50 – 
52 ˚C; IR (neat) 3438, 3355, 3248, 2200, 1646, 1507, 1236 cm-1; 1H NMR (400 MHz, 
CDCl3) δ 6.76 (s, 1H), 6.23 (s, 1H), 6.06 – 5.96 (m, 1H), 5.37 (app-dq, J = 17.2, 1.5 
Hz, 1H), 5.29 (app-dq, J = 10.4, 1.5 Hz, 1H), 4.55 (app-dt, J = 5.6, 1.5 Hz, 2H), 4.20 
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(br s, 2H), 3.76 (s, 3H); 13C (100 MHz, CDCl3) δ 153.4, 146.0, 141.9, 131.9, 118.6, 
118.1, 113.6, 100.3, 86.3, 69.5, 56.4; MS (ESI) m/z 205 (M+H)+, 246 
(M+MeCN+H)+; HRMS (ESI) m/z calc. for C11H13N2O2 205.0977 found: 205.0974. 
 
Methyl (5-(allyloxy)-2-cyano-4-methoxyphenyl)carbamate (73) 
  
Compound 73 was prepared as follows:226 To a solution of aniline 72 (1.382 g, 
6.77 mmol) and DIEA (4.7 mL, 27.1 mmol) in DMA – CH2Cl2 (10 mL : 5 mL) at 
0 ˚C was added methyl chloroformate (784 µL, 10.15 mmol). The mixture was 
allowed to stir overnight at room temperature. Water (30 mL) was added and the 
resulting precipitate was recovered, washed with water and dried under vacuum. It 
was re-dissolved in CH2Cl2 and washed with 1M aq. HCl, then with brine, dried 
(MgSO4) and rotary evaporated to afford the title compound 73 (1.415 g, 80%) as a 
white solid that was used in the next step without further purification: IR (neat) 2223, 
1734, 1600, 1524, 1213 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.85 (br s, 1H), 7.03 (br 
s, 1H), 6.93 (s, 1H), 6.12 – 6.02 (m, 1H), 5.46 (app-dq, J = 17.2, 1.3 Hz, 1H), 5.36 
(app-dq, J = 10.4, 1.3 Hz, 1H), 4.69 (app-dt, J = 5.4, 1.3 Hz, 2H), 3.86 (s, 3H), 3.81 (s, 
3H); 13C (100 MHz, CDCl3) δ 153.6, 152.8, 145.1, 136.4, 131.7, 119.3, 116.7, 113.1, 
104.4, 91.5, 69.9, 56.3, 52.8; MS (ESI) m/z 263 (M+H)+; HRMS (ESI) m/z calc. for 
C13H15N2O4 263.1032 found: 263.1033. 
 
7-(Allyloxy)-6-methoxyquinazoline-2,4(1H,3H)-dione (74) 
 
Compound 74 was prepared as follows:226 Carbamate 73 (1.415 g, 5.4 mmol) was 
added to a solution of H2O2 (10 mL of 35 wt% solution in water, 110 mmol) and 
NaOH (2.13 g, 54 mmol) in ethanol (100 mL) and the resulting mixture was allowed 
to stir for 4 h under reflux. Water (100 mL) was added and the solution was allowed 
to cool to room temperature, then acidified with 1 N aq. HCl. The resulting precipitate 
was recovered, washed with water and dried to afford the title compound 74 (932 mg, 
69%) as a white solid that was used in the next step without further purification: m.p. 
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202 – 204 ˚C; IR (neat) 1709, 1649, 1621, 1267, 1206 cm-1; 1H NMR (400 MHz, 
DMSO) δ 11.08 (br s, 1H), 10.90 (br s, 1H), 7.27 (s, 1H), 6.68 (s, 1H), 6.10 – 6.00 (m, 
1H), 5.44 (app-dq, J = 17.2, 1.5 Hz, 1H), 5.32 (app-dq, J = 10.4, 1.5 Hz, 1H), 4.60 
(app-dt, J = 5.4, 1.5 Hz, 2H), 3.79 (s, 3H); 13C (100 MHz, DMSO) δ 162.4, 153.7, 
150.4, 145.1, 136.4, 132.6, 118.6, 107.4, 106.3, 98.9, 69.0, 55.7; MS (ESI) m/z 249 
(M+H)+, 290 (M+MeCN+H)+; HRMS (ESI) m/z calc. for C12H13N2O4 249.0875, 
found: 249.0870. 
 
7-(Allyloxy)-2,4-dichloro-6-methoxyquinazoline (69) 
 
Compound 69 was prepared as follows:226 A mixture of quinazolinedione 74 (920 mg, 
3.69 mmol), N,N-diethylaniline (649 µL, 4.07 mmol) and POCl3 (20 mL) was allowed 
to stir under reflux for 1.5 h. The solution was slowly poured into a sat. aq. NaHCO3 
at 0 ˚C. The organic layer was separated and the aqueous layer was extracted with 
chloroform (2 × 50 mL). The combined organic layers were dried (MgSO4), rotary 
evaporated and purified by column chromatography (EtOAc : Hexanes, 3 : 7) to 
afford the title compound 69 (908 mg, 86%) as a white solid: m.p. 92 – 94 ˚C; IR 
(neat) 1614, 1549, 1500, 1415, 1237, 1147 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.30 
(s, 1H), 7.20 (s, 1H), 6.13 – 6.03 (m, 1H), 5.52 (app-dq, J = 17.2, 1.2 Hz, 1H), 5.37 
(app-dq, J = 10.4, 1.2 Hz, 1H), 4.75 (app-dt, J = 5.6, 1.2 Hz, 2H), 4.03 (s, 3H); 13C 
(100 MHz, CDCl3) δ 159.9, 156.6, 153.4, 151.7, 150.3, 131.1, 119.6, 117.7, 107.2, 
102.6, 70.2, 56.4; MS (ESI) m/z 285 (M+H)+; HRMS (ESI) m/z calc. for 
C12H11N2O2Cl2 285.0198, found: 285.0197. 
 
7-(Allyloxy)-N-(1-benzylpiperidin-4-yl)-2-chloro-6-methoxy-quinazolin-4-amine 
(75) 
 
Compound 75 was prepared as follows:226 A mixture of dichloroquinazoline 69 
(102 mg, 0.36 mmol), 4-amino-1-benzylpiperidine (64, 214 µL, 1.07 mmol) and 
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DIEA (92 µL, 0.536 mmol) in THF (2 mL) was allowed to stir for 8 h at room 
temperature. The solution was then rotary evaporated and purified by column 
chromatography (MeOH : CH2Cl2, 4 : 96) to afford the title compound 75 (133.5 mg, 
85%) as a white solid: m.p. 90 – 92 ˚C; IR (neat) 3313, 1584, 1510, 1452, 1253, 961 
cm-1; 1H NMR (400 MHz, CDCl3) δ 7.33 – 7.23 (m, 5H), 7.10 (s, 1H), 6.84 (s, 1H), 
6.11 – 6.01 (m, 1H), 5.50 (d, J = 7.8 Hz, 1H), 5.44 (app-dq, J = 17.3, 1.2 Hz, 1H), 
5.32 (app-dq, J = 10.5, 1.2 Hz, 1H), 4.67 (app-dt, J = 5.4, 1.2 Hz, 2H), 4.33 – 4.23 (m, 
1H), 3.96 (s, 3H), 3.55 (s, 2H), 2.90 (br app-d, J = 12.0 Hz, 2H), 2.23 (app-dt, J = 
12.0, 1.5 Hz, 2H), 2.12 (br app-d, J = 12.0 Hz, 2H), 1.64 (app-dq, J = 12.0, 3.5 Hz, 
2H); 13C (100 MHz, CDCl3) δ 159.1, 156.1, 153.8, 149.2, 147.8, 138.2, 131.7, 129.1 
(2C), 128.2 (2C), 127.1, 119.1, 108.4, 106.7, 99.9, 69.7, 62.9, 56.3, 52.2 (2C), 48.3, 
32.2 (2C); MS (ESI) m/z 439 (M+H)+; HRMS (ESI) m/z calc. for C24H28N4O2Cl 
439.1901, found: 439.1908. 
 
7-(allyloxy)-N4-(1-benzylpiperidin-4-yl)-N2-(3-(dimethylamino)propyl)-6-
methoxyquinazoline-2,4-diamine (76) 
 
Procedure 1:226 
A mixture of chloroquinazoline 75 (478 mg, 1.09 mmol) and N,N-dimethyl-1,3-
propanediamine (66, 1.5 mL, 11.4 mmol) in MeCN (1.5 mL) was allowed to stir for 3 
days at reflux. The solution was then diluted with CH2Cl2 (10 mL) and washed with 
sat. aq. NaHCO3 (10 mL). The organic layer was separated and the aqueous layer was 
extracted with CH2Cl2 (2 × 50 mL) and the combined organic layers were washed 
with brine, dried (MgSO4), rotary evaporated and purified by column chromatography 
(CH2Cl2 : 7M NH3 in MeOH; 9 : 1) to afford the title compound 75 (426 mg, 77%).  
 
Procedure 2 
Chloroquinazoline 75 (528 mg, 1.2 mmol) was refluxed in N,N-dimethyl-1,3-
propanediamine (66, 10 mL, excess) for 16 h. The crude reaction mixture was then 
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purified by column chromatography (CH2Cl2 : MeOH, 95 : 5, with 1% NH3 aq. 
solution) to afford the title compound 76 (274 mg, 45%). 
 
Compound 76 was obtained as a light yellow solid: m.p. 56 – 58 ˚C; IR (neat) 1579, 
1498, 1454, 1246, 979 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.33 – 7.20 (m, 5H), 6.85 
(s, 1H), 6.75 (s, 1H), 6.15 – 6.06 (m, 1H), 5.43 (app-dq, J = 17.3, 1.2 Hz, 1H), 5.31 
(app-dq, J = 10.5, 1.2 Hz, 1H), 5.13 (br d, J = 7.1 Hz, 1H), 5.09 (br s, 1H), 4.65 (app-
dt, J = 5.4, 1.2 Hz, 2H), 4.22 – 4.12 (m, 1H), 3.90 (s, 3H), 3.54 (s, 2H), 3.48 (app-q, J 
= 7.0 Hz, 2H), 2.89 (br app-d, J = 12.0 Hz, 2H), 2.37 (t, J = 7.0 Hz, 2H), 2.22 (s, 6H), 
2.19 (br app-td, J = 12.0, 2.1 Hz, 2H), 2.11 (br app-dd, J = 12.0, 3.2 Hz, 2H), 1.78 
(quint, J = 7.0 Hz, 2H), 1.60 (app-dq, J = 12.0, 3.2 Hz, 2H); 13C (100 MHz, CDCl3) δ 
159.0, 158.5, 153.5, 148.3, 145.5, 138.4, 132.3, 129.1 (2C), 128.2 (2C), 127.0, 118.6, 
106.5, 103.5, 101.3, 69.5, 63.1, 57.8, 56.5, 52.5 (2C), 48.1, 45.6 (2C), 40.2, 32.3 (2C), 
27.9; MS (ESI) m/z 505 (M+H)+; HRMS (ESI) m/z calc. for C29H41N6O2 505.3291, 
found: 505.3292. 
 
4-(1-benzylpiperidin-4-ylamino)-2-(3-(dimethylamino)propylamino)-6-
methoxyquinazolin-7-ol (68) 
 
Compound 68 was prepared as follows:239 Pd(PPh3)4 (34 mg, 0.029 mmol) was added 
to a solution of allyl protected quinazoline 76 (294 mg, 0.580 mmol) in MeOH 
(50 mL). After 5 min, K2CO3 (400 mg, 2.900 mmol) was added and the solution was 
allowed to stir for 4 h at 50 ˚C. The solvent was rotatory evaporated to afford a brown 
oil which was subsequently treated with 1 N aq. HCl (50 mL). The solution was then 
basified with 2 N aq. NaOH and extracted with CH2Cl2 (2 × 30 mL). The organic 
layers were then combined, dried (MgSO4) and rotary evaporated to afford the title 
compound 68 (crude, 286 mg). The obtained product was too polar to be purified by 
column chromatography and was thus used directly in the next step without further 
purification: 1H NMR (400 MHz, MeOD) δ 7.45 (br s, 1H), 7.36 – 7.27 (m, 5H), 6.50 
(br s, 1H), 4.26 – 4.20 (m, 1H), 3.98 (br s, 3H), 3.60 (s, 2H), 3.48 (br t, J = 7.0 Hz, 
2H), 3.01 (br app-d, J = 12.0 Hz, 2H), 2.51 (app-t, J = 7.0 Hz, 2H), 2.34 (s, 6H), 2.19 
O
OHN
N
HN
N
H
NBn
N
 	  
202	  
	  
	   	  
(br app-dt, J = 12.0, 1.8 Hz, 2H), 2.03 (br app-d, J = 12.0 Hz, 2H), 1.85 (quint, J = 
7.0 Hz, 2H), 1.78 (app-qd, J = 12.0, 3.3 Hz, 2H); MS (ESI) m/z 465 (M+H)+; HRMS 
(ESI) m/z calc. for C26H37N6O2 465.2978 found: 465.2974. 
 
4-phenylbutyl methane sulfonate (77)244 
 
To a solution of 4-phenylbutan-1-ol (78, 200 µL, 1.35 mmol) in CH2Cl2 (5 mL) at 
0 ˚C, was added Et3N (282 µL, 2.03 mmol), followed by methanesulfonyl chloride 
(109 µL, 1.41 mmol). The resulting mixture was allowed to stir for 2 h and allowed to 
warm to room temperature. Sat. aq. NH4Cl (5 mL) was added and the organic layer 
was rotatory evaporated. The aqueous layer was extracted with Et2O (2 × 50 mL) and 
the combined organic layers were dried (MgSO4) and rotary evaporated to afford the 
title compound 77 as a colourless oil (299 mg, 97%) that was used in the next step 
without further purification: 1H NMR (400 MHz, CDCl3) δ 7.31 – 7.27 (m, 2H), 7.22 
– 7.16 (m, 3H), 4.23 (t, J = 6.2 Hz, 2H), 2.98 (s, 3H), 2.66 (t, J = 6.7 Hz, 2H), 1.82 – 
1.71 (m, 4H); 13C (100 MHz, CDCl3) δ 141.5, 128.4 (2C), 128.4 (2C), 126.0, 69.8, 
37.3, 35.1, 28.6, 27.1; MS (CI) m/z 246 (M+NH4)+; HRMS (CI) m/z calc. for 
C11H20NO3S 246.1164, found: 246.1152. 
 
(4-Iodobutyl)benzene (79)245 
 
Compound 79 was prepared as follows:245 To a solution of NaI (284 mg, 1.927 mmol) 
in acetone (3 mL) was added sulfonate 77 (100 mg, 0.438 mmol). The resulting 
mixture was allowed to stir at room temperature for 16 h and then rotary evaporated. 
The residue was taken up in water (20 mL) and extracted with Et2O (2 × 30 mL) and 
the combined organic layers were dried (MgSO4) and rotary evaporated to afford the 
title compound 79 as a yellow oil that was used in the next step without further 
purification (103 mg, 90%). IR (neat) 1604, 1495, 1452, 1206, 1166 cm-1; 1H NMR 
(400 MHz, CDCl3) δ 7.32 – 7.28 (m, 2H), 7.22 – 7.18 (m, 3H), 3.21 (t, J = 7.2 Hz, 
2H), 2.65 (t, J = 7.3 Hz, 2H), 1.91 – 1.84 (m, 2H), 1.79 – 1.71 (m, 2H); 13C (100 MHz, 
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CDCl3) δ 141.8, 128.4 (4C), 125.9, 34.7, 32.9, 32.1, 6.7; MS (EI) m/z 260 (M+); 
HRMS (EI) m/z calc. for C10H13I 260.0062, found: 260.0054. 
 
N-(1-benzylpiperidin-4-yl)-2-chloro-6-methoxy-7-(4-phenylbutoxy)quinazolin-4-
amine (81) 
 
TBAB (4 mg, 0.013 mmol) and K2CO3 (26 mg, 0.187 mmol) were added to a solution 
of phenol 80 (50 mg, 0.125 mmol) in acetone (5 mL). Methane sulfonate 77 (34 mg, 
0.138 mmol) was then added and the mixture was allowed to stir overnight under 
reflux. NaI (18.7 mg, 0.125 mmol) was then added and the reaction was allowed to 
stir under reflux for an extra 20 h. After this time, the mixture was filtered, washed 
with CH2Cl2 and rotary evaporated. Purified by column chromatography (CH2Cl2 : 
MeOH, 95 : 5) afforded the title compound 81 as a colourless oil (30 mg, 45%): IR 
(neat) 1621, 1581, 1508, 1439, 1250, 1219 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.33 – 
7.18 (m, 10H), 7.08 (s, 1H), 6.87 (s, 1H), 5.59 (d, J = 7.9 Hz, 1H), 4.35 – 4.25 (m, 
1H), 4.09 (t, J = 6.5 Hz, 2H), 3.94 (s, 3H), 3.58 (s, 2H), 2.93 (br app-d, J = 12.0 Hz, 
2H), 2.68 (t, J = 7.5 Hz, 2H), 2.26 (app-dt, J = 12.0, 1.5 Hz, 2H), 2.12 (br app-d, J = 
12.0 Hz, 2H), 1.95 – 1.88 (m, 2H), 1.84 – 1.76 (m, 2H), 1.69 (app-dq, J = 12.0, 3.5 
Hz, 2H); 13C (100 MHz, CDCl3) δ 159.1, 156.0, 154.5, 149.2, 147.9, 141.9, 137.5, 
129.2 (2C), 128.4 (2C), 128.3 (2C), 128.2 (2C), 127.3, 125.8, 107.8, 106.5, 99.9, 68.9, 
62.8, 56.4, 52.2 (2C), 48.1, 35.4, 31.9 (2C), 28.2, 27.7; MS (ESI) m/z 531 (M+H)+; 
HRMS (ESI) m/z calc. for C31H36N4O2Cl 531.2527 found: 531.2528. 
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N4-(1-benzylpiperidin-4-yl)-N2-(3-(dimethylamino)propyl)-6-methoxy-7-(4-
phenylbutoxy)quinazoline-2,4-diamine (56) 
 
Procedure 1 : From phenol 68 (with Cs2CO3 in DMF) 
Crude phenol 68 (50 mg, 0.11 mmol) was dissolved in degassed DMF (2 mL). 
Cs2CO3 (52 mg, 0.16 mmol) was added followed by methane sulfonate 77 (27 mg, 
0.12 mmol). The resulting solution was allowed to stir at room temperature for 16 h 
then heated to 80 ˚C for 1 h. The mixture was then diluted with water (10 mL) and 
extracted with CH2Cl2 (3 × 20 mL) and the combined organic layers were washed 
with water (3 × 20 mL), dried (MgSO4) and rotary evaporated. Purification by column 
chromatography (CH2Cl2 : 7M NH3 in MeOH, 95 : 5) afforded the title compound 56 
(1.2 mg, 2%). 
 
Procedure 2 : From phenol 68 (with tBuOK in acetone) 
To a solution of crude phenol 68 (35 mg, 0.075 mmol) in acetone (3 mL) was added 
tBuOK (8.5 mg, 0.075 mmol) and methane sulfonate 77 (17.1 mg, 0.075 mmol) and 
the resulting solution was allowed to stir at 40 ˚C for 16 h. The mixture was then 
diluted with water (5 mL) and extracted with CH2Cl2 (3 × 10 mL). The combined 
organic layers were washed with water (3 × 20 mL), dried (MgSO4) and rotary 
evaporated. Purification by column chromatography (CH2Cl2 : 7M NH3 in MeOH, 
95 : 5) afforded the title compound 56 (4 mg, 9%). 
 
Procedure 3: From chloroquinazoline (81)  
N,N-dimethyl-1,3-propanediamine (66, 36 µL, 0.280 mmol) was added to a solution 
of chloroquinazoline 81 (30 mg, 0.056 mmol) in toluene (2 mL). The resulting 
mixture was heated under reflux for 16 h, then diluted with CH2Cl2 (3 mL) and then 
washed with sat. aq. NaHCO3. The organic layer was separated and the aqueous layer 
was extracted with CH2Cl2 (3 × 3 mL). The combined organic layers were dried 
(MgSO4), rotary evaporated and purified by column chromatography (CH2Cl2 : 7M 
NH3 in MeOH, 90 : 10) to afford the title compound 56 (12 mg, 36%). 
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Compound 56 was obtained as a colourless oil: IR (neat) 2154, 1645, 1608, 1585, 
1514, 1455, 1274 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.33 – 7.18 (m, 10H), 6.86 (s, 
1H), 6.77 (br s, 1H), 5.41 (br s, 1H), 4.18 – 4.08 (m, 1H), 4.09 (t, J = 6.5 Hz, 2H), 
3.91 (s, 3H), 3.55 (s, 2H), 3.51 – 3.47 (m, 2H), 2.91 (br app-d, J = 12.0 Hz, 2H), 2.69 
(t, J = 7.4 Hz, 2H), 2.39 (t, J = 7.0 Hz, 2H), 2.24 (s, 6H), 2.19 (app-dt, J = 12.0, 1.5 
Hz, 2H), 2.12 (br app-d, J = 12.0 Hz, 2H), 1.95 – 1.88 (m, 2H), 1.84 – 1.76 (m, 4H), 
1.64 (app-dq, J = 12.0, 3.5 Hz, 2H); 13C (100 MHz, CDCl3) δ 158.7, 155.3, 155.2, 
146.9 (2C), 141.9, 137.9, 129.1 (2C), 128.4 (2C), 128.3 (2C), 128.2 (2C), 127.1, 
125.8, 103.5, 102.1, 99.9, 69.2, 62.9, 57.1, 57.0, 52.4 (2C), 49.4, 45.2 (2C), 39.6, 35.4 
(2C), 31.4, 28.3, 27.6, 27.0; MS (ESI) m/z 597 (M+H)+; HRMS (ESI) m/z calc. for 
C36H49N6O2 597.3917 found: 597.3911. 
 
N-(1-benzylpiperidin-4-yl)-2-chloro-6,7-dimethoxyquinazolin-4-amine (84)226 
 
Compound 84 was prepared as follows:226 A mixture of dichloroquinazoline 83 
(300 mg, 1.15 mmol), 4-amino-1-benzylpiperidine (64, 0.700 mL, 3.45 mmol) and 
DIEA (0.300 mL, 1.72 mmol) in THF (5 mL) was allowed to stir at room temperature 
for 16 h. The solution was concentrated and purified by column chromatography 
(MeOH : CH2Cl2, 10 : 90) to afford the title compound 84 (478 mg, quant.) as a white 
solid: m.p. 116 – 118 ˚C; IR (neat) 2936, 1739, 1579, 1508, 1454, 1428, 1366 cm-1; 
1H NMR (400 MHz, CDCl3) δ 7.33 – 7.25 (m, 5H), 7.11 (s, 1H), 6.81 (s, 1H), 5.44 (d, 
J = 7.8 Hz, 1H), 4.33 – 4.23 (m, 1H), 3.97 (s, 3H), 3.95 (s, 3H), 3.55 (s, 2H), 2.90 (br 
app-d, J = 12.0 Hz, 2H), 2.23 (br app-td, J = 12.0, 1.6 Hz, 2H), 2.12 (br app-d, J = 
12.0 Hz, 2H), 1.63 (br app-qd, J = 12.0, 3.6 Hz, 2H); 13C (100 MHz, CDCl3) δ 159.1, 
156.2, 154.9, 149.0, 148.1, 138.1, 129.1 (2C), 128.2 (2C), 127.1, 107.3, 106.7, 99.6, 
62.9, 56.3, 56.2, 52.2 (2C), 48.3, 32.2 (2C); MS (ESI) m/z 413 (M+H)+; HRMS (ESI) 
m/z calc. for C22H26N4O2Cl 413.1744 found: 413.1757. 
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N-(1-benzylpiperidin-4-yl)-6,7-dimethoxy-2-(4-methyl-1,4-diazepan-1-
yl)quinazolin-4-amine) (2, BIX-01294)226,227 
 
Compound 2 was prepared as follows:226 1-Methyl-1,4-diazepane (85, 150 µL, 
1.210 mmol) was added to a solution of chloroquinazoline 84 (100 mg, 0.242 mmol) 
in toluene (2 mL). The reaction mixture was allowed to stir under reflux for 16 h, 
diluted with CH2Cl2 (3 mL) and washed with sat. aq. NaHCO3. The organic layer was 
separated and the aqueous layer was extracted with CH2Cl2 (3 × 3 mL). The combined 
organic layers were dried (MgSO4), rotary evaporated and purified by column 
chromatography (CH2Cl2 : 7M NH3 in MeOH, 90 : 10) to afford the title compound 2 
as a yellow oil (75 mg, 63%): IR (neat) 1573, 1493, 1423, 1213 cm-1; 1H NMR (400 
MHz, CDCl3) δ 7.35 – 7.25 (m, 5H), 6.91 (s, 1H), 6.78 (s, 1H), 5.15 (d, J = 7.0 Hz, 
1H), 4.16 – 4.09 (m, 1H), 4.01 – 3.98 (m, 2H), 3.94 (s, 3H), 3.92 (s, 3H), 3.89 (t, J = 
6.5 Hz, 2H), 3.56 (s, 2H), 2.92 (br app-d, J = 12.0 Hz, 2H), 2.72 – 2.70 (m, 2H), 2.59 
– 2.57 (m, 2H), 2.38 (s, 3H), 2.23 – 2.13 (m, 4H), 2.06 – 2.00 (m, 2H), 1.63 (br app-
qd, J = 12.0, 3.6 Hz, 2H); 13C (100 MHz, CDCl3) δ 158.6, 157.9, 154.1, 149.5, 144.8, 
138.4, 128.9 (2C), 128.1 (2C), 126.9, 105.9, 102.7, 100.7, 63.0, 58.9, 57.3, 56.2, 55.8, 
52.5 (2C), 48.3, 46.7, 45.8, 45.7, 32.1 (2C), 27.8; MS (ESI) m/z 491 (M+H)+; HRMS 
(ESI) m/z calc. for C28H39N6O2 491.3134 found: 491.3140. 
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Chiroptical measurements 
 
ECD spectroscopy 
The experimental spectra were recorded on an Applied Photophysics Chirascan 
spectrometer in dichloromethane (Temperature: 22 °C, Wavelength: from 180 to 
260 nm, Step: 0.5 nm, Band width: 1 nm, Time per point: 1 s) 
 
VCD spectroscopy 
VCD measurements were performed at the European Centre for Chirality by Prof. 
Wouter Herrebout.  
Solutions of the enantiomerically pure compounds of interest and of the 
corresponding racemates were prepared in CDCl3 (99.98%, Aldrich). All spectra were 
recorded using a demountable liquid cell equipped with BaF2 windows and 100 µm 
spacers. All spectra were recorded at 4 cm-1 resolution for approximately 13 h, 
accumulating 40 000 scans. Background corrections for VCD were introduced by 
subtracting the spectra of the enantiomerically pure compounds and those obtained for 
the corresponding racemates. 
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Computational simulations 
 
All calculations were performed by Prof. Henry Rzepa and Ya-Pei Lo 
(Chemistry Department, Imperial College London) using the procedures implemented 
in the Gaussian 09 program.26  
 
Chaetocin (1) and monosulfide analogue (3) 
Optical rotations (589 nm) and VCD were calculated at the ωB97XD/6-311G(d,p) 
level of theory and ECD at the ωB97XD/6-311++G(d,p) with a continuum solvation 
model for the solvent used for the experimental measurements. 
 
Dehydrogliotoxin (21) and dethiodehydrogliotoxin (22) 
ECD was calculated at the ωB97XD/6-311++G(d,p) level of theory, in 1,4-dioxane 
 
Gliotoxin analogue (25) and its monosulfide analogue (26) 
The mechanistic exploration was performed at the ωB97XD/6-311G(d,p) level of 
theory with a continuum solvation model for THF. 
Optical rotations (589 nm), ECD and VCD were calculated at the 
M062X/6-311++G(d,p) level of theory with a continuum solvation model for the 
solvent used for the experimental measurements. 
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Biological evaluation 
 
Biochemical assays  
 
In vitro EZH2 and SUV39H1 screen with assay kits 
Commercially available kits from BPS Bioscience (EZH2/EED/SUZ12/ 
RbAp48/AEBP2 cat. #52009, SUV39H1 Direct Activity Assay Kit #52006) were 
used according to the manufacturer’s instructions. 
The 96-well plates coated with Histone H3 peptide substrate were rehydrated 
with TBST buffer (1 x TBS, pH 8.0, containing 0.05% Tween-20) for 15 min. In the 
meantime, the enzyme was diluted with HMT assay buffer and was pre-incubated 
with SAM and the candidate inhibitor for 10 min in a different plate. The mixture was 
then added to the histone-coated plate and incubated for 1 h at room temperature. The 
plate was washed 3 times with TBST buffer and then incubated with blocking buffer 
for 10 min. The primary antibody (specific for methylated lysine residue) was diluted 
100-fold with blocking buffer and was added to each well and the mixture was 
incubated for 1 h with slow shaking. The plate was then washed 3 times with TBST 
buffer and incubated in blocking buffer. The secondary HRP-labelled antibody 
(specific for the primary antibody) was diluted 1000-fold with blocking buffer and 
added to each well. After 30 min incubation the plate was washed again 3 times with 
TBST buffer and incubated in blocking buffer. Just before use, HRP 
chemiluminescent substrates A and B were mixed on ice and were added to each well. 
The plate was immediately read with the chemiluminescence module on a PHERAstar 
Plus (BMG Labtech, Software Version 2.21). 
 
Materials for G9a and SUV39H1 AlphaLISA assay 
Human G9a (euchromatic histone-lysine N-methyltransferase 2, GenBank Accession 
No. NM_006709, amino-acids 785 – 1210, with N-terminal GST tag, MW = 74.6 kDa, 
expressed in a Baculovirus infected Sf9 cell expression system, specific activity: 10 
pmol/min/µg) and human SUV39H1 (GenBank Accession No. NM_003173, amino 
acids 82 – 412, with N-terminal GST tag, MW= 64 kDa, expressed in E. Coli, specific 
activity: 0.05 and 0.7 pmol/min/µg) used for all AlphaLISA experiments were 
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purchased from BPS Bioscience; Histone H3 (1 – 21) biotinylated peptides 
(H3K9mex x=0, 2, 3) were purchased from AnaSpec; Anti-methyl-histone H3 lysine 9 
(H3K9me2) AlphaLISA Acceptor Beads, AlphaScreen Streptavidin Donor beads and 
AlphaLISA Epigenetics Buffer were purchased from PerkinElmer; S-(5'-Adenosyl)-
L-methionine chloride (SAM) was purchased from Sigma and New England Biolabs 
(UK) Ltd, S-(5'-Adenosyl)-L-homocysteine (SAH), H2O2 solution (30% wt/wt), 
phenol red, and horseradish peroxidase (HRP), Hanks’ balanced salt solution (HBSS), 
NaCl solution, Trizma (Tris) buffer, Tween20 were purchased from Sigma. White 
low-volume 384-well plates, 384-well flat bottomed clear polystyrene microtiter 
plates, V-shape 96-well clear plates were bought from Greiner Bio-One, Gloucester, 
UK.  White low-volume 384-well plates were read on PHERAstar Plus with 
AlphaScreen module (excitation wavelength 680 nM, reading at 570 nM).  
 
Data Analysis 
Data was normalised to high (no inhibitor) and low (no enzyme) controls and plotted 
using GraphPad Prism V5.0.4. pIC50 (−log(IC50)) values were derived from 10-point 
curve using a four parameter fit. Assays were run in duplicates in at least 3 
independent experiments. The statistical significance was assessed by paired t-test or 
1-way ANOVA followed by Bonferroni's multiple comparison test. P value summary: 
***: P < 0.001 (Extremely significant), **: 0.001 < P < 0.01 (Very significant), *: 
0.01 < P < 0.05 (Significant), ns: P > 0.05 (Not statistically significant) 
 
Compound handling 
Compounds were stored as 10 mM DMSO solutions under N2 atmosphere (FluidX) or 
at −20 ˚C. Purity was assessed by NMR (>95% pure) and LCMS.  
Representative dilution scheme from 10 mM DMSO solution (final percentage of 
DMSO kept constant): 
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Initial DMSO plate: 2-fold serial dilution in DMSO – [C] in mM 
10.00 5.00 2.50 1.25 0.63 0.31 0.16 0.08 0.04 0.02 DMSO 
           Intermediate plate: 200 fold dilution from DMSO plate in assay buffer  
(0.5 µL DMSO solution + 100 µL buffer) – [C] in µM 
50.00 25.00 12.50 6.25 3.13 1.56 0.78 0.39 0.20 0.10 DMSO 
           Final Concentration in Assay Plate: 2.5 µL from Intermediate plate added to well 
of total volume 5 µL (2 fold dilution)– [C] in µM 
25.00 12.50 6.25 3.13 1.56 0.78 0.39 0.20 0.10 0.05 DMSO 
 
AlphaLISA inhibition assay 
1 nM G9a (or 50 nM SUV39H1) was incubated with compounds (up to 100 µM, up 
to 1% DMSO), 100 nM biotinylated H3 peptide and 15 µM (or 40 µM for SUV39H1) 
SAM in assay buffer (50 mM Tris-HCl, pH 9.0, 50 mM NaCl, 0.01% Tween-20 and 
optional 1 mM DTT) with a total volume of 5 µL for 30 min (or 1.5 h for SUV39H1) 
at 25 ˚C in white low-volume 384-well plates. The reaction was quenched by addition 
of Anti-methyl-Histone H3 Lysine 9 (H3K9me2) AlphaLISA acceptor beads in 
epigenetic buffer (10 µg/mL) and incubated for 1 h. AlphaScreen streptavidin donor 
beads in epigenetic buffer (10 µg/mL) were added and incubated for 30 min. The 
plates were then read on Pherastar Plus (AlphaScreen module). 
 
Representative plate layout for IC50 determination (I: Inhibitor, E: Enzyme) 
 1 2 3 4 5 6 7 8 9 10 11 12 
A Dilution of Compound 1: higher (column 1) to lower (column 10) NO I NO E B 
C Dilution of Compound 2 NO I NO E D 
E Dilution of Compound 3 NO I NO E F 
G Dilution of Compound 4 NO I NO E H 
I Dilution of Compound 5 NO I NO E J 
K Dilution of Compound 6 NO I NO E L 
M Dilution of Compound 7 NO I NO E N 
O Dilution of Compound 8 NO I NO E P 
                      
High 
Control 
Low 
Control 
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ROS generation test 
The ROS generation test was performed as described:134 Compounds (100 and 
10 µM) in Hanks’ balanced salt solution (HBSS) were incubated with 0.5 mM DTT 
for 15 min in 384-well flat bottomed, clear polystyrene microtiter plates. 100 µM 
H2O2 in HBSS was used as control (100%). Phenol red/HRP detection buffer 
(100 µg/ml phenol red and 60 µg/ml HRP in HBSS) was added and incubated for 5 
minutes. The reaction was stopped with addition of 1 M NaOH. Absorbance was then 
read at 610 µM on a BMG NOVOstar and values were normalised to 100 µM H2O2 
value. 
 
Time-dependency test 
Enzyme and inhibitor in assay buffer were pre-incubated for 5, 15, or 30 minutes 
prior to addition of the substrate in assay buffer (with and without DTT). For time 0 
pre-incubation data, the substrate was added just before adding the inhibitor. The 
assay was otherwise performed as stated above. 
 
Reversibility test by dilution139 
G9a (100 nM) was incubated with compound at a concentration of 10 × IC50 (total 
volume 2 µL) for 30 min in assay buffer (50 mM Tris-HCl, pH 9.0, 50 mM NaCl, 
0.01% Tween-20) with and without 1 mM DTT at room temperature in V-shape 
96-well plates. The enzyme was also incubated with DMSO as a positive control. 
After pre-incubation, the samples were diluted 100-fold with peptide H3 and SAM in 
assay buffer (with and without DTT) to decrease all reaction components to their 
usual assay concentrations (as described previously) and the inhibitor concentration to 
0.1 × IC50. After 30 min incubation, 5 µL of each reaction mixture was transferred to 
a white low-volume 384-well plate and acceptor and donor beads were added as 
described in the inhibition assay. The percentage activity was determined relative to 
DMSO control. 
 
SAM competition assay 
IC50 values were determined as stated above at various concentrations of SAM 
(concentration range 10 – 160 µM for G9a, 6 – 800 µM for SUV39H1) and with G9a 
at a concentration of 0.5 nM or SUV39H1 at 50 nM. Time courses were performed at 
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the highest SAM concentration to ensure the system was still in the linear phase under 
all these conditions. The assay was run in presence of 1 mM DTT to ensure the 
reversibility of the inhibition by chaetocin. Enzyme and inhibitor were incubated for 
30 min prior to addition of the substrates and the reactions were run for 30 min. For 
SUV39H1, pIC50 values were derived from 4-point curves at chosen concentrations 
around the IC50 region (0.2 – 0.05 µM). For G9a, the pIC50 values were derived from 
6-point curves (32 – 0.03 µM) 
 
Enzyme concentration dependency 
IC50 values were determined as stated above at various concentrations of enzyme: 50 
and 5 nM for SUV39H1. When SUV39H1 was used at the low concentration (5 nM), 
SAM was used at an increased concentration (4 mM) and the incubation time was 
increased to 4.5 h ensuring the reaction was in the linear phase. 
 
Inhibition assay in presence urea (G9a) 
A titration with increasing amounts of urea was performed to determine a 
concentration at which the overall enzyme activity was not too affected, typically 
about 70–80 % remaining activity (concentration range: 0.29 – 5 M for urea). The 
assays were then run as described above, with 0.7 M urea in assay buffer (1 mM 
DTT) and 30 min pre-incubation of enzyme and compound prior to addition of the 
substrates. 
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Mass spectrometry experiments 
 
Expression and purification of G9a for mass spectrometry experiments – Cloning and 
baculoviral expression (Performed by Jim Reid, Domainex) 
An N-terminally His-tagged DNA fragment, encoding a.a. 913 – 1193 of G9a, was 
subcloned into pFastBac for baculoviral expression using the Bac-to Bac system 
(Invitrogen).  Recombinant G9a was expressed in Sf9 cells grown to mid-log phase in 
Insect-Xpress media supplemented with 5% FCS (Lonza). The cells were infected 
with an MOI of 2.5 and grown for further 72 h at 27 ˚C.  
Protein purification – Harvested cells were resuspended in lysis buffer (50 mM 
HEPES pH 7.4, 300 mM NaCl, 5 mM MgCl2, 10% Glycerol, 1 mM TCEP 
supplemented with EDTA-free protease inhibitors). The cells were lysed by 
sonication and the clarified lysate bound to Ni-NTA resin (Qiagen). The resin was 
washed with lysis buffer supplemented with 50 mM imidazole and eluted in 50 mM 
HEPES pH 7.4, 300 mM NaCl, 5 mM MgCl2, 10% Glycerol, 1 mM TCEP, 250 mM 
imidazole. The protein was further purified to homogeneity by gel filtration using a 
Superdex S75 26/60 column (GE Healthcare) in 50 mM HEPES pH 7.4, 300 mM 
NaCl, 5 mM MgCl2, 10% Glycerol, 1 mM TCEP. Fractions corresponding to dimeric 
G9a were pooled and concentrated. 
 
Denaturing ESI - mass spectrometry analysis (Performed by Marina Demetriades in 
Prof. Chris Schofield Lab, Department of chemistry, Oxford University) 
G9a was desalted using an Amicon Ultra-0.5, Ultracel-10 Membrane, 10 kDa 
(Amicon, U.K.) in 15 mM ammonium acetate (pH 7.5). The stock solution was 
diluted with the same buffer to a final concentration of 100 µM. Chaetocin was 
dissolved to 200 mM in DMSO and then diluted to 200 µM, in buffer. EDTA was 
dissolved in water to 1 M and further to 1 mM. All reagents were mixed to a final 
concentration of G9a 19 µM, chaetocin 38 µM, in a total volume of 12 µL. For the 
experiments where DTT was used, its final concentration in the mixture was 190 µM. 
ESI-MS analysis was performed at 0 min and 30 min incubation after adding 1 µL of 
1% formic acid to 4 µL of the reaction mixture, just prior to analysis. Mass 
spectrometric data were acquired using a Q-TOF mass spectrometer (Q-TOF micro, 
Micromass, Altrincham, U.K.) interfaced with a NanoMate (Advion Biosciences, 
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Ithaca, NY) with a chip voltage of 1.70 kV and a delivery pressure 0.5 psi. The 
sample cone voltage was typically 60 V with a source temperature of 80 ˚C and with 
an acquisition/scan time of 1 s/1 s. Calibration and sample acquisition were performed 
in the positive ion mode in the range of 2000-4000 m/z. The pressure at the interface 
between the atmospheric source and the high vacuum region was fixed at 6.30 mbar. 
External instrument calibration was achieved using sodium formate. Data were 
processed with MassLynx 4.0 (Waters). 
 
Mass spectrometry analysis to identify the cysteine residues involved in bonding with 
chaetocin (Performed by Aaron Borg and Peter DiMaggio, Department of Chemical 
Engineering, Imperial College London) 
Recombinant G9a was dialysed into 100 mM NaCl, 1 mM TCEP (Sigma-Aldrich) 
and 50 mM HEPES pH 7.3 at 4 ˚C. Chaetocin was added to half of the G9a sample in 
a molar ratio of 2:1 and allowed to react at 25 ˚C for 30 min. The second half of the 
G9a sample was used as control experiment to which no chaetocin was added. To 
both the control and the treated samples, guanidine HCl (Promega) was added to a 
final concentration of 6 M to denature the G9a protein, and N-ethylmaleimide (NEM) 
(Sigma-Aldrich) was added to a final concentration of 14 mM and allowed to react for 
30 min at room temperature to covalently label cysteine residues not engaged in 
disulfide bonding. The samples were then reduced with a final concentration of 5 mM 
DTT for 1 h at 51 ˚C, and iodoacetamide (Sigma-Aldrich) was added at a final 
concentration of 14 mM and allowed to react in the dark for 45 min to label the 
reduced cysteines. Proteomics grade trypsin (Promega) was added at a 1:20 ratio to 
digest the G9a protein for 6 h at 37 ˚C. After quenching digestion, ZipTips were used 
to reconstitute both samples into the correct loading solvent for nanoLC-MS. 
The peptides were chromatographically resolved using a linear gradient on an 
Ultimate 3000 RSLCnano System (Dionex), with an Acclaim PepMap100, C18 
stationary phase, 3 µm particle size, 100 Å pore size, 75 µm internal diameter × 15 
cm length column (Thermo Fisher). The LC conditions comprised of a flow rate of 
0.3 µL/min and a linear gradient starting at 1% B (5% H2O, 95% MeCN, 0.1% 
Formic Acid and 99% A (0.1% FA, 100% H2O) and increased to 95% B over 70 min. 
Real time tandem mass spectra were acquired on an LTQ Velos Pro linear ion trap 
(Thermo Scientific) with an 80 min acquisition time over a 240 – 1800 m/z scan range 
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and CID fragmentation collision energy of 35%. Tandem mass spectra were collected 
using top 5 data-dependent acquisition, with a dynamic exclusion list (repeat count of 
2, repeat duration of 10 sec, exclusion list size 100 and exclusion duration of 100 sec) 
to provide sufficient MS/MS peptide coverage. 
Initial peptide identification from the LC-MS/MS data was performed using a Sequest 
search in Proteome discoverer 1.3 (Thermo Fisher) against the Uniprot database with 
G9a appended. Reverse decoy false discovery rate values of 0.01/0.05 were used 
(strict/relaxed), allowing for 2 missed cleavages and a 2 Da precursor mass tolerance. 
Dynamic side chain modifications included in the search were carbamidomethyl 
(+57.021; from iodoacetamide treament), NEM (+125.048) and NEM in oxidised 
form (143.058) on cysteine residues, and oxidation (+15.995) on methionine residues. 
The accuracy of the tandem MS identifications reported by Sequest was manually 
assessed, and the 2 most abundant charge states observed for each cysteine-containing 
peptide were then quantitated by peak integration of the precursor ion intensity in the 
extracted ion chromatogram. This was done for all possible combinations of 
modifications on the cysteine and methionine residues, and the raw abundances were 
normalised across all observed modified states of the same peptide sequence to 
determine the relative percentage of NEM (indicating an exposed cysteine) and 
carbamidomethyl (indicating a cysteine involved in disulfide bond formation) 
labelling for each cysteine residue. The fold change in carbamidomethyl-to-NEM 
labelling (i.e. disulfide bond formation) upon chaetocin treatment was evaluated by 
taking ratio between the abundances of the treated and control samples 
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Cell-based assay 
 
The cell-based assays were performed by Nadine Chapman-Rothe and Elham 
Shamsaei in Prof. Robert Brown Laboratories. 
 
Cell culture and compound treatment: MDA-MB-231 breast cancer cell lines were 
cultured in DMEM-Medium supplemented with 10% FCS (#02.00.830, First Link 
(UK), 2 mM L-Glutamine (#25030-024, Invitrogen), 100 U/mL Penicillin and 
100 µg/mL Streptavidin (#15070-063, Invitrogen) until they were ~60% confluent 
and then treated for either 48 h or 72 h with a compound. Compounds were diluted in 
DMSO at stocks of 10 mM.  
 
Real-time measurements for cell-based screening: Following compound treatment for 
48 h (in 6-well plates), media was removed and 1.5 mL of TRIzol (#155966018, 
Invitrogen) was added directly to lyse cells. Once cells were lysed, the protocol was 
continued with 1 mL (TRIzol, cell lysate) according to the manufacturer’s instructions. 
Purified RNA was dissolved in 35 µL of UltraPure DNase/RNase-free distilled water 
(#10977049, Invitrogen). Reverse transcription was done using the SuperScript III 
First-Strand Synthesis System (#18080-051, Invitrogen) according to the 
manufacturer’s instructions, using 7 µL of the purified RNA as starting material. For 
real-time measurements the 2x iQ SYBR Green Supermix (#170-8882, Bio-Rad), 
200 nM Primers and 0.4 µL of cDNA /per 20 µL reaction was used. The measurement 
was done in low-white 96-well plates (#MLL9651, Bio-Rad) on a CFX96 Real-time 
System/C1000 Thermal Cycler (Bio-Rad) with the following protocol: 95 ˚C for 
3 min; 95 ˚C for 10 s, 56 ˚C for 10 s, 72 ˚C for 30 s. 42 cycles followed by a melting 
curve from 72 ˚C to 95 ˚C in order to control for primer dimer or unwanted products. 
Each measurement was done in triplicate. For normalisation we have tested numerous 
‘house-keeping genes’ such as b-actin, HPRT1 as well as TBP, but in our hands, for 
drug treatment purposes only GAPDH as well as RNA pol II seem to be a reliable 
constant normaliser. In order to account for preparation/handling differences during 
drug treatment and real-time measurement, we are using a second GAPDH 
(GAPDH_2) primer pair, and would count an experiment as valid if the difference 
between these primer pairs is not greater than +/−0.15 fold for each real-time run. 
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Crystallographic data 
 
Crystallographic data for compound 25 
 
 
Table 1. Crystal data and structure refinement for 25. 
 
Identification code MF1301 
Formula C15 H16 N2 O2 S2 
Formula weight 320.42 
Temperature 173 K 
Diffractometer, wavelength OD Xcalibur 3, 0.71073 Å 
Crystal system, space group Triclinic, P-1 
Unit cell dimensions a = 9.9436(5) Å α = 71.694(3)° 
 b = 10.2460(3) Å β = 81.285(4)° 
 c = 15.4717(6) Å γ = 89.134(3)° 
Volume, Z 1478.35(11) Å3, 4 
Density (calculated) 1.440 Mg/m3 
Absorption coefficient 0.365 mm-1 
F(000) 672 
Crystal colour / morphology Colourless blocky needles 
Crystal size 0.44 x 0.40 x 0.28 mm3 
θ range for data collection 3.07 to 29.59° 
Index ranges -13<=h<=8, -12<=k<=13, -21<=l<=19 
Reflns collected / unique 12089 / 6834 [R(int) = 0.0211] 
Reflns observed [F>4σ(F)] 5475 
Absorption correction Analytical 
Max. and min. transmission 0.924 and 0.890 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 6834 / 0 / 381 
Goodness-of-fit on F2 1.029 
Final R indices [F>4σ(F)] R1 = 0.0414, wR2 = 0.0984 
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R indices (all data) R1 = 0.0564, wR2 = 0.1084 
Largest diff. peak, hole 0.358, -0.281 eÅ-3 
Mean and maximum shift/error 0.000 and 0.000 
 
Table 2. Bond lengths [Å] and angles [°] for 25. 
 
S(1A)-C(6A) 1.8822(18) 
S(1A)-S(2A) 2.0733(8) 
S(2A)-C(3A) 1.881(2) 
N(1A)-C(2A) 1.357(2) 
N(1A)-C(13A) 1.416(2) 
N(1A)-C(6A) 1.452(2) 
C(2A)-O(2A) 1.214(2) 
C(2A)-C(3A) 1.531(3) 
C(3A)-N(4A) 1.448(3) 
C(3A)-C(14A) 1.512(3) 
N(4A)-C(5A) 1.365(3) 
N(4A)-C(15A) 1.469(3) 
C(5A)-O(5A) 1.215(2) 
C(5A)-C(6A) 1.522(3) 
C(6A)-C(7A) 1.563(3) 
C(7A)-C(8A) 1.520(3) 
C(7A)-C(16A) 1.531(3) 
C(7A)-C(17A) 1.539(3) 
C(8A)-C(9A) 1.384(3) 
C(8A)-C(13A) 1.390(3) 
C(9A)-C(10A) 1.387(3) 
C(10A)-C(11A) 1.381(3) 
C(11A)-C(12A) 1.388(3) 
C(12A)-C(13A) 1.387(3) 
S(1B)-C(6B) 1.8881(18) 
S(1B)-S(2B) 2.0743(8) 
S(2B)-C(3B) 1.886(2) 
N(1B)-C(2B) 1.359(2) 
N(1B)-C(13B) 1.417(2) 
N(1B)-C(6B) 1.447(2) 
C(2B)-O(2B) 1.214(2) 
C(2B)-C(3B) 1.521(3) 
C(3B)-N(4B) 1.449(3) 
C(3B)-C(14B) 1.518(3) 
N(4B)-C(5B) 1.372(3) 
N(4B)-C(15B) 1.460(3) 
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C(5B)-O(5B) 1.213(2) 
C(5B)-C(6B) 1.524(2) 
C(6B)-C(7B) 1.565(3) 
C(7B)-C(8B) 1.509(3) 
C(7B)-C(16B) 1.530(3) 
C(7B)-C(17B) 1.541(3) 
C(8B)-C(13B) 1.383(3) 
C(8B)-C(9B) 1.387(3) 
C(9B)-C(10B) 1.386(3) 
C(10B)-C(11B) 1.376(4) 
C(11B)-C(12B) 1.401(3) 
C(12B)-C(13B) 1.390(3) 
 
C(6A)-S(1A)-S(2A) 98.04(6) 
C(3A)-S(2A)-S(1A) 99.52(7) 
C(2A)-N(1A)-C(13A) 127.48(16) 
C(2A)-N(1A)-C(6A) 120.41(15) 
C(13A)-N(1A)-C(6A) 109.85(14) 
O(2A)-C(2A)-N(1A) 124.81(18) 
O(2A)-C(2A)-C(3A) 123.68(18) 
N(1A)-C(2A)-C(3A) 111.45(17) 
N(4A)-C(3A)-C(14A) 114.77(18) 
N(4A)-C(3A)-C(2A) 111.43(16) 
C(14A)-C(3A)-C(2A) 110.72(19) 
N(4A)-C(3A)-S(2A) 110.38(15) 
C(14A)-C(3A)-S(2A) 105.91(14) 
C(2A)-C(3A)-S(2A) 102.81(13) 
C(5A)-N(4A)-C(3A) 118.05(16) 
C(5A)-N(4A)-C(15A) 116.79(19) 
C(3A)-N(4A)-C(15A) 119.57(19) 
O(5A)-C(5A)-N(4A) 124.08(18) 
O(5A)-C(5A)-C(6A) 122.59(19) 
N(4A)-C(5A)-C(6A) 113.20(17) 
N(1A)-C(6A)-C(5A) 112.23(16) 
N(1A)-C(6A)-C(7A) 105.02(14) 
C(5A)-C(6A)-C(7A) 118.53(15) 
N(1A)-C(6A)-S(1A) 109.25(12) 
C(5A)-C(6A)-S(1A) 101.53(12) 
C(7A)-C(6A)-S(1A) 110.13(12) 
C(8A)-C(7A)-C(16A) 113.10(16) 
C(8A)-C(7A)-C(17A) 107.52(16) 
C(16A)-C(7A)-C(17A) 110.01(16) 
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C(8A)-C(7A)-C(6A) 100.39(14) 
C(16A)-C(7A)-C(6A) 113.65(16) 
C(17A)-C(7A)-C(6A) 111.73(16) 
C(9A)-C(8A)-C(13A) 119.12(18) 
C(9A)-C(8A)-C(7A) 129.58(18) 
C(13A)-C(8A)-C(7A) 111.23(16) 
C(8A)-C(9A)-C(10A) 119.27(19) 
C(11A)-C(10A)-C(9A) 120.50(19) 
C(10A)-C(11A)-C(12A) 121.57(19) 
C(13A)-C(12A)-C(11A) 116.91(19) 
C(12A)-C(13A)-C(8A) 122.61(17) 
C(12A)-C(13A)-N(1A) 128.81(17) 
C(8A)-C(13A)-N(1A) 108.55(16) 
C(6B)-S(1B)-S(2B) 97.67(6) 
C(3B)-S(2B)-S(1B) 99.48(7) 
C(2B)-N(1B)-C(13B) 128.60(15) 
C(2B)-N(1B)-C(6B) 120.27(15) 
C(13B)-N(1B)-C(6B) 110.05(14) 
O(2B)-C(2B)-N(1B) 124.07(18) 
O(2B)-C(2B)-C(3B) 123.96(18) 
N(1B)-C(2B)-C(3B) 111.89(16) 
N(4B)-C(3B)-C(14B) 114.86(17) 
N(4B)-C(3B)-C(2B) 110.52(16) 
C(14B)-C(3B)-C(2B) 110.70(18) 
N(4B)-C(3B)-S(2B) 110.81(13) 
C(14B)-C(3B)-S(2B) 105.93(15) 
C(2B)-C(3B)-S(2B) 103.32(12) 
C(5B)-N(4B)-C(3B) 118.06(15) 
C(5B)-N(4B)-C(15B) 117.00(18) 
C(3B)-N(4B)-C(15B) 120.68(19) 
O(5B)-C(5B)-N(4B) 123.34(18) 
O(5B)-C(5B)-C(6B) 123.24(18) 
N(4B)-C(5B)-C(6B) 113.22(16) 
N(1B)-C(6B)-C(5B) 112.25(14) 
N(1B)-C(6B)-C(7B) 104.75(14) 
C(5B)-C(6B)-C(7B) 118.66(15) 
N(1B)-C(6B)-S(1B) 109.57(12) 
C(5B)-C(6B)-S(1B) 101.21(12) 
C(7B)-C(6B)-S(1B) 110.30(12) 
C(8B)-C(7B)-C(16B) 113.50(16) 
C(8B)-C(7B)-C(17B) 107.18(16) 
C(16B)-C(7B)-C(17B) 109.67(17) 
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C(8B)-C(7B)-C(6B) 100.71(14) 
C(16B)-C(7B)-C(6B) 113.87(17) 
C(17B)-C(7B)-C(6B) 111.48(15) 
C(13B)-C(8B)-C(9B) 119.76(19) 
C(13B)-C(8B)-C(7B) 111.33(16) 
C(9B)-C(8B)-C(7B) 128.74(19) 
C(10B)-C(9B)-C(8B) 118.7(2) 
C(11B)-C(10B)-C(9B) 120.8(2) 
C(10B)-C(11B)-C(12B) 121.9(2) 
C(13B)-C(12B)-C(11B) 116.0(2) 
C(8B)-C(13B)-C(12B) 122.87(18) 
C(8B)-C(13B)-N(1B) 108.59(15) 
C(12B)-C(13B)-N(1B) 128.52(18) 
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Crystallographic data for compound 49 
 
 
 
Table 1. Crystal data and structure refinement for 49. 
 
Identification code MF1302 
Formula C15 H15 F N2 O2 S2 
Formula weight 338.41 
Temperature 173 K 
Diffractometer, wavelength OD Xcalibur 3, 0.71073 Å 
Crystal system, space group Triclinic, P-1 
Unit cell dimensions a = 7.5855(3) Å α = 106.977(4)° 
 b = 14.5072(6) Å β = 99.642(3)° 
 c = 14.9344(6) Å γ = 104.652(3)° 
Volume, Z 1468.07(12) Å3, 4 
Density (calculated) 1.531 Mg/m3 
Absorption coefficient 0.382 mm-1 
F(000) 704 
Crystal colour / morphology Pale yellow blocks 
Crystal size 0.38 x 0.25 x 0.15 mm3 
θ range for data collection 2.80 to 29.55° 
Index ranges -10<=h<=10, -18<=k<=20, -20<=l<=20 
Reflns collected / unique 12227 / 6794 [R(int) = 0.0241] 
Reflns observed [F>4σ(F)] 5616 
Absorption correction Analytical 
Max. and min. transmission 0.951 and 0.897 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 6794 / 0 / 399 
Goodness-of-fit on F2 1.032 
Final R indices [F>4σ(F)] R1 = 0.0408, wR2 = 0.1039 
R indices (all data) R1 = 0.0521, wR2 = 0.1137 
Largest diff. peak, hole 0.423, -0.340 eÅ-3 
Mean and maximum shift/error 0.000 and 0.001 
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Table 2. Bond lengths [Å] and angles [°] for 49. 
 
S(1A)-C(6A) 1.8944(19) 
S(1A)-S(2A) 2.0825(7) 
S(2A)-C(3A) 1.895(2) 
N(1A)-C(2A) 1.364(2) 
N(1A)-C(13A) 1.420(2) 
N(1A)-C(6A) 1.447(2) 
C(2A)-O(2A) 1.217(2) 
C(2A)-C(3A) 1.521(3) 
C(3A)-N(4A) 1.447(2) 
C(3A)-C(14A) 1.516(3) 
N(4A)-C(5A) 1.372(2) 
N(4A)-C(15A) 1.464(2) 
C(5A)-O(5A) 1.216(2) 
C(5A)-C(6A) 1.517(3) 
C(6A)-C(7A) 1.561(2) 
C(7A)-C(8A) 1.520(3) 
C(7A)-C(16A) 1.528(3) 
C(7A)-C(17A) 1.538(3) 
C(8A)-C(13A) 1.385(2) 
C(8A)-C(9A) 1.388(3) 
C(9A)-C(10A) 1.382(3) 
C(10A)-F(10A) 1.363(2) 
C(10A)-C(11A) 1.377(3) 
C(11A)-C(12A) 1.389(3) 
C(12A)-C(13A) 1.381(3) 
S(1B)-C(6B) 1.8972(19) 
S(1B)-S(2B) 2.0617(7) 
S(2B)-C(3B) 1.904(2) 
N(1B)-C(2B) 1.366(2) 
N(1B)-C(13B) 1.420(2) 
N(1B)-C(6B) 1.448(2) 
C(2B)-O(2B) 1.211(2) 
C(2B)-C(3B) 1.530(3) 
C(3B)-N(4B) 1.441(2) 
C(3B)-C(14B) 1.512(3) 
N(4B)-C(5B) 1.374(2) 
N(4B)-C(15B) 1.464(2) 
C(5B)-O(5B) 1.217(2) 
C(5B)-C(6B) 1.519(2) 
C(6B)-C(7B) 1.557(2) 
C(7B)-C(8B) 1.523(2) 
C(7B)-C(16B) 1.525(3) 
C(7B)-C(17B) 1.540(3) 
C(8B)-C(9B) 1.380(3) 
C(8B)-C(13B) 1.387(3) 
C(9B)-C(10B) 1.382(3) 
C(10B)-F(10B) 1.359(2) 
C(10B)-C(11B) 1.373(3) 
C(11B)-C(12B) 1.393(3) 
C(12B)-C(13B) 1.385(3) 
 
C(6A)-S(1A)-S(2A) 97.43(6) 
C(3A)-S(2A)-S(1A) 99.19(6) 
C(2A)-N(1A)-C(13A) 127.51(15) 
C(2A)-N(1A)-C(6A) 119.89(15) 
C(13A)-N(1A)-C(6A) 109.64(14) 
O(2A)-C(2A)-N(1A) 124.33(18) 
O(2A)-C(2A)-C(3A) 123.93(16) 
N(1A)-C(2A)-C(3A) 111.64(15) 
N(4A)-C(3A)-C(14A) 114.22(16) 
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N(4A)-C(3A)-C(2A) 112.29(15) 
C(14A)-C(3A)-C(2A) 110.89(15) 
N(4A)-C(3A)-S(2A) 110.58(12) 
C(14A)-C(3A)-S(2A) 106.44(14) 
C(2A)-C(3A)-S(2A) 101.52(13) 
C(5A)-N(4A)-C(3A) 118.32(15) 
C(5A)-N(4A)-C(15A) 117.71(16) 
C(3A)-N(4A)-C(15A) 119.65(15) 
O(5A)-C(5A)-N(4A) 124.12(17) 
O(5A)-C(5A)-C(6A) 123.09(16) 
N(4A)-C(5A)-C(6A) 112.59(15) 
N(1A)-C(6A)-C(5A) 113.13(14) 
N(1A)-C(6A)-C(7A) 104.11(14) 
C(5A)-C(6A)-C(7A) 118.41(15) 
N(1A)-C(6A)-S(1A) 110.26(12) 
C(5A)-C(6A)-S(1A) 100.58(11) 
C(7A)-C(6A)-S(1A) 110.38(12) 
C(8A)-C(7A)-C(16A) 114.50(17) 
C(8A)-C(7A)-C(17A) 106.82(15) 
C(16A)-C(7A)-C(17A) 110.31(17) 
C(8A)-C(7A)-C(6A) 99.96(14) 
C(16A)-C(7A)-C(6A) 114.71(16) 
C(17A)-C(7A)-C(6A) 109.88(15) 
C(13A)-C(8A)-C(9A) 119.51(18) 
C(13A)-C(8A)-C(7A) 110.25(16) 
C(9A)-C(8A)-C(7A) 129.84(17) 
C(10A)-C(9A)-C(8A) 116.85(18) 
F(10A)-C(10A)-C(11A) 118.11(19) 
F(10A)-C(10A)-C(9A) 117.94(19) 
C(11A)-C(10A)-C(9A) 123.94(19) 
C(10A)-C(11A)-C(12A) 119.09(19) 
C(13A)-C(12A)-C(11A) 117.43(18) 
C(12A)-C(13A)-C(8A) 123.15(17) 
C(12A)-C(13A)-N(1A) 128.29(16) 
C(8A)-C(13A)-N(1A) 108.56(15) 
C(6B)-S(1B)-S(2B) 97.48(6) 
C(3B)-S(2B)-S(1B) 98.52(6) 
C(2B)-N(1B)-C(13B) 127.35(15) 
C(2B)-N(1B)-C(6B) 120.06(15) 
C(13B)-N(1B)-C(6B) 108.85(14) 
O(2B)-C(2B)-N(1B) 124.49(17) 
O(2B)-C(2B)-C(3B) 124.02(17) 
N(1B)-C(2B)-C(3B) 111.36(15) 
N(4B)-C(3B)-C(14B) 114.86(16) 
N(4B)-C(3B)-C(2B) 111.69(15) 
C(14B)-C(3B)-C(2B) 110.96(15) 
N(4B)-C(3B)-S(2B) 112.30(13) 
C(14B)-C(3B)-S(2B) 105.92(13) 
C(2B)-C(3B)-S(2B) 99.98(12) 
C(5B)-N(4B)-C(3B) 118.74(15) 
C(5B)-N(4B)-C(15B) 117.61(15) 
C(3B)-N(4B)-C(15B) 120.32(15) 
O(5B)-C(5B)-N(4B) 123.92(17) 
O(5B)-C(5B)-C(6B) 123.35(16) 
N(4B)-C(5B)-C(6B) 112.57(15) 
N(1B)-C(6B)-C(5B) 112.35(15) 
N(1B)-C(6B)-C(7B) 104.26(14) 
C(5B)-C(6B)-C(7B) 119.99(15) 
N(1B)-C(6B)-S(1B) 111.01(12) 
C(5B)-C(6B)-S(1B) 100.06(11) 
C(7B)-C(6B)-S(1B) 109.17(13) 
C(8B)-C(7B)-C(16B) 113.87(16) 
C(8B)-C(7B)-C(17B) 106.88(15) 
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C(16B)-C(7B)-C(17B) 110.06(16) 
C(8B)-C(7B)-C(6B) 99.66(14) 
C(16B)-C(7B)-C(6B) 114.77(16) 
C(17B)-C(7B)-C(6B) 110.98(16) 
C(9B)-C(8B)-C(13B) 120.40(17) 
C(9B)-C(8B)-C(7B) 129.48(17) 
C(13B)-C(8B)-C(7B) 110.08(16) 
C(8B)-C(9B)-C(10B) 116.78(18) 
F(10B)-C(10B)-C(11B) 118.39(17) 
F(10B)-C(10B)-C(9B) 118.07(19) 
C(11B)-C(10B)-C(9B) 123.53(18) 
C(10B)-C(11B)-C(12B) 119.74(18) 
C(13B)-C(12B)-C(11B) 117.09(18) 
C(12B)-C(13B)-C(8B) 122.41(18) 
C(12B)-C(13B)-N(1B) 128.77(17) 
C(8B)-C(13B)-N(1B) 108.73(15) 
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Crystallographic data for compound 50 
 
 
 
Table 1. Crystal data and structure refinement for 50. 
 
Identification code MF1303 
Formula C15 H15 F N2 O2 S 
Formula weight 306.35 
Temperature 173 K 
Diffractometer, wavelength OD Xcalibur 3, 0.71073 Å 
Crystal system, space group Monoclinic, P2(1)/n 
Unit cell dimensions a = 12.1110(3) Å α = 90° 
 b = 9.0355(3) Å β = 90.632(3)° 
 c = 12.9502(4) Å γ = 90° 
Volume, Z 1417.04(7) Å3, 4 
Density (calculated) 1.436 Mg/m3 
Absorption coefficient 0.245 mm-1 
F(000) 640 
Crystal colour / morphology Colourless blocks 
Crystal size 0.51 x 0.42 x 0.33 mm3 
θ range for data collection 3.36 to 29.55° 
Index ranges -16<=h<=15, -11<=k<=11, -17<=l<=17 
Reflns collected / unique 11162 / 3424 [R(int) = 0.0218] 
Reflns observed [F>4σ(F)] 2958 
Absorption correction Analytical 
Max. and min. transmission 0.940 and 0.915 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3424 / 0 / 192 
Goodness-of-fit on F2 1.055 
Final R indices [F>4σ(F)] R1 = 0.0341, wR2 = 0.0845 
R indices (all data) R1 = 0.0412, wR2 = 0.0896 
Largest diff. peak, hole 0.307, -0.242 eÅ-3 
Mean and maximum shift/error 0.000 and 0.001 
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Table 2. Bond lengths [Å] and angles [°] for 50. 
 
S(1)-C(3) 1.8447(13) 
S(1)-C(6) 1.8591(14) 
N(1)-C(2) 1.3926(17) 
N(1)-C(13) 1.4197(16) 
N(1)-C(6) 1.4856(16) 
C(2)-O(2) 1.2096(16) 
C(2)-C(3) 1.5510(19) 
C(3)-N(4) 1.4717(17) 
C(3)-C(14) 1.4981(19) 
N(4)-C(5) 1.3551(17) 
N(4)-C(15) 1.4519(17) 
C(5)-O(5) 1.2164(16) 
C(5)-C(6) 1.5493(18) 
C(6)-C(7) 1.5405(18) 
C(7)-C(8) 1.5223(19) 
C(7)-C(16) 1.5337(19) 
C(7)-C(17) 1.5407(19) 
C(8)-C(9) 1.3867(19) 
C(8)-C(13) 1.3934(19) 
C(9)-C(10) 1.383(2) 
C(10)-F(10) 1.3637(17) 
C(10)-C(11) 1.375(2) 
C(11)-C(12) 1.392(2) 
C(12)-C(13) 1.3857(19) 
 
C(3)-S(1)-C(6) 78.27(6) 
C(2)-N(1)-C(13) 124.24(11) 
C(2)-N(1)-C(6) 109.36(10) 
C(13)-N(1)-C(6) 107.56(10) 
O(2)-C(2)-N(1) 126.49(13) 
O(2)-C(2)-C(3) 126.85(12) 
N(1)-C(2)-C(3) 106.65(11) 
N(4)-C(3)-C(14) 115.70(11) 
N(4)-C(3)-C(2) 106.63(11) 
C(14)-C(3)-C(2) 115.06(11) 
N(4)-C(3)-S(1) 102.60(8) 
C(14)-C(3)-S(1) 115.86(10) 
C(2)-C(3)-S(1) 98.97(8) 
C(5)-N(4)-C(15) 124.00(12) 
C(5)-N(4)-C(3) 111.87(10) 
C(15)-N(4)-C(3) 124.13(11) 
O(5)-C(5)-N(4) 126.40(12) 
O(5)-C(5)-C(6) 127.44(12) 
N(4)-C(5)-C(6) 106.13(11) 
N(1)-C(6)-C(7) 106.17(10) 
N(1)-C(6)-C(5) 104.73(10) 
C(7)-C(6)-C(5) 123.50(11) 
N(1)-C(6)-S(1) 102.39(8) 
C(7)-C(6)-S(1) 116.44(9) 
C(5)-C(6)-S(1) 101.25(9) 
C(8)-C(7)-C(16) 113.42(12) 
C(8)-C(7)-C(6) 100.00(10) 
C(16)-C(7)-C(6) 112.45(11) 
C(8)-C(7)-C(17) 107.82(11) 
C(16)-C(7)-C(17) 110.10(11) 
C(6)-C(7)-C(17) 112.66(11) 
C(9)-C(8)-C(13) 119.88(13) 
C(9)-C(8)-C(7) 128.83(13) 
C(13)-C(8)-C(7) 111.18(11) 
C(10)-C(9)-C(8) 116.87(14) 
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F(10)-C(10)-C(11) 118.17(14) 
F(10)-C(10)-C(9) 117.91(15) 
C(11)-C(10)-C(9) 123.91(14) 
C(10)-C(11)-C(12) 119.28(14) 
C(13)-C(12)-C(11) 117.58(14) 
C(12)-C(13)-C(8) 122.48(13) 
C(12)-C(13)-N(1) 128.11(12) 
C(8)-C(13)-N(1) 109.40(11) 
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